Tokushima University / Educator and Researcher Directory --- Ikushima, Hitoshi

Field of Study

○	Medicine, Radiation Oncology

Subject of Study

○	Imaging biomarkers for radiotherapy (radiotherapy, cancer, imaging biomarker)

Book / Paper

Book:

1.	Hitoshi Ikushima : 放射線治療計画ガイドライン2024・婦人科, Nov. 2024.
2.	Hitoshi Ikushima : がん・放射線療法改定第8版・子宮頸癌・術後照射, 株式会社Gakken, Sep. 2023.
3.	Hitoshi Ikushima : 癌治療に求められる基礎的知識ー放射線療法概論ー, Aug. 2022.
4.	Hitoshi Ikushima : 密封小線源治療診療・物理QAマニュアル第2版, 金原出版株式会社, Apr. 2022. (Keyword) radiation therapy / 小線源治療
5.	Hitoshi Ikushima : 放射線療法概論, 日本癌治療認定医機構, Oct. 2021.
6.	戸板孝文, Hitoshi Ikushima and 加藤眞吾 : 子宮頸癌取り扱い規約臨床編第4版，放射線療法, KANEHARA & CO., LTD., Tokyo, Dec. 2020.
7.	Hitoshi Ikushima : がん治療認定医教育セミナーテキスト第14版放射線療法概論, 一般社団法人日本がん治療認定医機構, Oct. 2020.
8.	Hitoshi Ikushima : 放射線治療計画ガイドライン2020婦人科の章, 金原出版, Oct. 2020.
9.	Hitoshi Ikushima and Shunsuke Furutani : 放射線療法概論, Sep. 2019.
10.	Hitoshi Ikushima and Akihiro Haga : やさしくわかる放射線治療学(担当:編集，放射線治療物理), 秀潤社, Oct. 2018.
11.	Hitoshi Ikushima : 子宮体がん治療ガイドライン, 金原出版株式会社, Sep. 2018.
12.	Hitoshi Ikushima : 高線量率密封小線源治療ガイダンス2017, Jul. 2018.
13.	Hitoshi Ikushima : がん放射線療法2017ー子宮頸癌術後照射の項ー, 秀潤社, Jul. 2017.
14.	Minoru Sakama, Shinsaku Takeda, Erika Matsumoto, Tomoki Harukuni, Hitoshi Ikushima, Yukihiko Satou and Keisuke Sueki : Monte Carlo Evaluation of Internal Dose and Distribution Imaging Due to Insoluble Radioactive Cs-Bearing Particles of Water Deposited Inside Lungs via Pulmonary Inhalation Using PHITS Code Combined with Voxel Phantom Data, Springer, Feb. 2016. (Link to Publication Site) ● Publication site (DOI): 10.1007/978-4-431-55848-4_19 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84960330123 (DOI: 10.1007/978-4-431-55848-4_19, Elsevier: Scopus)
15.	Hitoshi Ikushima : 放射線治療総論・放射線治療の適応と方法, 日本婦人科腫瘍学会, 東京都, Jul. 2015.
16.	Hitoshi Ikushima : 骨病変のマネージメント，放射線療法, 医薬ジャーナル社, Mar. 2013.
17.	Hitoshi Ikushima : 各論，子宮体がん, 南江堂, Oct. 2012.
18.	Hitoshi Ikushima : 放射線治療計画ガイドライン2012，婦人科, 日本放射線腫瘍学会, Oct. 2012.
19.	戸板孝文, 山下康行, Hitoshi Ikushima, 加藤真吾 and 茶谷正史 : 子宮体癌取り扱い規約第3版・第1部・臨床的取り扱い・4．治療法b.放射線療法, KANEHARA & CO., LTD., Tokyo, Apr. 2012.
20.	戸板孝文, 山下康行, Hitoshi Ikushima, 加藤真吾 and 茶谷正史 : 子宮頸癌取り扱い規約第3版・第1部・臨床的取り扱い・4．治療法c.放射線療法, Apr. 2012.
21.	Hitoshi Ikushima : 放射線治療が必要な場合とその方法は, 日本医事新報社, Jun. 2011. (Keyword) 乳癌 / 放射線治療
22.	Hitoshi Ikushima : がん放射線療法2010，第7章，子宮頸癌術後照射, 篠原出版新社, Nov. 2010. (Keyword) 子宮頸癌 / 放射線治療
23.	Hitoshi Ikushima and Yoshihiro Takegawa : 癌·放射線療法 2002, 株式会社篠原出版新社, Tokyo, Mar. 2002.
24.	Yoshihiro Takegawa, Hitoshi Ikushima, Nishimoto Yasuo and Ishikawa Takonori : 図解診療放射線技術実践ガイド, 文光堂, Tokyo, Mar. 2002.
25.	Yoshihiro Takegawa, Hitoshi Ikushima and Hironori Matuki : 癌の臨床特集第29回放射線による制癌シンポジウムー21世紀に向けての放射線治療, 株式会社篠原出版新社, Tokyo, Apr. 2000.

Academic Paper (Judged Full Paper):

1.	NAKANO Shoma, Motoharu Sasaki, Nakaguchi Yuji, Takeshi Kamomae, Kanako Sakuragawa, YAMAJI Yuto and Hitoshi Ikushima : Comparative evaluation of two dose-volume histogram prediction tools for treatment planning: treatment planning quality and dose verification accuracy, Technical Innovations & Patient Support in Radiation Oncology, 2025. (Keyword) verification / RapidPlan / PlanIQ / Volumetric-modulated arc therapy
2.	Kojima Toru, Okamoto Hiroyuki, Kurooka Masahiro, Tohyama Naoki, Tsuruoka Ichiro, Nemoto Mikio, Shimomura Kohei, Myojoyama Atsushi, Hitoshi Ikushima, Ohno Tatsuya and Ohnishi Hiroshi : Current status of the working environment of brachytherapy in Japan: A nationwide survey-based analysis focusing on radiotherapy technologists and medical physicists Journal of Radiation Research, Journal of Radiation Research, 2024.
3.	Bollos Christine Anne Leah Locsin, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Koji Yamaguchi, Tomomi Matsuura, Tamaki Otani, Takanori Bandoh, Yuya Ueki, Noritake Matsuda, Satoru Takashi, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis Secondary to Atrial Fibrillation Ablation, Asia Oceania Journal of Nuclear Medicine & Biology, Vol.13, No.1, 62-69, 2024. (Summary) We present two patients with a history of paroxysmal atrial fibrillation who developed pulmonary vein stenosis (PVS) following atrial fibrillation (AF) ablation. Case 1 involved a female patient in her 50s who was asymptomatic for pulmonary symptoms but was found to have a high degree of left superior PVS 15 months after AF ablation. This was demonstrated using contrast-enhanced computed tomography (CE-CT) and supported by findings of perfusion defects on ventilation-perfusion (V/Q) scan. Case 2 was a male patient in his 60s who developed progressive left superior PVS nine months after AF ablation, evidenced by serial CE-CT and V/Q scans. PVS is a rare but well-known complication of pulmonary vein ablation for the treatment of AF that can lead to severe complications if left untreated. V/Q scans effectively assess the functional significance of PVS by detecting abnormal blood flow segments. Although a V/Q mismatch characterized by reduced perfusion defects is more commonly used in evaluating pulmonary embolism, PVS should not be disregarded as a differential diagnosis. Few studies emphasize the utility of V/Q scans in managing PVS and highlight V/Q mismatch as a notable finding. This case report aimed to highlight their significance. (Link to Publication Site) ● Publication site (DOI): 10.22038/AOJNMB.2024.79650.1561 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.22038/AOJNMB.2024.79650.1561 (DOI: 10.22038/AOJNMB.2024.79650.1561)
4.	若月優, 安藤謙, 小此木範之, 兼安祐子, Hitoshi Ikushima, 加藤真吾 and 大野達也 : 子宮頸癌IGBTにおける子宮体部・腟側に対する線量評価に関するアンケート調査, J Jpn Coll Radiol, Vol.4, 31-35, 2024.
5.	Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Akira Tsuzuki, Sohma Sawada, Kohki Shibuya, Masataka Oita, Masahide Tominaga, Yuki Tominaga and Hitoshi Ikushima : Comparative analysis of two dose-volume histogram prediction tools for treatment planning in volumetric-modulated arc therapy: A multi-planner study, Medical Dosimetry, Vol.49, No.3, 271-275, 2024. (Summary) The increase in high-precision radiation therapy, particularly volumetric-modulated arc therapy (VMAT), has increased patient numbers and expanded treatment sites. However, a significant challenge in VMAT treatment planning is the inconsistent plan quality among different planners and facilities. This study explored the use of dose-volume histogram (DVH) prediction tools to address these disparities, specifically focusing on RapidPlan (Varian Medical Systems) and PlanIQ (Sun Nuclear). RapidPlan predicts achievable DVHs and automatically generates optimization objectives. While it has demonstrated organ-at-risk (OAR) dose reduction benefits, the quality of the plan used to build its model significantly affects its predictions. On the other hand, PlanIQ offers ease of use and does not require prior model-building. Five planners participated in this study, each creating two treatment plans: one referencing RapidPlan and the other using PlanIQ. The planners had the freedom to adjust parameters while referencing the DVH predictions. The plans were evaluated using "Plan Quality Metric" (PQM) scores to assess the planning target volume excluding the rectum and OARs. The results revealed that RapidPlan-referenced plans often outperformed PlanIQ-based plans, with less interplanner variability. PlanIQ played a pivotal role in the construction of the RapidPlan model. This study is the first to compare plans generated by multiple planners using both tools. This study provides insights into optimizing treatment planning by considering the characteristics of both RapidPlan and PlanIQ. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.meddos.2024.02.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38556402 ● Search Scopus @ Elsevier (PMID): 38556402 ● Search Scopus @ Elsevier (DOI): 10.1016/j.meddos.2024.02.002 (DOI: 10.1016/j.meddos.2024.02.002, PubMed: 38556402)
6.	Nagi Masumoto, Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Yuki Kanazawa and Hitoshi Ikushima : Knowledge-based model building for treatment planning for prostate cancer using commercial treatment planning quality assurance software tools, Radiological Physics and Technology, Vol.17, No.1, 337-345, 2024. (Summary) This study devised a method to efficiently launch the RapidPlan model for volumetric-modulated arc therapy for prostate cancer in small- and medium-sized facilities using high-quality treatment plans with the PlanIQ software as a reference. Treatment plans were generated for 30 patients with prostate cancer to construct the RapidPlan model using PlanIQ as a reference. In the context of PlanIQ-referenced treatment planning, treatment plans were developed, such that the feasibility dose-volume histogram of each organ-at-risk fell within F ≤ 0.1. For validation of the RapidPlan model, treatment plans were formulated for 20 patients using both RapidPlan and PlanIQ, and the differences were evaluated. The results of RapidPlan model validity assessment revealed that the RapidPlan-produced treatment plans exhibited higher quality in 11 of 20 patients. No significant differences were found between the treatment plans. In conclusion, high-quality treatment plans formulated using PlanIQ as reference facilitated efficient implementation of RapidPlan modeling. (Keyword) RapidPlan / PlanIQ / treatment planning quality (Link to Publication Site) ● Publication site (DOI): 10.1007/s12194-023-00759-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37938420 ● Search Scopus @ Elsevier (PMID): 37938420 ● Search Scopus @ Elsevier (DOI): 10.1007/s12194-023-00759-6 (DOI: 10.1007/s12194-023-00759-6, PubMed: 37938420)
7.	Hitoshi Ikushima, Noriko Ii, Shin-ei Noda, Koji Masui, Naoya Murakami, Ken Yoshida, Miho Watanabe, Shinji Kawamura, Toru Kojima, Yoshihito Nomoto, Takafumi Toita, Tatsuya Ohno, Hideyuki Sakurai and Hiroshi Ohnishi : Patterns of care for brachytherapy in Japan, Journal of Radiation Research, Vol.65, No.2, 168-176, 2023. (Summary) This study aimed to assess the current state of brachytherapy (BT) resources, practices and resident education in Japan. A nationwide survey was undertaken encompassing 177 establishments facilitating BT in 2022. Questionnaires were disseminated to each BT center, and feedback through online channels or postal correspondence was obtained. The questionnaire response rate was 90% (159/177), and every prefecture had a response in at least one center. The number of centers in each prefecture ranged from 0.6 to 3.6 (median: 1.3) per million population. The annual number of patients in each center ranged from 0 to 272 (median: 31). While most prefectures provided intracavitary (IC) BT for gynecological cancers and interstitial (IS) BT for prostate cancer, only one-third of the prefectures provided IS BT for cancer sites other than the prostate. The institutional image-guided BT implementation rate was 71%. IC and IS BT was performed for 15.4% of IC BT cases of gynecological cancer. Only 47% of the BT training centers answered that they could provide adequate training in BT for residents. The most common reason for this finding was the insufficient number of patients in each center. The results show that, although BT has achieved uniformity in terms of facility penetration, new technologies are not yet widespread enough. Furthermore, IS BT, which requires advanced skills, is limited to a few BT centers, and considerable number of BT training centers do not have sufficient caseloads to provide the necessary experience for their residents. (Keyword) Brachytherapy / Patterns of care / National Survey / Resident education (Tokushima University Institutional Repository) ● Metadata: 118868 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rrad099 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38151923 ● Search Scopus @ Elsevier (PMID): 38151923 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rrad099 (Tokushima University Institutional Repository: 118868, DOI: 10.1093/jrr/rrad099, PubMed: 38151923)
8.	Daisuke Satoh, Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Yuki Kanazawa, Masataka Oita, Akimi Kajino, Akira Tsuzuki and Hitoshi Ikushima : Differences between professionals in planning treatment for patients with stage III lung cancer using treatment-planning QA software, Reports of Practical Oncology and Radiotherapy, Vol.28, No.5, 671-680, 2023. (Summary) The quality of treatment planning for stage III non-small cell lung cancer varies within and between facilities due to the different professions involved in planning. Dose estimation parameters were calculated using a feasibility dose-volume histogram (FDVH) implemented in the treatment planning quality assurance software PlanIQ. This study aimed to evaluate differences in treatment planning between occupations using manual FDVH-referenced treatment planning to identify their characteristics. The study included ten patients with stage III non-small cell lung cancer, and volumetric-modulated arc therapy was used as the treatment planning technique. Fifteen planners, comprising five radiation oncologists, five medical physicists, and five radiological technologists, developed treatment strategies after referring to the FDVH. Medical physicists had a higher mean dose at D98% of the planning target volume (PTV) and a lower mean dose at D2% of the PTV than those in other occupations. Medical physicists had the lowest irradiation lung volumes (V5 Gy and V13 Gy) compared to other professions, and radiation oncologists had the lowest V20 Gy and mean lung dose. Radiological technologists had the highest irradiation volumes for dose constraints at all indexes on the normal lung volume. The quality of the treatment plans developed in this study differed between occupations due to their background expertise, even when an FDVH was used as a reference. Therefore, discussing and sharing knowledge and treatment planning techniques among professionals is essential to determine the optimal treatment plan for each facility and patient. (Keyword) Non-small-cell lung cancer / PlanIQ / Treatment planning quality / Volumetric-modulated arc therapy (Link to Publication Site) ● Publication site (DOI): 10.5603/rpor.97511 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38179286 ● Search Scopus @ Elsevier (PMID): 38179286 ● Search Scopus @ Elsevier (DOI): 10.5603/rpor.97511 (DOI: 10.5603/rpor.97511, PubMed: 38179286)
9.	Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori, Yoshiteru Ueno, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Hiro-omi Kanayama and Masayuki Takahashi : Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer., Anticancer Research, Vol.43, No.10, 4627-4635, 2023. (Summary) Positive core ratios observed on prostate biopsy correlated with higher recurrence rates after LDR-BT. This indicates that the proportion of positive cores in the biopsy may be an important factor in predicting the likelihood of recurrence, especially for patients with GG3 PCa. (Keyword) Male / Humans / Retrospective Studies / Brachytherapy / Prostatic Neoplasms / Neoplasm Grading / Biopsy / Prostate-Specific Antigen (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.16657 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37772553 ● Search Scopus @ Elsevier (PMID): 37772553 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.16657 (DOI: 10.21873/anticanres.16657, PubMed: 37772553)
10.	Toru Kojima, Shinji Kawamura, Yuki Otani, Takashi Hanada, Yuichiro Wakitani, Kenta Naniwa, Atsunori Yorozu, Hitoshi Ikushima and Takushi Dokiya : Current status and issues with the dosimetric assay of iodine-125 seed sources at medical facilities in Japan: a questionnaire-based survey, Journal of Radiation Research, Vol.64, No.6, 962-966, 2023. (Summary) In conducting dosimetric assays of seed sources containing iodine-125 (125I), several major guidelines require the medical physicist to verify the source strength before patient treatment. Japanese guidelines do not mandate dosimetric assays at medical facilities, but since 2017, three incidents have occurred in Japan wherein seeds with incorrect strengths were delivered to medical facilities. Therefore, this study aimed to survey the current situation and any barriers to conducting the dosimetric assay of iodine-125 seeds at medical facilities in Japan. We conducted a questionnaire-based survey from December 2020 to April 2021, to examine whether seed assay and verification of the number of seeds delivered were being performed. We found that only 9 facilities (16%) performed seed assay and 28 (52%) verified the number of seeds. None of the facilities used an assay method that ensured traceability. The reasons for not performing an assay were divided into two categories: lack of resources and legal issues. Lack of resources included lack of instruments, lack of knowledge of assay methods, shorthand, or all of the above, whereas legal issues included the inability to resterilize iodine-125 seeds distributed in Japan and/or purchase seeds dedicated to the assay. Dosimetric assays, including simple methods, are effective in detecting calibration date errors and non-radioactive seeds. The study findings suggest that familiarization of medical personnel with these assay methods and investigation of the associated costs of labor and equipment should be recommended, as these measures will lead to medical reimbursement for quality assurance. (Keyword) Humans / Iodine Radioisotopes / Brachytherapy / Japan / Surveys and Questionnaires / Radiotherapy Dosage (Tokushima University Institutional Repository) ● Metadata: 119413 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rrad063 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37697653 ● Search Scopus @ Elsevier (PMID): 37697653 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rrad063 (Tokushima University Institutional Repository: 119413, DOI: 10.1093/jrr/rrad063, PubMed: 37697653)
11.	Tamaki Ohtani, Hitoshi Ikushima, Yoshimi Bando, Michiko Yamashita, Kenmei Kuwahara, Hideki Otsuka, Kazuya Kondo and Hirokazu Miyoshi : Early Prediction of Radiotherapeutic Effecacy in a Mouse Model of Non-Small Cell Lung Carcinoma Using 18F-FLT and 18F-FDG PET/CT, The Journal of Medical Investigation : JMI, Vol.70, No.3,4, 361-368, 2023. (Summary) This study investigated the usefulness of [18F]-3'-deoxy-3'-fluorothymidine (18F-FLT) and [18F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging for predicting the therapeutic efficacy of non-small cell lung cancer (NSCLC) irradiation at an early stage after radiation treatment. Mice were xenografted with the human lung adenocarcinoma line A549 or large cell lung cancer line FT821. Tumour uptake of 18F-FLT and 18F-FDG was imaged using PET/CT before and 1 week after irradiation. In A549 tumours, 18F-FLT uptake was significantly decreased, and 18F-FDG uptake was unchanged post-irradiation compared with pre-irradiation. In FT821 tumours, uptake of both 18F-FLT and 18F-FDG uptake was substantially decreased post-irradiation compared with pre-irradiation. In both xenografts, tumour volumes in the irradiated groups were significantly decreased compared with those in the control group. 18F-FLT is expected to contribute to individual NSCLC therapy because it accurately evaluates the decrease in tumour activity that cannot be captured by 18F-FDG. 18F-FDG may be useful for evaluating surviving cells without being affected by the inflammatory reaction at an extremely early stage, approximately 1 week after irradiation. Combined use of 18F-FLT and 18F-FDG PET/CT imaging may increase the accurate prediction of radiotherapy efficacy, which may lead to improved patient outcomes and minimally invasive personalised therapy. J. Med. Invest. 70 : 361-368, August, 2023. (Keyword) Humans / Mice / Animals / Carcinoma, Non-Small-Cell Lung / Fluorodeoxyglucose F18 / Positron Emission Tomography Computed Tomography / Lung Neoplasms / Radiopharmaceuticals / Positron-Emission Tomography (Tokushima University Institutional Repository) ● Metadata: 118771 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.361 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940520 ● Search Scopus @ Elsevier (PMID): 37940520 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.361 (Tokushima University Institutional Repository: 118771, DOI: 10.2152/jmi.70.361, PubMed: 37940520)
12.	Takafumi Toita, kentaro Wada, Shinya Sutani, Rei Umezawa, Hitoshi Maemoto, Noriko Ii, Tomoko Kawamura, Hitoshi Ikushima, Ryosuke Takenaka, Koji Konishi, Atsunori Yorozu, Keiichi Jingu, Takuro Ariga, Yoshihito Nomoto and Hideomi Yamashita : Definitive radiotherapy consisting of external beam radiotherapy without central shielding and 3D image-guided brachytherapy for patients with cervical cancer: feasibility for Japanese patients and dose-response analyses for local control in the low-dose range, Japanese Journal of Clinical Oncology, Vol.53, No.6, 480-488, 2023. (Summary) To assess the feasibility of external beam radiotherapy without central shielding in definitive radiotherapy for Japanese patients with cervical cancer. We retrospectively analysed the data of cervical cancer patients treated with definitive radiotherapy consisting of external beam radiotherapy without central shielding and three-dimensional-image-guided brachytherapy. The study included 167 patients (T1 + 2 = 108, T3 + 4 = 59) from eight Japanese institutions. For three-dimensional-image-guided brachytherapy, intra-cavitary and interstitial brachytherapy was utilized in 33 patients (20%). The median follow-up was 26.6 months (interquartile range, 20-43.2). The maximum rectal D2 (75 Gy)/bladder D2 (90 Gy) constraints were deviated by 6%/10% and 10%/5% for T1 + 2 and T3 + 4, respectively. The 2-year incidence of ≥grade 3 proctitis/cystitis was 4%/1% for T1 + 2 and 10%/2% for T3 + 4. The 2-year local progression-free survival was 89% for T1 + 2 and 82% for T3 + 4. For T1 + 2, the 2-year local progression-free survival for the high-risk clinical target volume D90 ≥ 68 Gy (indicated by receiver operating characteristic analysis; area under the curve = 0.711) was 92% versus 67% for <68 Gy (log-rank; P = 0.019). Cox multivariate analysis indicated that the high-risk clinical target volume D90 was one of independent predictors of local failure (P = 0.0006). For T3 + 4, the 2-year local progression-free survival was 87% for the high-risk clinical target volume <82 cm3 (area under the curve = 0.67) and 43% for ≥82 cm3 (P = 0.0004). Only the high-risk clinical target volume was an independent predictor of local failure (P = 0.0024). Definitive radiotherapy consisting of external beam radiotherapy without central shielding and three-dimensional-image-guided brachytherapy was feasible for Japanese patients with cervical cancer. Dose de-escalation from the current global standards is suggested for patients with T1 + 2 disease. (Keyword) intensity-modulated / cervix neoplasms / dosages / radiotherapy / brachytherapy (Link to Publication Site) ● Publication site (DOI): 10.1093/jjco/hyad022 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36974716 ● Summary page in Scopus @ Elsevier: 2-s2.0-85160969528 (DOI: 10.1093/jjco/hyad022, PubMed: 36974716, Elsevier: Scopus)
13.	Naoya Murakami, Koji Masui, ken Yoshida, Shin-ei Noda, Miho Watanabe, Tadashi Takenaka, Noriko Ii, Kazushige Atsumi, Rei Umezawa, Koji Inaba, Kotaro Iijima, Akiko Kubo, Hiroshi Igaki, Naoto Shikama and Hitoshi Ikushima : Hands-on seminar for image-guided adaptive brachytherapy and intracavitary/interstitial brachytherapy for uterine cervical cancer, Japanese Journal of Clinical Oncology, Vol.53, No.6, 508-513, 2023. (Summary) Compared with the implementation speed of image-guided adaptive brachytherapy for uterine cervical cancer, that of intracavitary and interstitial brachytherapy is slow, possible because it requires more invasive procedure of inserting needles directly into tumours. To accelerate the implementation speed of intracavitary and interstitial brachytherapy, a first hands-on seminar for image-guided adaptive brachytherapy and intracavitary and interstitial brachytherapy for uterine cervical cancer was held on 26 November 2022, supported by Japanese Society for Radiology and Oncology. This article deals with this hands-on seminar and difference of degree of confidence of participants in starting intracavitary and interstitial brachytherapy before and after the seminar. The seminar consisted of lectures regarding intracavitary and interstitial brachytherapy in the morning and hands-on practice of needle insertion and contouring, as well as dose calculation practice using the radiation treatment system in the evening. Prior to and following the seminar, participants completed a questionnaire asking about their level of confidence in performing intracavitary and interstitial brachytherapy, expressed between 0 and 10 (the higher the number, the stronger the confidence). A total of 15 physicians, six medical physicists and eight radiation technologists from 11 institutions attended the meeting. The median level of confidence before and after the seminar was 3 (range, 0-6) and 5.5 (range, 3-7), respectively, and a statistically significant improvement was observed (P<0.001). It was suggested that the hands-on seminar on intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer improved the level of confidence of the attendees and propelled their motivation, through which it is expected that the implementation of intracavitary and interstitial brachytherapy will be accelerated. (Keyword) Female / Humans / Radiotherapy Dosage / Brachytherapy / Uterine Cervical Neoplasms / Radiotherapy Planning, Computer-Assisted (Link to Publication Site) ● Publication site (DOI): 10.1093/jjco/hyad012 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36810684 ● Summary page in Scopus @ Elsevier: 2-s2.0-85160969573 (DOI: 10.1093/jjco/hyad012, PubMed: 36810684, Elsevier: Scopus)
14.	Yoshiteru Ueno, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Masayuki Takahashi and Hiro-omi Kanayama : Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer., In Vivo, Vol.37, No.2, 738-746, 2023. (Summary) PSA levels at 5 years post-treatment were associated with long-term recurrence of localized prostate cancer, which can help alleviate patient anxiety concerning prostate cancer recurrence if PSA levels remain low at 5 years after LDR-BT. (Keyword) Male / Humans / Prostate-Specific Antigen / Brachytherapy / Cohort Studies / East Asian People / Prostatic Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.13136 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36881090 ● Search Scopus @ Elsevier (PMID): 36881090 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.13136 (DOI: 10.21873/invivo.13136, PubMed: 36881090)
15.	Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Shoji Ueda, Yuto Endo, Daisuke Satoh and Hitoshi Ikushima : Predicting the complexity of head-and-neck volumetric-modulated arc therapy planning using a radiation therapy planning quality assurance software, Reports of Practical Oncology and Radiotherapy, Vol.27, No.6, 963-972, 2022. (Summary) The more complex the treatment plan, the higher the possibility of errors in dose verification. Recently, a treatment planning quality assurance (QA) software (PlanIQ) with a function to objectively evaluate the quality of volumetric-modulated arc therapy (VMAT) treatment plans by scoring and calculating the ideal dose-volume histogram has been marketed. This study aimed to assess the association between the scores of ideal treatment plans identified using PlanIQ and the results of dose verification and to investigate whether the results of dose verification can be predicted based on the complexity of treatment plans. Dose verification was performed using an ionization chamber dosimeter, a radiochromic film, and a three-dimensional dose verification system, Delta4 PT. Correlations between the ideal treatment plan scores obtained by PlanIQ and the results of the absolute dose verification and dose distribution verification were obtained, and it was examined whether dose verifications could be predicted from the complexity of the treatment plans. Even when the score from the ideal treatment plan was high, the results of absolute dose verification and dose distribution verification were sometimes poor. However, even when the score from the ideal treatment plan was low, the absolute volume verification and dose distribution verification sometimes yielded good results. Treatment plan complexity can be determined in advance from the ideal treatment plan score calculated by PlanIQ. However, it is difficult to predict the results of dose verification using an ideal treatment plan. (Keyword) volumetric-modulated arc therapy / dose verification / PlanIQ (Link to Publication Site) ● Publication site (DOI): 10.5603/RPOR.a2022.0122 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36632304 ● Search Scopus @ Elsevier (PMID): 36632304 ● Search Scopus @ Elsevier (DOI): 10.5603/RPOR.a2022.0122 (DOI: 10.5603/RPOR.a2022.0122, PubMed: 36632304)
16.	小島徹, 高橋健夫, 遠山尚樹, 川守田龍, 小高喜久雄, 新保宗史, 谷正司, 友田達伸, 島田秀樹, Hitoshi Ikushima and 細野眞 : 診療用放射線照射装置使用室(RALS室)に併設された診療用CTエックス線撮影装置の単独使用に関するアンケート報告, Radioisotopes, Vol.71, No.3, 225-232, 2022. (Link to Publication Site) ● Publication site (DOI): 10.3769/radioisotopes.71.225 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3769/radioisotopes.71.225 (DOI: 10.3769/radioisotopes.71.225)
17.	Naoya Murakami, Miho Watanabe, Takashi Uno, Shuhei Sekii, Kayoko Tsujino, Takahiro Kasamatsu, Yumiko Machitori, Tomomi Aoshika, Shingo Kato, Hisako Hirowatari, Yuko Kaneyasu, Tomio Nakagawa, Hitoshi Ikushima, Ken Ando, Masumi Murata, Ken Yoshida, Hiroko Yoshioka, Kazutoshi Murata, Tatsuya Ohno, Noriyuki Okonogi, Anneyuko Saito, Mayumi Ichikawa, Takahito Okuda, Keisuke Tsuchida, Hideyuki Sakurai, Ryouichi Yoshimura, Yasuo Yoshioka, Atsunoti Yorozu, Hiroyuki Okamoto, KOji Inaba, Tomoyasu Kato, Hiroshi Igaki and Jun Itami : Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial, Japanese Journal of Clinical Oncology, Vol.52, No.8, 851-860, 2022. (Summary) This is the preliminary results of a multi-center prospective clinical trial evaluating the feasibility of the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer. Patients with FIGO stage IB2, IIA2, IIB, IIIA, IIIB and IVA uterine cervical cancer pretreatment width of which was ≥5 cm measured by MRI were eligible. Protocol therapy consisted of 30-30.6 Gy in 15-17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP, followed by 24 Gy in 4 fractions of hybrid of intracavitary and interstitial and pelvic radiotherapy with central shield up to 50-50.4 Gy in 25-28 fractions. The primary endpoint of phase I part was that the rate of grade ≥ 3 acute non-hematologic adverse events related to hybrid of intracavitary and interstitial would be <10%. Between October 2015 and October 2019, 74 patients underwent primary registration, with 52 patients eventually proceeding to the secondary registration. The median pretreatment tumor width was 5.7 cm, and FIGO Stages were IB2 10, IIA2 2, IIB 20 and IIIB 20, respectively. The median high-risk clinical target volume D90 was 72.0 Gy (54.8-86.6 Gy, EQD2), rectum D2cc was 53.7 Gy (29.3-80.3 Gy) and bladder D2cc was 69.8 Gy (38.9-84.8 Gy). The rate of grade ≥ 3 non-hematologic adverse events related to hybrid of intracavitary and interstitial was 1.9% (1/52), and 17.3% (9/52) of patients experienced non-hematologic adverse events related to hybrid of intracavitary and interstitial of any grade. In multivariate analysis, high-risk clinical target volume ≥ 35 ml was associated with an increased risk of any grade of acute non-hematologic adverse events related to hybrid of intracavitary and interstitial (P = 0.036). The feasibility and reproducibility of hybrid of intracavitary and interstitial were demonstrated from a multi-center prospective clinical trial. (Keyword) Brachytherapy / Female / Humans / Prospective Studies / Radiotherapy Dosage / Reproducibility of Results / Uterine Cervical Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1093/jjco/hyac072 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35470390 ● Search Scopus @ Elsevier (PMID): 35470390 ● Search Scopus @ Elsevier (DOI): 10.1093/jjco/hyac072 (DOI: 10.1093/jjco/hyac072, PubMed: 35470390)
18.	Naoya Murakami, Tatsuya Ohno, Takafumi Toita, Ken Ando, Noriko Ii, Hiroyuki Okamoto, Toru Kojima, Kayoko Tsujino, Koji Masui, Ken Yoshida and Hitoshi Ikushima : Japanese Society for Radiation Oncology Consensus Guidelines of combined intracavitary and interstitial brachytherapy for gynecological cancers., Journal of Radiation Research, Vol.63, No.3, 402-411, 2022. (Summary) It has been postulated that the combination of intracavitary and interstitial brachytherapy (IC/IS) is effective and safe for large and irregularly shaped uterine cervical cancer patients. However, due to its invasiveness compared to conventional intracavitary brachytherapy (ICBT), it has to be said that the implementation speed of IC/IS is slow. Until now, there have been no guidelines for required equipment, human resources, and procedural guide focusing solely on IC/IS. The purpose of this guideline is to provide radiation oncologists and medical physicists who wish to start IC/IS with practical and comprehensive guidance for a safe IC/IS introduction and to help accelerate the spread of the utilization of IC/IS nationwide. This is the English translation of the Japanese IC/IS Guidelines, and it was created in an effort to share the Japanese approach to the management of locally advanced uterine cervical cancer worldwide. (Keyword) Guidelines / Cervical cancer / Brachytherapy (Tokushima University Institutional Repository) ● Metadata: 117568 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rrac011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35349700 ● Search Scopus @ Elsevier (PMID): 35349700 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rrac011 (Tokushima University Institutional Repository: 117568, DOI: 10.1093/jrr/rrac011, PubMed: 35349700)
19.	Takaharu Kudoh, Akihiro Haga, Keiko Kudoh, Akira Takahashi, Motoharu Sasaki, Yasusei Kudo, Hitoshi Ikushima and Youji Miyamoto : Radiomics analysis of [18F]-fluoro-2-deoxyglucose positron emission tomography for the prediction of cervical lymph node metastasis in tongue squamous cell carcinoma, Oral Radiology, 2022. (Summary) This study aimed to create a predictive model for cervical lymph node metastasis (CLNM) in patients with tongue squamous cell carcinoma (SCC) based on radiomics features detected by [F]-fluoro-2-deoxyglucose (F-FDG) positron emission tomography (PET). A total of 40 patients with tongue SCC who underwent F-FDG PET imaging during their first medical examination were enrolled. During the follow-up period (mean 28 months), 20 patients had CLNM, including six with late CLNM, whereas the remaining 20 patients did not have CLNM. Radiomics features were extracted from F-FDG PET images of all patients irrespective of metal artifact, and clinicopathological factors were obtained from the medical records. Late CLNM was defined as the CLNM that occurred after major treatment. The least absolute shrinkage and selection operator (LASSO) model was used for radiomics feature selection and sequential data fitting. The receiver operating characteristic curve analysis was used to assess the predictive performance of the F-FDG PET-based model and clinicopathological factors model (CFM) for CLNM. Six radiomics features were selected from LASSO analysis. The average values of the area under the curve (AUC), accuracy, sensitivity, and specificity of radiomics analysis for predicting CLNM from F-FDG PET images were 0.79, 0.68, 0.65, and 0.70, respectively. In contrast, those of the CFM were 0.54, 0.60, 0.60, and 0.60, respectively. The F-FDG PET-based model showed significantly higher AUC than that of the CFM. The F-FDG PET-based model has better potential for diagnosing CLNM and predicting late CLNM in patients with tongue SCC than the CFM. (Tokushima University Institutional Repository) ● Metadata: 116770 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11282-022-00600-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35254609 ● Summary page in Scopus @ Elsevier: 2-s2.0-85125757133 (Tokushima University Institutional Repository: 116770, DOI: 10.1007/s11282-022-00600-7, PubMed: 35254609, Elsevier: Scopus)
20.	Akiko Abe, Masao Yuasa, Yoshie Imai, Tomohiro Kagawa, Ayuka Mineda, Masato Nishimura, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Takeshi Iwasa : Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy, International Journal of Clinical Oncology, Vol.27, No.5, 983-991, 2022. (Summary) Human papillomavirus vaccination is not widespread in Japan, and the low screening rates result in many cases of locally advanced cervical cancer. We investigated the prognostic significance of sarcopenia in patients with cervical cancer to guide healthcare policies to improve treatment outcomes. This retrospective study included 83 patients with cervical cancer without distant metastasis who underwent primary concurrent chemoradiotherapy between 2013 and 2018. We analyzed the indicators of physical condition and muscle quantity using the SYNAPSE VINCENT software. Muscle mass and the relationship between treatment toxicity and prognosis were evaluated. The patients' median age was 60 (range 33-80) years. Cancer stage distribution was as follows: cT2b or higher, 84.3%; N1, 65.1%; and MA, 27.7%. The overall sarcopenia (skeletal muscle index [SMI] < 38.5) rate was 30.1%, and the rate was 33.9 and 22.2% in patients aged < 64 and ≥ 65 years, respectively. No correlation was observed between clinical stage and musculoskeletal indices. Treatment resulted in decreased body weight and SMI; after treatment, the sarcopenia rate increased to 37.3%. A higher intramuscular adipose tissue content (IMAC) reduced the number of chemotherapy cycles needed. Treatment-associated SMI decreases of ≥ 7% indicated poor prognosis, with significant differences in progression-free survival and overall survival (p = 0.013 and p = 0.012, respectively). Patients who were very lean (body mass index < 18.5 kg/m) before treatment had a poor prognosis (p = 0.016 and p < 0.001). Our findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer. (Keyword) Adult / Aged / Aged, 80 and over / Chemoradiotherapy / Female / Humans / Middle Aged / Muscle, Skeletal / Papillomavirus Infections / Papillomavirus Vaccines / Prognosis / Retrospective Studies / Sarcopenia / Thinness / Uterine Cervical Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02140-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35212828 ● Summary page in Scopus @ Elsevier: 2-s2.0-85125283470 (DOI: 10.1007/s10147-022-02140-w, PubMed: 35212828, Elsevier: Scopus)
21.	Kanako Sakuragawa, Motoharu Sasaki, Takeshi Kamomae, Yokoishi Michihiro, Ryosuke Kasai, KAJINO Akimi and Hitoshi Ikushima : Differences in image density adjustment parameters on the image matching accuracy of a floor-mounted kV X-ray image-guided radiation therapy system, Journal of Applied Clinical Medical Physics, Vol.23, No.2, e13505, 2022. (Summary) This study aimed to investigate the effect of two different image density adjustment parameters on the results of image matching at six degrees of freedom using radiographic images generated by the ExacTrac X-ray system in brain stereotactic radiosurgery (SRS). This study comprised 32 patients who underwent brain SRS at our hospital from January 2020 to December 2020. In this study, (1) the default parameter (an image density parameter between "tissue" and "bone") was an image density parameter for digitally reconstructed radiograph (DRR) generation used at many facilities, and (2) the bone parameter was the steepest contrast parameter used at our hospital. Of the 32 patients, 24 (75%) had a couch angle of 0.5 mm or more in the translational direction or 0.5° or more in the rotational direction, and 10 (31%) had a couch angle of 1.0 mm or more in the translational direction or 1.0° or more in the rotational direction. Among the 131 cases of all couch angles, 46 (35%) cases had a translational direction of 0.5 mm or more or a rotational direction of 0.5° or more, and 15 (11%) had a translational direction of 1.0 mm or more or a rotational direction of 1.0° or more. The results of this study indicate the usefulness of using appropriate DRR parameters for each case, rather than using the default settings. The use of appropriate DRR parameters can lead to accurate position matching results, leading to fewer image-guided radiation therapy shots and a lower imaging dose. (Keyword) Stereotactic radiosurgery / digitally reconstructed radiograph / ExacTrac / brain metastasis (Tokushima University Institutional Repository) ● Metadata: 117228 (Link to Publication Site) ● Publication site (DOI): 10.1002/acm2.13505 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34931431 ● Summary page in Scopus @ Elsevier: 2-s2.0-85121471034 (Tokushima University Institutional Repository: 117228, DOI: 10.1002/acm2.13505, PubMed: 34931431, Elsevier: Scopus)
22.	Jun Itami, Naoya Murakami, Miho Watanabe, Shuhei Sekii, Takahiro Kasamatsu, Shingo Kato, Hisako Hirowatari, Hitoshi Ikushima, Ken Ando, Tatsuya Ohno, Hiroyuki Okamoto, Kae Okuma and Hiroshi Igaki : Combined Interstitial and Intracavitary High-Dose Rate Brachytherapy of Cervical Cancer, Frontiers in Oncology, Vol.11, 809825, 2022. (Summary) High-dose-rate brachytherapy by remote afterloading is now performed under three-dimensional image guidance by CT or MRI. Three-dimensional image-guided brachytherapy in cervical cancer disclosed that the traditional intracavitary brachytherapy by Manchester method cannot deliver an adequate dose to the large tumor with resulting local recurrence. To improve the local control rate, combined interstitial and intracavitary (hybrid) brachytherapy can increase the dose to the large parametrial involvement without increasing the dose to the rectum and bladder. Whether hybrid brachytherapy can be performed safely on a multi-institutional basis remains to be studied. From 2015, phase I/II study of hybrid brachytherapy was launched in Japan, and it was revealed that hybrid brachytherapy can be performed safely and with a high quality of radiation dose distribution in a multi-institutional study. In Japan, the number of patients undergoing hybrid brachytherapy in cervical cancer is rapidly rising. Education and clinical trial are very important to establish hybrid brachytherapy in the management of cervical cancer. (Tokushima University Institutional Repository) ● Metadata: 117447 (Link to Publication Site) ● Publication site (DOI): 10.3389/fonc.2021.809825 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35096614 ● Search Scopus @ Elsevier (PMID): 35096614 ● Search Scopus @ Elsevier (DOI): 10.3389/fonc.2021.809825 (Tokushima University Institutional Repository: 117447, DOI: 10.3389/fonc.2021.809825, PubMed: 35096614)
23.	Hitoshi Ikushima, Akihiro Haga, Ken Ando, Shingo Kato, Yuko Kaneyasu, Takashi Uno, Noriyuki Okonogi, Kenji Yoshida, Takuro Ariga, Fimiaki Isohashi, Yoko Harima, Ayae Kanemoto, Noriko Ii, Masaru Wakatsuki and Tatsuya Ohno : Prediction of out-of-field recurrence after chemoradiotherapy for cervical cancer using a combination model of clinical parameters and magnetic resonance imaging radiomics: a multi-institutional study of the Japanese Radiation Oncology Study Group, Journal of Radiation Research, 2021. (Keyword) Radiomics / radiation therapy / Cervical cancer / Out of field recurrence (Tokushima University Institutional Repository) ● Metadata: 118065 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rrab104 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rrab104 (Tokushima University Institutional Repository: 118065, DOI: 10.1093/jrr/rrab104)
24.	Harima Yoko, Ariga Takuro, Kaneyasu Yuko, Hitoshi Ikushima, Tokumaru Sunao, Shimamoto Shigetoshi, Takahashi Takeo, Ii Noriko, Tsujino Kayoko, Saito I. Anneyuko, Ushijima Hiroki, Toita Takafumi and Ohno Tatsuya : Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study, PLoS ONE, Vol.A16, No.11, e0259235, 2021. (Summary) There are currently no reliable, established serum biomarkers to predict the prognosis of radiotherapy for advanced cervical cancer. We aimed to identify serum biomarkers for survival after radiotherapy for cervical cancer. In this multicenter prospective cohort study, the usefulness of pre- and posttreatment serum protein levels of potential biomarkers, including squamous cell carcinoma antigen (SCC-Ag), apolipoprotein C-II (ApoC-II), matrix metalloproteinase (MMP)1, and MMP2, were evaluated together with clinical factors in 145 cervical cancer patients in order to determine their suitability to predict survival. Progression-free survival (PFS) was the primary endpoint, and overall survival (OS), pelvic PFS (PPFS), and distant metastasis-free survival (DMFS) were the secondary endpoints. Blood samples were collected before and 1 month after radiotherapy to measure serum biomarker levels. ApoC-II was measured using a monoclonal antibody-based enzyme-linked immunosorbent assay, which was developed for this purpose. Kaplan-Meier method, log-rank test, and univariate and multivariate Cox proportional hazards models were used for statistical analyses. In multivariate analysis, larger tumor size was independently associated with shorter PFS, OS, PPFS, and DMFS, while longer overall treatment time was independently associated with shorter PPFS. Higher pretreatment SCC-Ag (P < 0.001) was associated with shorter DMFS. Higher posttreatment SCC-Ag (P = 0.017) was also associated with shorter DMFS. Pretreatment ApoC-II was associated with PPFS in univariate analysis (P = 0.048), but not in multivariate analysis. Patients with pretreatment ApoC-II levels ≤ 25.8 μg/ml had shorter PPFS than those with pretreatment ApoC-II levels > 25.8 μg/ml (P = 0.023, log-rank test). Pre- and posttreatment serum SCC-Ag and pretreatment serum ApoC-II levels may be important biomarkers to predict survival outcomes of patients with cervical cancer after radiotherapy. Pre- and posttreatment SCC-Ag and pretreatment ApoC-II might be useful in clinical settings for screening patients to improve treatment strategies in cervical cancer. (Keyword) Biomarker / Radiation Therapy (Tokushima University Institutional Repository) ● Metadata: 116867 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0259235 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34727105 ● Summary page in Scopus @ Elsevier: 2-s2.0-85118387313 (Tokushima University Institutional Repository: 116867, DOI: 10.1371/journal.pone.0259235, PubMed: 34727105, Elsevier: Scopus)
25.	Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Akimi Kajino and Hitoshi Ikushima : Impact of treatment planning quality assurance software on volumetric-modulated arc therapy plans for prostate cancer patients, Medical Dosimetry, Vol.46, No.4, e1-e6, 2021. (Summary) Software that evaluates the quality of treatment plans (PlanIQ) has become commercially available in recent years. It includes a feasibility assessment tool that provides the ideal dose volume histogram (DVH) for each organ at risk, based on the ideal dose falloff from the prescribed dose at the target boundary. It is important to investigate whether the PlanIQ assessment tool (Feasibility DVH) can assist treatment planners who have limited to no experience in treatment planning. Therefore, the present study aimed to evaluate this tool's usefulness for improving the quality of treatment plans. This study included 5 patients with prostate cancer. The treatment planners were 2 graduate students, 2 undergraduate students, and one clinical planner. All students were radiological technology and medical physics students with no clinical experience. Two different volumetric-modulated arc therapy (VMAT) plans were developed before and after Feasibility DVH. The quality of each treatment plan was evaluated based on a scoring system implemented in PlanIQ. Of 5 patients included, 4 received improved treatment plans when Feasibility DVH was used. Moreover, 4 of 5 treatment planners showed improvement in treatment planning using Feasibility DVH. The findings suggest that using the Feasibility DVH tool may improve treatment plans for different planners and patients. However, planners at any level of experience should be trained to check the dose distribution in addition to checking the DVH, which depends on the adequacy of the contours. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.meddos.2021.03.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33972163 ● Search Scopus @ Elsevier (PMID): 33972163 ● Search Scopus @ Elsevier (DOI): 10.1016/j.meddos.2021.03.013 (DOI: 10.1016/j.meddos.2021.03.013, PubMed: 33972163)
26.	Yohsuke Kanoh, Hitoshi Ikushima, Motoharu Sasaki and Akihiro Haga : Automatic Contour Segmentation of Cervical Cancer using Artificial Intelligence, Journal of Radiation Research, Vol.62, No.5, 934-944, 2021. (Summary) In cervical cancer treatment, radiation therapy is selected based on the degree of tumor progression, and radiation oncologists are required to delineate tumor contours. To reduce the burden on radiation oncologists, an automatic segmentation of the tumor contours would prove useful. To the best of our knowledge, automatic tumor contour segmentation has rarely been applied to cervical cancer treatment. In this study, diffusion-weighted images (DWI) of 98 patients with cervical cancer were acquired. We trained an automatic tumor contour segmentation model using 2D U-Net and 3D U-Net to investigate the possibility of applying such a model to clinical practice. A total of 98 cases were employed for the training, and they were then predicted by swapping the training and test images. To predict tumor contours, six prediction images were obtained after six training sessions for one case. The six images were then summed and binarized to output a final image through automatic contour segmentation. For the evaluation, the Dice similarity coefficient (DSC) and Hausdorff distance (HD) was applied to analyze the difference between tumor contour delineation by radiation oncologists and the output image. The DSC ranged from 0.13 to 0.93 (median 0.83, mean 0.77). The cases with DSC <0.65 included tumors with a maximum diameter < 40 mm and heterogeneous intracavitary concentration due to necrosis. The HD ranged from 2.7 to 9.6 mm (median 4.7 mm). Thus, the study confirmed that the tumor contours of cervical cancer can be automatically segmented with high accuracy. (Keyword) cervical cancer / automatic tumor contour segmentation / radiation therapy / diffusion-weighted imaging / Dice similarity coefficient (Tokushima University Institutional Repository) ● Metadata: 116749 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rrab070 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34401914 ● Search Scopus @ Elsevier (PMID): 34401914 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rrab070 (Tokushima University Institutional Repository: 116749, DOI: 10.1093/jrr/rrab070, PubMed: 34401914)
27.	Erika Matsumoto-Kawaguchi, Minoru Sakama, Ken'ichi Fujimoto and Hitoshi Ikushima : Dose Assessment on the Mean Absorbed Estimates Derived from the Simple Approach Method Applying Marinelli-Quimbys Formula for Ambient Risk Organs to Thyroid Uptake in the Administered 131I Radiopharmaceutical of Graves Disease Using PHITS and ICRP Reference Computational Voxel Phantom, Radiation Environment and Medicine, Vol.10, No.2, 87-95, 2021. (Keyword) PHITS / Reference ICRP computational voxel phantom / Mean absorbed dose / thyroid gland / iodine-131 (Tokushima University Institutional Repository) ● Metadata: 116282 (Link to Publication Site) ● Publication site (DOI): 10.51083/radiatenvironmed.10.2_87 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.51083/radiatenvironmed.10.2_87 (Tokushima University Institutional Repository: 116282, DOI: 10.51083/radiatenvironmed.10.2_87)
28.	Yuichi Nishiyama, Akinori Morita, Bing Wang, Takuma Sakai, Dwi Ramadhani, Kaoru Tanaka, Megumi Sasatani, Shintaro Ochi, Masahide Tominaga, Hitoshi Ikushima, Junji Ueno, Mitsuru Nenoi and Shin Aoki : Evaluation of sodium orthovanadate as a radioprotective agent under total-body irradiation and partial-body irradiation conditions in mice., International Journal of Radiation Biology, Vol.97, No.9, 1241-1251, 2021. (Tokushima University Institutional Repository) ● Metadata: 116409 (Link to Publication Site) ● Publication site (DOI): 10.1080/09553002.2021.1941377 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34125648 ● Search Scopus @ Elsevier (PMID): 34125648 ● Search Scopus @ Elsevier (DOI): 10.1080/09553002.2021.1941377 (Tokushima University Institutional Repository: 116409, DOI: 10.1080/09553002.2021.1941377, PubMed: 34125648)
29.	Motoharu Sasaki, Nakaguchi Yuji, Takeshi Kamomae, Tsuzuki Akira, Kobuchi Satoshi, Kuwahara Kenmei, Shoji Ueda, Yuto Endoh and Hitoshi Ikushima : Analysis of prostate intensity- and volumetric-modulated arc radiation therapy planning quality with PlanIQTM, Journal of Applied Clinical Medical Physics, Vol.22, No.4, 132-142, 2021. (Summary) The purpose of this study was to assess the quality of treatment planning using the PlanIQ software and to investigate whether it is possible to improve the quality of treatment planning using the "Feasibility dose-volume histogram (DVH) " implemented in the PlanIQ software. Using the PlanIQ software, we retrospectively analyzed the learning curve regarding the quality of the treatment plans for 148 patients of prostate intensity-modulated radiation therapy and volumetric-modulated radiation therapy performed at our institution over the past eight years. We also sought to examine the possibility of improving treatment planning quality by re-planning in 47 patients where the quality of the target dose and the dose limits for organs at risk (OARs) were inadequate. The re-planning treatment plans referred to the Feasibility DVH implemented in the PlanIQ software and modified the treatment planning system based on the target dose and OAR constraints. Analysis of the learning curve of the treatment plans quality using PlanIQ software retrospectively showed a trend of improvement in the treatment plan quality from year to year. The improvement in the treatment plans quality was more influenced by dose reduction in the OARs than by target coverage. In all cases where re-planning was performed, the improvement in the treatment plan's quality resulted in a better treatment plan than the one adopted for delivery to patients in the clinical plan. The PlanIQ provided insights into the quality of the treatment plans at our institution and identified problems and areas for improvement in the treatment plans, allowing for the development of appropriate treatment plans for specific patients. (Keyword) Humans / Male / Organs at Risk / Prostate / Radiotherapy Dosage / Radiotherapy Planning, Computer-Assisted / Radiotherapy, Intensity-Modulated / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116342 (Link to Publication Site) ● Publication site (DOI): 10.1002/acm2.13233 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33768648 ● Search Scopus @ Elsevier (PMID): 33768648 ● Search Scopus @ Elsevier (DOI): 10.1002/acm2.13233 (Tokushima University Institutional Repository: 116342, DOI: 10.1002/acm2.13233, PubMed: 33768648)
30.	Hiroaki Hayashi, Natsumi Kimoto, Tatsuya Maeda, Emi Tomita, Takashi Asahara, Sota Goto, Yuki Kanazawa, Yasufumi Shitakubo, Kanako Sakuragawa, Hitoshi Ikushima, Tohru Okazaki and Takuya Hashizume : A disposable OSL dosimeter for in-vivo measurement of rectum dose during brachytherapy, Medical Physics, Vol.Online ahead of print, 2021. (Summary) We aimed to develop a disposable rectum dosimeter and to demonstrate its ability to measure exposure dose to the rectum during brachytherapy for cervical cancer treatment using high-dose rate Ir. Our rectum dosimeter measures the dose with an optically stimulated luminescence (OSL) sheet which was furled to a catheter. The catheter we used is 6 mm in diameter; therefore, it is much less invasive than other rectum dosimeters. The rectum dosimeter developed in this study has the characteristics of being inexpensive and disposable. It is also an easy-to-use detector that can be individually sterilized, making it suitable for clinical use. To obtain a dose calibration curve, phantom experiments were performed. Irradiation was performed using a cubical acrylic phantom, and the response of the OSL dosimeter was calibrated with the calculation value predicted by the treatment planning system (TPS). Additionally, the dependence of catheter angle on the dosimeter position and repeatability were evaluated. We also measured the absorbed dose to the rectum of patients who were undergoing brachytherapy for cervical cancer (n = 64). The doses measured with our dosimeters were compared with the doses calculated by the TPS. In order to examine the causes of large differences between measured and planned doses, we classified the data into common and specific cases when performing this clinical study. For specific cases, the following three categories were considered: (a) patient movement, (b) gas in the vagina and/or rectum, and (c) artifacts in the X-ray image caused by applicators. A dose calibration curve was obtained in the range of 0.1 Gy-10.0 Gy. From the evaluation of the dependence of catheter angle on the dosimeter position and repeatability, we determined that our dosimeter can measure rectum dose with an accuracy of 3.1% (k = 1). In this clinical study, we succeeded in measuring actual doses using our rectum dosimeter. We found that the deviation of the measured dose from the planned dose was derived to be 12.7% (k = 1); this result shows that the clinical study included large elements of uncertainty. The discrepancies were found to be due to patient motion during treatment, applicator movement after planning images were taken, and artifacts in the planning images. We present the idea that a minimally invasive rectum dosimeter can be fabricated using an OSL sheet. Our clinical study demonstrates that a rectum dosimeter made from an OSL sheet has sufficient ability to evaluate rectum dose. Using this dosimeter, valuable information concerning organs at risk can be obtained during brachytherapy. (Link to Publication Site) ● Publication site (DOI): 10.1002/mp.14857 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33760234 ● Search Scopus @ Elsevier (PMID): 33760234 ● Search Scopus @ Elsevier (DOI): 10.1002/mp.14857 (DOI: 10.1002/mp.14857, PubMed: 33760234)
31.	Kenta Kitagawa, Hitoshi Ikushima, Motoharu Sasaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Takaharu Kudoh, Yohsuke Kanoh and Tsuzuki Akira : Effect of dental metal artifact conversion volume on dose distribution in head-and-neck volumetric-modulated arc therapy, Journal of Applied Clinical Medical Physics, Vol.21, No.12, 253-262, 2020. (Summary) Purpose: During treatment planning for head-and-neck volumetric-modulated arc therapy (VMAT), manual contouring of the metal artifact area of artificial teeth is done, and the area is replaced with water computed tomography (CT) values for dose calculation. This contouring of the metal artifact areas, which is performed manually, is subject to human variability. The purpose of this study is to evaluate and analyze the effect of inter-observer variation on dose distribution.Methods: The subjects were 25 cases of cancer of the oropharynx for which VMAT was performed. Six radiation oncologists (ROs) performed metal artifact contouring for all of the cases. Gross tumor volume, clinical target volume, planning target volume (PTV), and oral cavity were evaluated. The contouring of the six ROs was divided into two groups, small and large groups. A reference RO was determined for each group and the dose distribution was compared with those of the other radiation oncologists by gamma analysis (GA).As an additional experiment, we changed the contouring of each dental metal artifact area, creating enlarged contours (L), reduced contours (S), and undrawn contours (N) based on the contouring by the six ROs and compared these structure-sets.Results: The evaluation of inter-observer variation showed no significant difference between the large and small groups, and the GA pass rate was 100%. Similar results were obtained comparing structure-sets L and S, but in the comparison of structure-sets L and N, there were cases with pass rates below 70%.Conclusions: The results show that the artificial variability of manual artificial tooth metal artifact contouring has little effect on the dose distribution of VMAT. However, it should be noted that the dose distribution may change depending on the contouring method in cases where the overlap between PTV and metal artifact areas is large. (Keyword) dental metal artifact / head-and-neck / volumetric-modulated arc therapy (Tokushima University Institutional Repository) ● Metadata: 115924 (Link to Publication Site) ● Publication site (DOI): 10.1002/acm2.13101 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33226172 ● Summary page in Scopus @ Elsevier: 2-s2.0-85097008301 (Tokushima University Institutional Repository: 115924, DOI: 10.1002/acm2.13101, PubMed: 33226172, Elsevier: Scopus)
32.	Motoharu Sasaki, Hitoshi Ikushima, Kanako Sakuragawa, Michihiro Yokoishi, Akira Tsuzuki and Wataru Sugimoto : Determination of reproducibility of end-exhaled breath-holding in stereotactic body radiation therapy, Journal of Radiation Research, Vol.61, No.6, 977-984, 2020. (Keyword) dice similarity coefficient / Hausdorff distance / breath-hold irradiation / lung cancer (Tokushima University Institutional Repository) ● Metadata: 116210 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rraa079 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32930802 ● Search Scopus @ Elsevier (PMID): 32930802 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rraa079 (Tokushima University Institutional Repository: 116210, DOI: 10.1093/jrr/rraa079, PubMed: 32930802)
33.	Motoharu Sasaki, Hitoshi Ikushima, Akira Tsuzuki and Wataru Sugimoto : The effect of rectal gas on dose distribution during prostate cancer treatment using full arc and partial arc Volumetric Modulated Arc Therapy (VMAT) treatment plans, Reports of Practical Oncology and Radiotherapy, Vol.25, No.6, 974-980, 2020. (Summary) In this study, we investigated the effect of rectal gas on the dose distribution of prostate cancer using a volumetric modulated arc therapy (VMAT) treatment planning. The first is the original structure set, clinical target volume (CTV), the rectum, and the bladder used clinically. The second is a structure set (simulated gas structure set) in which the overlapping part of the rectum and PTV is overwritten with Hounsfield Unit -950 as gas. Full arc and limited gantry rotation angle with VMAT were the two arcs. The VMAT of the full arc was 181°-179° in the clockwise (CW) direction and 179°-181° in the counterclockwise (CCW) direction. Three partial arcs with a limited gantry rotation angle were created: 200°-160 °CW and 160°-200 °CCW; 220°-140 °CW and 140°-220 °CCW; and finally, 240°-120 °CW and 120°-240 °CCW. The evaluation items were dose difference, distance to agreement, and gamma analysis. In the CTV, the full arc was the treatment planning technique with the least effect of rectal gas. In the rectum, when the gantry rotation angle range was short, the pass rate tended to reduce for all evaluation indices. The bladder showed no characteristic change between the treatment planning techniques in any of the evaluation indices. The VMAT treatment planning with the least effect on dose distribution caused by rectal gas was shown to be a full arc. (Keyword) Volumetric modulated arc therapy / Gas / Dose distribution / Prostate cancer (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rpor.2020.09.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33100914 ● Search Scopus @ Elsevier (PMID): 33100914 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rpor.2020.09.013 (DOI: 10.1016/j.rpor.2020.09.013, PubMed: 33100914)
34.	Motoharu Sasaki and Hitoshi Ikushima : Impact of Changes in Body Contours on Radiation Therapy Dose Distribution After Uterine Cervical Cancer Surgery, Japanese Journal of Radiology, Vol.38, No.11, 1099-1107, 2020. (Summary) Patients receiving postoperative irradiation for uterine cervical cancer might not be able to eat during radiation therapy because of the effects of concurrent chemo-radiotherapy; this may lead to changes in the patient's body shape during treatment. When performing image-guided radiotherapy, it is necessary to determine immediately whether treatment can be performed on the day or whether re-planning is required. The purpose of this study was to determine indicators for re-planning by examining the effects of changing body contours on radiation therapy dose. The original body contour was reduced by 1 cm in the front portion (structure-set 1). Based on the original dose distribution, the dose recalculation was performed with a structure set created using the body contour of structure-set 1. The difference between the original and recalculated dose distributions of structure-set 1 was evaluated through gamma analysis (GA). In the GA results for dose distribution obtained via recalculation with structure-set 1, a pass rate of 90% or more was obtained for a criterion of 2 mm/2% in all cases. The results suggest that dose re-planning is rarely required when the body shape is reduced by only 1 cm in the front. (Keyword) body shape change / after uterine cervical cancer surgery / VMAT (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-020-01011-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32617837 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087392393 (DOI: 10.1007/s11604-020-01011-6, PubMed: 32617837, Elsevier: Scopus)
35.	Okamoto Hiroyuki, Kito Satoshi, Tohyama Naoki, Yonai Shunsuke, Kawamorita Ryu, Nakamura Masaru, Fujimoto Takahiro, Tani Syoji, Yomoda Akihiro, Isobe Toru, Furukawa Hiroshi, Kotaka Kikuo, Itami Jun, Hitoshi Ikushima, Dokiya Takushi and Shioyama Yoshiyuki : Radiation protection in radiological imaging: a survey of imaging modalities used in Japanese institutions for verifying applicator placements in high-dose-rate brachytherapy, Journal of Radiation Research, 2020. (Tokushima University Institutional Repository) ● Metadata: 116458 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rraa088 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rraa088 (Tokushima University Institutional Repository: 116458, DOI: 10.1093/jrr/rraa088)
36.	Yuko Kaneyasu, Hisaya Fujiwara, Tetsuo Nishimura, Hideyuki Sakurai, Tomoko Kazumoto, Hitoshi Ikushima, Takashi Uno, Sunao Tokumaru, Yoko Harima, Hiromichi Gomi, Takafumi Toita, Midori Kita, Shin-ei Noda, Takeo Takahashi, Shingo Kato, Ayako Ohkawa, Akiko Tozawa-Ono, Hiroyuki Ushijima, Yoko Hasumi, Yasuyuki Hirashima, Yuzuru Niibe, Tomio Nakagawa, Tomoyuki Akita, Junko Tanaka and Tatsuya Ohno : A multi-institutional survey of the quality of life after treatment for uterine cervical cancer: a comparison between radical radiotherapy and surgery in Japan, Journal of Radiation Research, Vol.62, No.2, 269-284, 2020. (Summary) This study aimed to research the post-treatment quality of life (QOL) between radiotherapy (RT)- and operation (OP)-treated early cervical cancer survivors, using separate questionnaires for physicians and patients. We administered an observational questionnaire to patients aged 20-70 years old with Stages IB1-IIB cervical cancer who had undergone RT or OP and without recurrence as outpatients for ≥6 months after treatment. We divided 100 registered patients equally into two treatment groups (n = 50 each). The average age was 53 and 44 years in the RT and OP groups, respectively. The RT group included 34 and 66% Stage I and II patients, respectively, whereas the OP group included 66 and 34% Stage I and II patients, respectively. The OP group included 58% of patients with postoperative RT. Combination chemotherapy was performed in 84 and 48% of patients in the RT and OP groups, respectively. On the physicians' questionnaire, we observed significant differences in bone marrow suppression (RT) and leg edema (OP). On the patients' questionnaire, significantly more patients had dysuria and leg edema in the OP group than in the RT group, and severe (Score 4-5) leg edema was significantly higher in the post-operative RT group than in the OP only group. The frequency of sexual intercourse decreased after treatment in both groups. On the patients' questionnaire, there were no significant differences between the two groups regarding sexual activity. These findings are useful to patients and physicians for shared decision-making in treatment choices. The guidance of everyday life and health information including sexual life after treatment is important. (Tokushima University Institutional Repository) ● Metadata: 116457 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rraa107 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33415337 ● Search Scopus @ Elsevier (PMID): 33415337 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rraa107 (Tokushima University Institutional Repository: 116457, DOI: 10.1093/jrr/rraa107, PubMed: 33415337)
37.	Motoharu Sasaki, Wataru Sugimoto and Hitoshi Ikushima : Simplification of Head and Neck Volumetric Modulated Arc Therapy Patient-specific Quality Assurance, Using a Delta4 PT, Reports of Practical Oncology and Radiotherapy, Vol.25, No.5, 793-800, 2020. (Summary) In many facilities, intensity-modulated radiation therapy (IMRT), and volumetric modulated arc therapy (VMAT) use intensity-modulated beams, formed by a multi-leaf collimator (MLC). In IMRT and VMAT, MLC and linear accelerator errors (both geometric and dose), can significantly affect the doses administered to patients. Therefore, IMRT and VMAT treatment plans must include the use of patient-specific quality assurance (QA) before treatment to confirm dose accuracy. In this study, we compared and analyzed the results of dose verification using a multi-dimensional dose verification system Delta4 PT, an ionization chamber dosimeter, and gafchromic film, using data from 52 patients undergoing head and neck VMAT as the test material. Based on the results of the absolute dose verification for the ionization chamber dosimeter and Delta4 PT, taking an axial view, the upper limit of the 95% confidence interval was 3.13%, and the lower limit was -3.67%, indicating good agreement. These results mean that as long as absolute dose verification for the axial view does not deviate from this range, Delta4 PT can be used as an alternative to an ionization chamber dosimeter for absolute dose verification. When we then reviewed dose distribution verification, the pass rate for Delta4 PT was acceptable, and was less varied than that of gafchromic film. This results in that provided the pass rate result for Delta4 PT does not fall below 96%, it can be used as a substitute for gafchromic film in dose distribution verification. These results indicate that patient-specific QA could be simplified. (Keyword) Delta4 PT / volumetric modulated radiation therapy / head and neck / patient-specific quality assurance (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rpor.2020.07.004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32879621 ● Search Scopus @ Elsevier (PMID): 32879621 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rpor.2020.07.004 (DOI: 10.1016/j.rpor.2020.07.004, PubMed: 32879621)
38.	Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama : Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma., Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020. (Summary) The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC. (Tokushima University Institutional Repository) ● Metadata: 115325 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-020-01705-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196 (Tokushima University Institutional Repository: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus)
39.	Motoharu Sasaki, Hitoshi Ikushima, Wataru Sugimoto and Kenta Kitagawa : Long-term stability of a three-dimensional dose verification system., Radiological Physics and Technology, Vol.13, No.1, 83-91, 2020. (Summary) Recently, the number of patients undergoing intensity-modulated radiation therapy and volumetric modulated arc therapy has increased with the expansion of the adaptation site. However, it is necessary to improve the efficiency of time-consuming dose verification. Therefore, patient-specific quality assurance is expected to shift from dose verification using a conventional ionization chamber dosimeter and film to a three-dimensional dose verification system. However, caution is required when using a three-dimensional dose verification system, especially when it comes to the calibration of the detector. Calibration is performed regularly, but not all necessary verifications are done routinely. There are many uncertainties on how the sensitivity of the three-dimensional dose verification system changes over time. In this study, on the same day, when dose verification using a three-dimensional system for one head and neck case was performed, dose verification using a conventional ionization chamber dosimeter and film was also performed once every two months, for 2 years. From the results of the absolute dose and dose distribution verification using the ionization chamber dosimeter and Gafchromic film, the output of the linear accelerator, mechanical accuracy and precision were secured. From the results of the three-dimensional dose verification system, when the distance to agreement was evaluated at 2 mm and 3 mm, and gamma analysis was performed at 2 mm/2% and 3 mm/3%, the passing rate was almost 100%, and a sensitivity change in 2 years was not observed. (Keyword) Long-term stability / Patient-specific QA / Three-dimensional dose verification system / VMAT (Link to Publication Site) ● Publication site (DOI): 10.1007/s12194-020-00554-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32006217 ● Summary page in Scopus @ Elsevier: 2-s2.0-85078907756 (DOI: 10.1007/s12194-020-00554-7, PubMed: 32006217, Elsevier: Scopus)
40.	Chisato Tonoiso, Hitoshi Ikushima, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Takahiro Yoshida, Hiroshi Miyamoto, Masafumi Harada, Tetsuji Takayama and Akira Tangoku : Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer, The Journal of Medical Investigation : JMI, Vol.66, No.1, 2, 99-105, 2019. (Summary) Purpose To assess the treatment results of definitive radiotherapy for esophageal cancer at Tokushima University Hospital and clarify the prognostic factors. Methods Seventy consecutive patients with esophageal cancer who underwent definitive radiotherapy between May 2004 and March 2012 were included in the present study. Local control rate, overall survival rate, and radiation morbidity were examined and univariate and multivariate analyses were performed to investigate prognostic factors. Results The 5-yearoverall survival rates of stages I, II, III, and IVA were 81%, 71%, 0%, and 9%, respectively. Performance status, clinical stage, and neoadjuvant chemotherapy were significant prognostic factors. A past history of interstitial pneumonia was associated with severe radiation-induced lung injury. Conclusions Patients who underwent definitive chemoradiotherapy for esophageal cancer in stage I/II showed good prognosis. However, treatment results of the patients in stage III/IV were not satisfactory, and those who could not undergo surgery after neoadjuvant chemotherapy had the worst prognosis.J.Med.Invest.66:99-105, February, 2019. (Keyword) esophageal cancer / radiotherapy / chemoradiotherapy (Tokushima University Institutional Repository) ● Metadata: 113342 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.99 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064964 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065782310 (Tokushima University Institutional Repository: 113342, DOI: 10.2152/jmi.66.99, PubMed: 31064964, Elsevier: Scopus)
41.	Shunsuke Furutani, Hitoshi Ikushima, Motoharu Sasaki, Chisato Tonoiso, Ayaka Takahashi, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : Clinical outcomes of hypofractionated image-guided multifocal irradiation using volumetric-modulated arc therapy for brain metastases., Journal of Radiation Research, Vol.60, No.1, 134-141, 2019. (Summary) Volumetric-modulated arc therapy (VMAT) can be used to design hypofractionated radiotherapy treatment plans for multiple brain metastases. The purpose of this study was to evaluate treatment outcomes of hypofractionated image-guided multifocal irradiation using VMAT (HFIGMI-VMAT) for brain metastases. From July 2012 to December 2016, 67 consecutive patients with 601 brain metastases were treated with HFIGMI-VMAT at our institution. The prescribed dose was 50 Gy to a 95% volume of the planning target volume in 10 fractions. Fifty-five of the 67 patients had non-small-cell lung cancer, and the remaining 12 had other types of cancer. The median number of brain metastases was five, and the median maximum diameter was 1.2 cm. The median duration of follow-up was 12.0 months (range, 1.9-44.8 months), and the median survival time 18.7 months. Four patients with six lesions had local recurrences. The local control rate in the 64 assessed patients was 98.4% and 95.3% at 6 and 12 months, respectively (three died before assessment). The local control rate for the 572 assessed lesions was 99.8% and 99.3% at 6 and 12 months, respectively. Thirty-nine patients developed distant brain metastases, the distant brain control rate being 59.7% and 40.5% at 6 and 12 months, respectively. Acute toxicities were generally mild (Grade 1-2). Three patients (4.5%) developed radiation necrosis requiring corticosteroid therapy. The HFIGMI-VMAT technique with flat dose delivery was well tolerated and achieved excellent local control. This technique is a promising treatment option for patients with multiple and large brain metastases. (Tokushima University Institutional Repository) ● Metadata: 115535 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rry091 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30445426 ● Search Scopus @ Elsevier (PMID): 30445426 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rry091 (Tokushima University Institutional Repository: 115535, DOI: 10.1093/jrr/rry091, PubMed: 30445426)
42.	Takashi Asahara, Hiroaki Hayashi, Emi Tomita, Kanako Sakuragawa, Hiroshi Saegusa, Yasufumi Shitakubo, Hitoshi Ikushima, Yuki Kanazawa, Yoshiki Mihara, Yoshinori Miyahara, Tohru Okazaki, Takuya Hashizume and Vergil LE Cruz : Development of Novel Rectum Dosimeter using OSL sheet with the aim of Direct Dose Measurement of Organ Dose during Brachytherapy, Progress in Nuclear Science and Technology, Vol.6, 30-33, 2019. (Link to Publication Site) ● Publication site (DOI): 10.15669/pnst.6.30 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.15669/pnst.6.30 (DOI: 10.15669/pnst.6.30)
43.	Emi Tomita, Hiroaki Hayashi, Takashi Asahara, Kanako Sakuragawa, Yasufumi Shitakubo, Hiroshi Saegusa, Hitoshi Ikushima, Yuki Kanazawa, Sota Goto, Tohru Okazaki, Takuya Hashizume and Vergil LE Cruz : Direct Radiation Dose Measurement of Rectum during High-Dose-Rate ¹⁹²Ir Brachytherapy for Cervical Cancer Treatment, Progress in Nuclear Science and Technology, Vol.6, 39-42, 2019. (Link to Publication Site) ● Publication site (DOI): 10.15669/pnst.6.39 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.15669/pnst.6.39 (DOI: 10.15669/pnst.6.39)
44.	兼安祐子, 藤原久也, 西村哲夫, 加藤真吾, 大野達也, 櫻井英幸, 猪本智子, Hitoshi Ikushima, 宇野隆, 徳丸直郎, 播磨洋子, 五味弘道, 喜多みどり, 野田真永, 高橋健夫, 新部譲 and 戸板孝文 : 子宮頸癌患者に対する日本語版QOL調査票の開発, Japanese Journal of Gynecological Oncology, Vol.36, No.4, 682-691, 2018. (Keyword) cervical cancer / radiation therapy / surgery / QOL (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522543655400711552 (CiNii: 1522543655400711552)
45.	Takafumi Toita, Tatsuya Ohno, Hitoshi Ikushima, Tetsuo Nishimura, Takashi Uno, Kazuhiko Ogawa, Hiroshi Onishi, Takushi Dokiya and Jun Itami : National survey of intracavitary brachytherapy for intact uterine cervical cancer in Japan, Journal of Radiation Research, Vol.59, No.4, 469-476, 2018. (Summary) To review the current status of, and labor expended for (in terms of time required), intracavitary brachytherapy (ICBT) in definitive radiotherapy/chemoradiotherapy for cervical cancer patients, two national surveys were performed. The first survey was conducted between July and August 2016 and consisted of a questionnaire of 12 items regarding ICBT procedures for cervical cancer, which was sent to 173 centers installed with high-dose-rate remote after-loading brachytherapy systems. Between November and December 2016, another survey was performed in 79 centers to evaluate labor required for ICBT procedures in terms of time spent and number of staff involved. In the first survey, the response rate was 77% of the 173 centers. ICBT was performed for cervical cancer in 118 (89%) centers. Imaging modalities used after applicator insertion were X-ray alone in 46 (40%), computed tomography in 69 (60%) and magnetic resonance imaging in 5 (4%) centers. Three-dimensional (3D) planning was performed in 55 centers (48%). Fifty-five (70%) centers responded to the second survey regarding ICBT-mandated labor. The median cumulative duration of the entire ICBT procedure was 330 min (the sum of the times spent by each staff member) and was longer in the 3D image-guided brachytherapy (3D-IGBT) (405 min) than in the X-ray group (230 min). This trend was significant for the specific processes of image acquisition and treatment planning, especially for radiation oncologists. In definitive radiotherapy/chemoradiotherapy for cervical cancer patients, 3D-IGBT use has been gradually spreading in Japan. The present survey revealed that ICBT, especially 3D-IGBT, requires substantial labor and time from staff. (Keyword) Adult / Aged / Aged, 80 and over / Brachytherapy / Female / Humans / Japan / magnetic resonance imaging / Middle Aged / Surveys and Questionnaires / Tomography, X-Ray Computed / Uterine Cervical Neoplasms (Tokushima University Institutional Repository) ● Metadata: 115537 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rry035 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29986113 ● Summary page in Scopus @ Elsevier: 2-s2.0-85051034841 (Tokushima University Institutional Repository: 115537, DOI: 10.1093/jrr/rry035, PubMed: 29986113, Elsevier: Scopus)
46.	Toshiaki Saito, Tsutomu Tabata, Hitoshi Ikushima, Hiroyuki Yanai, Hironori Tashiro, Hitoshi Niikura, Takeo Minaguchi, Toshinari Muramatsu, Tsukasa Baba, Wataru Yamagami, Kazuya Ariyoshi, Kimio Ushijima, Mikio Mikami, Satoru Nagase, Masanori Kaneuchi, Nobuo Yaegashi, Yasuhiro Udagawa and Hidetaka Katabuchi : Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer, International Journal of Clinical Oncology, Vol.23, No.2, 201-234, 2017. (Summary) Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines for the treatment of vulvar cancer and vaginal cancer was published in 2015 in Japanese. The JSGO committee decided to publish the English version of the JSGO guidelines worldwide, and hope it will be a useful guide to physicians in a similar situation as in Japan. The guideline was created according to the basic principles in creating the guidelines of JSGO. The guidelines consist of five chapters and five algorithms. Prior to the first chapter, basic items are described including staging classification and history, classification of histology, and definition of the methods of surgery, radiation, and chemotherapy to give the reader a better understanding of the contents of the guidelines for these rare tumors. The first chapter gives an overview of the guidelines, including the basic policy of the guidelines. The second chapter discusses vulvar cancer, the third chapter discusses vaginal cancer, and the fourth chapter discusses vulvar Paget's disease and malignant melanoma. Each chapter includes clinical questions, recommendations, backgrounds, objectives, explanations, and references. The fifth chapter provides supplemental data for the drugs that are mentioned in the explanation of clinical questions. Overall, the objective of these guidelines is to clearly delineate the standard of care for vulvar and vaginal cancer with the goal of ensuring a high standard of care for all women diagnosed with these rare diseases. (Keyword) Female / Humans / Japan / Middle Aged / Paget Disease, Extramammary / Vaginal Neoplasms / Vulvar Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-017-1193-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29159773 ● Summary page in Scopus @ Elsevier: 2-s2.0-85034589264 (DOI: 10.1007/s10147-017-1193-z, PubMed: 29159773, Elsevier: Scopus)
47.	Hitoshi Ikushima, Wakatsuki Masaru, Ariga Takuro, Kaneyasu Yuko, Tokumaru Sunao, Isohashi Fumiaki, Ii Noriko, Uno Takashi, Ohno Yatsuya, Kokichi Arisawa and Toita Takafumi : Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group, International Journal of Clinical Oncology, 1-7, 2017. (Summary) Our aim was to assess the patterns of practice and treatment outcomes of definitive radiotherapy (RT) for vaginal cancer in Japan. RT methods and outcomes of patients with vaginal cancer treated with definitive RT or chemoradiotherapy at 10 institutes of the Japanese Radiation Oncology Study Group between January 2000 and March 2010 were retrospectively evaluated. A total of 90 patients were enrolled in the study. The clinical stages were I, II, III, and IVA in 34, 36, 16, and 4 patients, respectively. Seventy patients were treated with three-dimensional conformal RT (3DCRT) and brachytherapy (BT), 12 with BT alone, and 8 with 3DCRT alone. Chemotherapy was administered to 29 patients. The 5-year overall survival and local control rates were 77 and 83% with a median follow-up period of 94 months for surviving or lost patients. The 5-year overall survival rates according to stage were 94, 71, 56, and 75% for stages I, II, III, and IVA, respectively. The 5-year local control rates according to stage were 94, 77, 74, and 75% for stages I, II, III, and IVA, respectively. Twenty-nine percent (6 of 21 patients) of local recurrences occurred between 5 and 10 years after RT. The 10-year local control rate of all patients was 71%. Significant prognostic factors for overall survival by univariate and multi-variate analyses were performance status, tumor size, and pelvic lymph node metastasis. Grade 3 late radiation morbidity of the rectum, pelvic bone, urinary bladder, and skin developed in 9% (8 of 90 patients). Good outcomes similar to those of cervical cancer can be achieved with definitive RT delivered by 3DCRT and/or BT for vaginal cancer. Long follow-up is necessary for a continuing risk of local recurrence after 5 years. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-017-1205-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29086206 ● Search Scopus @ Elsevier (PMID): 29086206 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-017-1205-z (DOI: 10.1007/s10147-017-1205-z, PubMed: 29086206)
48.	Hidehisa Mori, Tomoharu Fukumori, KEI DAIZUMOTO, MEGUMI TSUDA, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Predictive Factors for Prolonged Urination Disorder After Permanent 125I Brachytherapy for Localized Prostate Cancer, In Vivo, Vol.31, No.4, 755-761, 2017. (Summary) We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder. Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution. In cases with prostate volume more than 30 cm, radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment. On multivariate analysis, baseline IPSS more than 8 points and D90 more than 160 Gy were significant predictors for delayed IPSS resolution. Our data suggest that higher baseline IPSS and higher D90 were predictors for prolonged urination disorder. (Keyword) Aged / Aged, 80 and over / Brachytherapy / Humans / Iodine Radioisotopes / male / Middle Aged / Prostate / Prostate-Specific Antigen / Prostatic Neoplasms / Urination Disorders (Tokushima University Institutional Repository) ● Metadata: 113626 (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28652453 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028539877 (Tokushima University Institutional Repository: 113626, DOI: 10.21873/invivo.11127, PubMed: 28652453, Elsevier: Scopus)
49.	Motoharu Sasaki, Masahide Tominaga, Kamomae Takeshi, Hitoshi Ikushima, Kitaoka Motonori, Bando Ryota, Kanako Sakuragawa and Masataka Oita : Influence of multi-leaf collimator leaf transmission on head and neck intensity-modulated radiation therapy and volumetric-modulated arc therapy planning., Japanese Journal of Radiology, Vol.35, No.9, 511-525, 2017. (Summary) The aim of this study was to quantify the effect of multi-leaf collimators (MLCs) with different leaf widths on the planning of intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT). Toward this objective, dose transmission through a high-definition 120-leaf MLC (HD120MLC) and 120-leaf Millennium MLC (M120MLC) was investigated, using it with a test case and clinical case studies. In test case, studies with IMRT and VMAT plans, the difference in MLC leaf width had a limited effect on planning target volumes (PTVs). Organs at risk (OARs) were more affected by a reduction in dose transmission through the MLC than by a reduction in MLC leaf width. The results of the test case studies and clinical case studies were mostly similar. In the latter, the different MLCs had no effect on the PTV regardless of the treatment method; however, the HD120MLC plans achieved dose reductions to OARs similar to or larger than the dose reduction of the M120MLC plans. The similar results of the test case and clinical case studies showed that despite a limitation of the irradiation field size, the HD120MLC plans were superior. (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-017-0661-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28647834 ● Summary page in Scopus @ Elsevier: 2-s2.0-85021229873 (DOI: 10.1007/s11604-017-0661-8, PubMed: 28647834, Elsevier: Scopus)
50.	Takaharu Kudoh, Hitoshi Ikushima, Keiko Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Natsumi Takamaru, Tetsuya Tamatani and Youji Miyamoto : Effectiveness of Newly Developed Water-Equivalent Mouthpiece during External Beam Radiotherapy for Oral Cancer, Ann Carcinog, Vol.2, No.1, 2017. (Tokushima University Institutional Repository) ● Metadata: 113606 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570009752882329984 (Tokushima University Institutional Repository: 113606, CiNii: 1570009752882329984)
51.	T Ohno, M Wakatsuki, T Toita, Y Kaneyasu, K Yoshida, S kato, N Li, S Tokumaru, Hitoshi Ikushima, T Uno, SE Noda, T kazumoto and Y harima : Recommendations for high-risk clinical target volume definition with comp@uted tomography for three-dimensional image-guided brachytherapy in cervical cancer patients., Journal of Radiation Research, Vol.58, No.3, 341-350, 2016. (Summary) Our purpose was to develop recommendations for contouring the computed tomography (CT)-based high-risk clinical target volume (CTVHR) for 3D image-guided brachytherapy (3D-IGBT) for cervical cancer. A 15-member Japanese Radiation Oncology Study Group (JROSG) committee with expertise in gynecological radiation oncology initiated guideline development for CT-based CTVHR (based on a comprehensive literature review as well as clinical experience) in July 2014. Extensive discussions occurred during four face-to-face meetings and frequent email communication until a consensus was reached. The CT-based CTVHR boundaries were defined by each anatomical plane (cranial-caudal, lateral, or anterior-posterior) with or without tumor progression beyond the uterine cervix at diagnosis. Since the availability of magnetic resonance imaging (MRI) with applicator insertion for 3D planning is currently limited, T2-weighted MRI obtained at diagnosis and just before brachytherapy without applicator insertion was used as a reference for accurately estimating the tumor size and topography. Furthermore, utilizing information from clinical examinations performed both at diagnosis and brachytherapy is strongly recommended. In conclusion, these recommendations will serve as a brachytherapy protocol to be used at institutions with limited availability of MRI for 3D treatment planning. (Tokushima University Institutional Repository) ● Metadata: 115538 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rrw109 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27837120 ● Search Scopus @ Elsevier (PMID): 27837120 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rrw109 (Tokushima University Institutional Repository: 115538, DOI: 10.1093/jrr/rrw109, PubMed: 27837120)
52.	T Sato, K Hayakawa, M Noda, N Kamikonya, T Wanatabe, D Kato, Y Sakai, M Hiraoka, M Shimada, Hitoshi Ikushima, H Baba, N Oya, K Nemoto-Murofushi, M Takeuchi and M Watanabe : A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)., Radiotherapy and Oncology, Vol.120, No.2, 222-227, 2016. (Summary) Preoperative 5-fluorouracil-based chemoradiotherapy is a standard treatment for locally advanced lower rectal cancer (LALRC). We performed a phase I study to develop a new regimen combining irinotecan and S-1. Patients with LALRC (T3-4, N0-2) were studied. The radiation dose was 45Gy in 25 fractions. S-1 (80mg/m(2)/day) was administered on days 1-5, 8-12, 22-26, and 29-33. Irinotecan was administered on days 1, 8, 22, and 29. The dose of irinotecan was initially 60mg/m(2) (level 1). Surgery was performed 6-10weeks after the chemoradiotherapy. Twenty patients were enrolled, of whom 18 patients were analyzed. Dose-limiting toxicity (DLT) did not occur in the first 3 patients treated with irinotecan at 80mg/m(2) (level 2), but developed in 3 of the 6 patients who received irinotecan at 90mg/m(2) (level 3). Then DLT occurred in 3 other patients at level 2. At level 2 or 3, DLT comprised neutropenia, thrombocytopenia, and diarrhea. Level 2 was designated as the maximum tolerated dose, and level 1 as a recommended dose (RD). The pathological complete response rate was 28%, and the down-staging rate was 56%. Our results suggested that the RD of irinotecan when combined with preoperative S-1 and pelvic radiation was 60mg/m(2). (Tokushima University Institutional Repository) ● Metadata: 115706 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.radonc.2016.06.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27317556 ● Search Scopus @ Elsevier (PMID): 27317556 ● Search Scopus @ Elsevier (DOI): 10.1016/j.radonc.2016.06.002 (Tokushima University Institutional Repository: 115706, DOI: 10.1016/j.radonc.2016.06.002, PubMed: 27317556)
53.	Hirokazu Ogino, Masaki Hanibuchi, Hiromitsu Takizawa, Shoji Sakiyama, Sumitomo Hiroyuki, Seiji Iwamoto, Hitoshi Ikushima, Nakajima Kohei, Shinji Nagahiro, Yamago Taito, Yuko Toyoda, Yoshimi Bando and Yasuhiko Nishioka : Primary Pulmonary Synovial Sarcoma Showing a Prolonged Survival with Multimodality Therapy, Internal Medicine, Vol.55, No.4, 381-387, 2016. (Summary) A 54-year-old man was referred to our hospital due to a mass shadow noted on a chest X-ray. Thoracoscopic lobectomy yielded a diagnosis of primary pulmonary synovial sarcoma according to the histology and SYT-SSX1 gene analyses. Five months after the thoracic surgery, he developed brain metastasis; therefore, we performed resection of the brain metastatic focus followed by radiotherapy. As a local recurrence in the thoracic cavity concurrently emerged, systemic chemotherapy was also administered. These observations indicated that a multidisciplinary approach may be useful against primary pulmonary synovial sarcoma, although there is presently no established therapeutic strategy due to its rarity and highly aggressive nature. (Tokushima University Institutional Repository) ● Metadata: 114387 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.55.5169 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26875964 ● Search Scopus @ Elsevier (PMID): 26875964 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.55.5169 (Tokushima University Institutional Repository: 114387, DOI: 10.2169/internalmedicine.55.5169, PubMed: 26875964)
54.	Motoharu Sasaki, Hitoshi Ikushima, Masahide Tominaga, T Kamomae, T Kishi, Masataka Oita and Masafumi Harada : Dose impact of rectal gas on prostatic IMRT and VMAT, Japanese Journal of Radiology, Vol.33, No.12, 723-733, 2015. (Summary) In this study, we compared the dose impact of the heterogeneity caused by rectal gas using two methods of treatment planning for intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT). In addition to the structure set used for the standard treatment plan, we created a structure set for evaluation for each patient. These sets were transferred to the same isocenter as the respective treatment plans for IMRT and VMAT that were to become the standard. Values were then recalculated. During the standard prostatic IMRT and VMAT treatment planning, all study participants met dose restrictions in place at our hospital. Dose restrictions were fulfilled in treatment plans for evaluation, excluding those with a clinical target volume (CTV) of V(100%) and planning target volume (PTV) of D95 when the rectum was excluded. However, in treatment plans for evaluation, IMRT was shown to have a higher concordance rate with standard treatment plans than VMAT. If rectal gas is present during either IMRT or VMAT, a dose decrease will occur in relation to CTV and PTV, suggesting that a plan does not eliminate adverse effects on organs at risk. (Tokushima University Institutional Repository) ● Metadata: 109667 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-015-0481-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26573828 ● Search Scopus @ Elsevier (PMID): 26573828 ● Search Scopus @ Elsevier (DOI): 10.1007/s11604-015-0481-7 (Tokushima University Institutional Repository: 109667, DOI: 10.1007/s11604-015-0481-7, PubMed: 26573828)
55.	Tomokazu Senzaki, Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy., Urologia Internationalis, Vol.95, No.4, 457-464, 2015. (Summary) The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥ 6 months in patients with localized prostate cancer. A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥ 6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥ 6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) < 180 Gy, neoadjuvant CAB exerted a favorable impact on BRFR (p = 0.0429). On multivariate analyses, neoadjuvant CAB and D90 were independent predictors of BRFR (p = 0.0061 and p < 0.0001, respectively). Neoadjuvant CAB for ≥ 6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90. (Link to Publication Site) ● Publication site (DOI): 10.1159/000439573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26461847 ● Search Scopus @ Elsevier (PMID): 26461847 ● Search Scopus @ Elsevier (DOI): 10.1159/000439573 (DOI: 10.1159/000439573, PubMed: 26461847)
56.	Takahiro Goji, Tetsuo Kimura, Hiroshi Miyamoto, Masanori Takehara, kaizo Kagamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, Sayo Matsumoto, Toshi Takaoka, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Masahiro Sogabe, Naoki Muguruma, Toshiya Okahisa, Yasuhiro Sato, Tamotsu Sagawa, Koji Fujikawa, Yasushi Sato, Hitoshi Ikushima and Tetsuji Takayama : A Phase I/II Study of Fixed-dose-rate Gemcitabine and S-1 with Concurrent Radiotherapy for Locally Advanced Pancreatic Cancer, Cancer Chemotherapy and Pharmacology, Vol.76, No.3, 615-620, 2015. (Summary) This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28 fractions) was delivered concurrently. Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300 mg/m(2) of gemcitabine and 60 mg/m(2) of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rates were 16.0 months and 73%, respectively. The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC. (Tokushima University Institutional Repository) ● Metadata: 110046 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-015-2835-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26220846 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939568942 (Tokushima University Institutional Repository: 110046, DOI: 10.1007/s00280-015-2835-3, PubMed: 26220846, Elsevier: Scopus)
57.	D Gomez, R Komaki, J Yu, Hitoshi Ikushima and A Bezjak : Radiation therapy definitions and reporting guidelines for thymic malignancies, Chinese Journal of Lung Cancer, Vol.17, No.2, 110-115, 2014. (Keyword) Thymic malignancies / Radiation therapy (Link to Publication Site) ● Publication site (DOI): 10.3779/j.issn.1009-3419.2014.02.08 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24581161 ● Search Scopus @ Elsevier (PMID): 24581161 ● Search Scopus @ Elsevier (DOI): 10.3779/j.issn.1009-3419.2014.02.08 (DOI: 10.3779/j.issn.1009-3419.2014.02.08, PubMed: 24581161)
58.	Youichi Otomi, Hideki Otsuka, Kaori Terazawa, Hayato Nose, Michiko Kubo, Kenji Matsuzaki, Hitoshi Ikushima, Yoshimi Bando and Masafumi Harada : Comparing the performance of visual estimation and standard uptake value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography for detecting malignancy in pancreatic tumors other than invasive ductal carcinoma., The Journal of Medical Investigation : JMI, Vol.61, No.1-2, 171-179, 2014. (Summary) The utility of FDG PET/CT for the detection and evaluation of invasive ductal carcinoma has been widely reported, but a few studies have assessed the utility of FDG PET/CT to detect malignancy in a variety of pancreatic lesions other than invasive ductal carcinoma. To compare the diagnostic performance of visual estimation with the semi-quantitative scores of FDG PET/CT for detecting malignancy in a variety of pancreatic lesions other than invasive ductal carcinoma. Images of pathologically proven pancreatic lesions from 32 patients were retrospectively evaluated: 14 benign lesions, 7 borderline (low malignant) lesions, and 11 malignant lesions. The average scores from visual estimation by the two observers were compared to two semi-quantitative analyses of FDG uptake in the lesions, namely the maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean). Visual analysis value, SUVmax and SUVmean were 0.33 ± 0.21, 1.8 ± 0.7 and 1.5 ± 0.7 for the benign lesions, 0.70 ± 0.28, 5.0 ± 2.6 and 3.1±1.7 for the borderline lesions, and 0.73 ± 0.18, 4.7 ± 2.5 and 3.2 ± 1.6 for the malignant lesions, respectively. Receiver operating characteristic analysis revealed the areas under the curves for detecting non-benign (malignant or borderline) lesions through visual analysis, SUVmax, and SUVmean were 0.914, 0.954, and 0.875, respectively. For a variety of pancreatic lesions other than invasive ductal carcinoma, visual analysis and semi-quantitative analyses all showed strong diagnostic performance. However, semi-quantitative analysis with SUVmax proved to be the most effective method for detecting non-benign pancreatic lesions. (Tokushima University Institutional Repository) ● Metadata: 106141 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.171 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705763 ● Search Scopus @ Elsevier (PMID): 24705763 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.61.171 (Tokushima University Institutional Repository: 106141, DOI: 10.2152/jmi.61.171, PubMed: 24705763)
59.	Motoharu Sasaki, Masahide Tominaga, t Kamomae, Hitoshi Ikushima, T Kishi, T Kawashita, A Tada, M Shigemitsu and Masataka Oita : Clinical evaluation of automatic contours for head and neck region using deformable image registration software, Japanese Journal of Radiological Technology, Vol.69, No.11, 1250-1260, 2013. (Summary) The purpose of this study was to clinically evaluate the automatic outline extraction properties using general-purpose deformable image registration (DIR) software for the head and neck region. To this end, we evaluated the following: (1) the difference between manual outline extraction carried out by a radiation therapy specialist and automatic outline extraction using the DIR software, and (2) the precision of the automatic outline extraction for the diachronic figure change and change in the organ shape. The manually-extracted outline and that extracted using the DIR software closely resembled each other at 0.70. Further, in the same case, the automatic outline extraction precision of the DIR software was greater at about 0.80. Our findings suggest DIR software to be useful for lessening the work involved in outline extraction. (Keyword) deformable image registration (DIR) / auto-segmentation / head and neck (Link to Publication Site) ● Publication site (DOI): 10.6009/jjrt.2013_JSRT_69.11.1250 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24256648 ● CiNii @ National Institute of Informatics (CRID): 1390001206363278720 ● Summary page in Scopus @ Elsevier: 2-s2.0-84896689742 (DOI: 10.6009/jjrt.2013_JSRT_69.11.1250, PubMed: 24256648, CiNii: 1390001206363278720, Elsevier: Scopus)
60.	Motoharu Sasaki, Hitoshi Ikushima, Y Nakaguchi, T Kishi, M Kimura, R Bandou and M Oita : A comparison of four commercial radiation treatment planning systems for prostate intensity modulated radiation therapy, Japanese Journal of Radiological Technology, Vol.69, No.7, 761-772, 2013. (Summary) At present, every manufacturer of intensity modulated radiation therapy (IMRT) equipment uses multi-leaf collimators (MLCs); however, each company's intensity modulation methods and dose calculation algorithms differ. This study used four typical radiation treatment planning systems (RTPSs) employed domestically for prostate IMRT plans to carry out 15 case studies by one planner based on the dose limits at this clinic. The results were used to compare the differences, if any, in RTPS treatment plans. With prostate IMRT plans, an overlap area exists between the PTV and the rectum. For this reason, while observing dose limits of 60-75 Gy (within the dose tolerated by the rectum), securing uniformity and concentration of dose is essential to create the most appropriate treatment plan for the PTV and other targets. Although each RTPS uses different planning methods, it was generally possible to observe this clinic's dose limits by adjusting the parameter values. When identical beam data is used, it is possible to create similar treatment plans. (Keyword) Algorithms / Humans / Male / Prostatic Neoplasms / Radiotherapy Planning, Computer-Assisted / Radiotherapy, Intensity-Modulated (Link to Publication Site) ● Publication site (DOI): 10.6009/jjrt.2013_JSRT_69.7.761 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23877154 ● Search Scopus @ Elsevier (PMID): 23877154 ● Search Scopus @ Elsevier (DOI): 10.6009/jjrt.2013_JSRT_69.7.761 (DOI: 10.6009/jjrt.2013_JSRT_69.7.761, PubMed: 23877154)
61.	Bado Ryota, Hitoshi Ikushima, Takashi Kawanaka, Takaharu Kudoh, Motoharu Sasaki, Masahide Tominaga, Taro Kishi, Shunsuke Furutani, Akiko Kubo and Koichi Tamura : Changes of tumor and normal structures of the neck during radiation therapy for head and neck cancer requires adaptive strategy., The Journal of Medical Investigation : JMI, Vol.60, No.1,2, 46-51, 2013. (Summary) The treatment period over which radiation therapy is administered extends over several weeks. Since tumor shrinkage in response to radiation therapy and weight loss due to radiation-induced mucositis may impact on the dose distribution in both target and organ at risk in patients with head and neck cancer, the anatomical changes of tumor and neck volumes during this period should be taken into consideration. We investigated the anatomical changes that occurred in the target and normal structure of the neck during radiation therapy for pharyngeal cancer, and evaluated the necessity of an adaptive strategy. Ten patients with pharyngeal cancer who underwent radical chemoradiation therapy using 3-dimensional conformal radiation therapy RT (66-70 Gy in 33-35 fractions) between April 2009 and September 2010 were enrolled in the study. Patients underwent CT scans every week during their course of treatment. We analyzed the CT data in the radiation treatment planning system and measured changes of tumor, organ at risk, and neck volume. Gross tumor volume (GTV) was rapidly reduced by 28% of the original volume on average in the first 3 weeks. The right and left submandibular glands volume decreased to 70% and 63% of their initial volumes on average, respectively. The volume of the neck in the radiation fields decreased to 89% of its initial volume on average by the sixth week mainly caused by body weight loss due to acute radiation morbidity. Considerable anatomical change in the radiation filed that will affect dose distribution of the target and organ at risk was observed during radiation therapy for head and neck cancer. (Keyword) adaptive strategy / chemoradiotherapy / head and neck cancer (Tokushima University Institutional Repository) ● Metadata: 106041 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.46 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614911 ● Search Scopus @ Elsevier (PMID): 23614911 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.46 (Tokushima University Institutional Repository: 106041, DOI: 10.2152/jmi.60.46, PubMed: 23614911)
62.	Yoshihiro Tanaka, Hitoshi Ikushima, Kazuya Kondo, Koichiro Kenzaki, Yoshimi Bando, Youichi Otomi and Hiroshi Maezawa : The value of diagnostic imaging in neoadjuvant chemoradiation therapy for non-small cell lung cancer, Japanese Journal of Clinical Radiology, Vol.58, No.1, 222-228, 2013. (Keyword) 非小細胞肺癌 / 術前導入化学放射線療法 / 癌画像診断 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522825130745084544 ● Summary page in Scopus @ Elsevier: 2-s2.0-84873164822 (CiNii: 1522825130745084544, Elsevier: Scopus)
63.	Takaharu Kudoh, Hitoshi Ikushima and Eiichi Honda : Shielding Effect of a Customized Intraoral Mold Including Lead Material in High-dose-rate 192-Ir Brachytherapy for Oral Cavity Cancer., Journal of Radiation Research, Vol.53, No.1, 130-137, 2012. (Summary) A high-dose-rate (HDR) 192-Ir brachytherapy using a customized intraoral mold is effective for superficial oral cavity cancer, and the surrounding normal tissue is kept away from the radioactive source with gauze pads and/or mouth piece for reducing the dose on the normal tissues. In the Tokushima university hospital, the mold has a lead shield which utilizes the space prepared with sufficient border-molding by a specific dental technique using modeling compound. In HDR 192-Ir brachytherapy using a lead shielded customized intraoral mold, there are no reports measuring the absorbed dose. The purpose of the present study is to measure the absorbed dose and discuss the optimum thickness of lead in HDR 192-Ir brachytherapy using a customized intraoral mold with lead shield using a 1 cm thickness mimic mold. The thickness of lead in the mold could be changed by varying the arrangement of 0.1 cm thickness sheet of the acrylic resin plate and lead. The measured doses at the lateral surface of the mold with thermo-luminescence dosimeter were reduced to 1.12, 0.79, 0.57, 0.41, 0.31, 0.24 and 0.19 Gy and the ratios to the prescription dose were reduced to 56, 40, 29, 21, 16, 12 and 10 percent as lead thickness increased from 0 to 0.6 cm in 0.1 cm increments, respectively. A 0.3 cm thickness lead was considered to be required for a 1 cm thickness mold, and it was necessary to thicken the lead as much as possible with the constraint of limited space in the oral cavity, especially at the fornix vestibule. (Keyword) Absorption / Acrylic Resins / Agar / Brachytherapy / Dental Impression Materials / Dose Fractionation / Dose-Response Relationship, Radiation / Equipment Design / Humans / Iridium Radioisotopes / Lead / Materials Testing / Mouth Neoplasms / Mouth Protectors / Organs at Risk / Radiation Injuries / Radiation Protection / Radiometry / Radiotherapy Dosage (Link to Publication Site) ● Publication site (DOI): 10.1269/jrr.11102 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22223463 ● CiNii @ National Institute of Informatics (CRID): 1390282680194392704 ● Search Scopus @ Elsevier (PMID): 22223463 ● Search Scopus @ Elsevier (DOI): 10.1269/jrr.11102 (DOI: 10.1269/jrr.11102, PubMed: 22223463, CiNii: 1390282680194392704)
64.	K Kishi, T Sonomura, S Shirai, Y Noda, M Sato, Hitoshi Ikushima and RJ Oh : Reirradiation of paraaortic lymph node metastasis by brachytherapy with hyaluronate injection via paravertebral approach: With DVH comparison to IMRT., Brachytherapy, Vol.12, No.1, 8-13, 2011. (Summary) PURPOSE/INTRODUCTION: To safely irradiate retroperitoneal targets as paraaortic lymph node by separating abdominal at-risk organs from the target during irradiation, we created a percutaneous paravertebral approach of high-dose-rate brachytherapy with hyaluronate gel injection (HGI). We report a case treated with this technique. We encountered a patient with symptomatic regrowth of paraaortic lymph node metastasis from prostatic cancer. He had previously received 58.4Gy of radiotherapy to the same region 12 months prior. Brachytherapy needles and a HGI needle were deployed via the paravertebral approach under local anesthesia at our outpatient clinic. A single dose of 22.5Gy (equivalent to 60.94Gy in 2Gy per fraction schedule calculated at α/β=10) was delivered to the target, with preservation of the surrounding small intestine by HGI with D(2cc) (minimum dose to the most irradiated volume of 2mL) of 5.05Gy. Therapeutic ratio was 3.64 times higher for this brachytherapy plan compared with an intensity-modulated radiation therapy plan. At followup at 1 year after brachytherapy, the symptoms had disappeared, tumor size had reduced with no fluorodeoxyglucose accumulation, and prostate-specific antigen level had decreased. We consider that high-dose-rate brachytherapy with the HGI procedure offers effective treatment even in this type of reirradiation situation. (Keyword) Aged / Brachytherapy / Humans / Hyaluronic Acid / Lymphatic Metastasis / Male / Neoplasm Recurrence, Local / Prostatic Neoplasms / Radiation Injuries / Radiation Protection / Radiotherapy, Conformal / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.brachy.2011.12.004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22209390 ● Search Scopus @ Elsevier (PMID): 22209390 ● Search Scopus @ Elsevier (DOI): 10.1016/j.brachy.2011.12.004 (DOI: 10.1016/j.brachy.2011.12.004, PubMed: 22209390)
65.	D Gomez, R Komaki, J Yu, Hitoshi Ikushima and A Bezjak : Radiation therapy definitions and reporting guidelines for thymic malignancies., Journal of Thoracic Oncology, Vol.6, No.3, S1743-1748, 2011. (Keyword) Humans / Practice Guidelines as Topic / Radiotherapy Planning, Computer-Assisted / Radiotherapy, Intensity-Modulated / Terminology as Topic / Thymus Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1097/JTO.0b013e31821ea60c (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21847057 ● Search Scopus @ Elsevier (PMID): 21847057 ● Search Scopus @ Elsevier (DOI): 10.1097/JTO.0b013e31821ea60c (DOI: 10.1097/JTO.0b013e31821ea60c, PubMed: 21847057)
66.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 中間リスク群，高リスク群前立腺癌に対するI-125密封小線源療法の治療成績, Japanese Journal of Endourology, Vol.24, No.1, 131-135, 2011. (Keyword) prostate cancer / brachytherapy / risk group classification (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205509858560 (CiNii: 1390001205509858560)
67.	Motoharu Sasaki, Masahide Tominaga, Hitoshi Ikushima, 岸太郎, 川下徹也, Yasuo Hara, 福永有希子, Masashi Kimura, Yasufumi Shitakubo, Satoru Takashi and Masataka Oita : Impact of multileaf collimator leaf positioning accuracy on intensity modulated radiation therapy., Japanese Journal of Radiological Technology, Vol.67, No.5, 497-506, 2011. (Summary) In multileaf collimator (MLC)-based intensity modulated radiation therapy (IMRT), the dose is influenced by the uncertainty of MLC driving control. In this study, we examined the influence of MLC driving control accuracy on dose evaluation (gamma analysis) by evaluating 60-day MLC driving control accuracy (stationary positioning accuracy and positioning reproducibility) once a week as well as measuring IMRT dose distribution. The MLC positioning accuracy accompanied variation over time and tended to expand by 0.1 to 0.15 mm in one week and about 1 mm in 60 days. In terms of reproducibility, errors were within 0.2 mm for more than 95%. For prostate IMRT, when MLC stationary positioning accuracy was around 1 mm, no significant difference was observed in the pass rate in gamma analysis. Therefore, the results suggest that regular maintenance by setting a permissible value determined by the MLC positioning accuracy test can be an effective indicator in the future for maintaining the safety of IMRT. (Keyword) multileaf collimator / positioning error / intensity modulated radiation therapy / dose distribution (Link to Publication Site) ● Publication site (DOI): 10.6009/jjrt.67.497 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21666373 ● CiNii @ National Institute of Informatics (CRID): 1390282681337851008 ● Summary page in Scopus @ Elsevier: 2-s2.0-84863934579 (DOI: 10.6009/jjrt.67.497, PubMed: 21666373, CiNii: 1390282681337851008, Elsevier: Scopus)
68.	Motoharu Sasaki, Masahide Tominaga, Hitoshi Ikushima, 岸太郎, 川下徹也, 原康男, 福永有希子, Kenji Yamada, Masataka Oita and Hiromu Nishitani : 強度変調放射線治療におけるradiographic filmと radiochromic filmの比較評価, Japanese Journal of Radiological Technology, Vol.66, No.5, 525-534, 2010. (Summary) Purpose: Radiographic film is generally used for inspection of dose distribution in intensity modulated radiation therapy (IMRT) at many institutions. However, the distribution of filmless systems can be expected to be used increasingly in the future. Therefore, we confirmed the utility of radiochromic film by comparing it with radiographic film that does not need an automatic processor. Result: Difference in does measured by radiographic film and radiochromic film tended to increase in the low does area, but it was limited in a range of 1.5%. Conclusion: When the dose distribution was verified in a highly accurate radiation therapy such as IMRT, the results suggested that radiochromic film can be useful in addition to radiographic film. (Keyword) radiochromic film / radiochromic film / dose distribution / dose distribution / intensity-modulated radiation therapy / intensity-modulated radiation therapy / radiographic film / radiographic film (Link to Publication Site) ● Publication site (DOI): 10.6009/jjrt.66.525 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001206361620480 ● Summary page in Scopus @ Elsevier: 2-s2.0-77955931427 (DOI: 10.6009/jjrt.66.525, CiNii: 1390001206361620480, Elsevier: Scopus)
69.	Hitoshi Ikushima, P Balter, R Komaki, S Hunjun, MK Bucci, Z Liao, MF Mcaleer, ZH Yu, Y Zhang, JY Chang and L Dong : Daily Alignment Results of In-Room Computed Tomography-Guided Stereotactic Body Radiation Therapy for Lung Cancer, International Journal of Radiation OncologyBiologyPhysics, Vol.79, No.2, 473-480, 2010. (Summary) To determine the extent of interfractional setup errors and day-to-day organ motion errors by assessing daily bone alignment results and changes in soft tissue tumor position during hypofractionated, in-room computed tomography (CT)-guided stereotactic body radiation therapy (SBRT) of lung cancer. Daily alignment results during SBRT were analyzed for 117 tumors in 112 patients. Patients received 40-50 Gy of SBRT in four to five fractions using an integrated CT-LINAC system. The free-breathing CT scans acquired during treatment setup were retrospectively realigned to match with each of the bony references and the gross tumor volume (GTV) defined on the reference CT by rigid-body registration, and the daily deviations were calculated. The mean magnitude (± SD) three-dimensional shift from the initial skin marks to the final bone-aligned positions was 9.4 ± 5.7 mm. The mean daily GTV deviation from the bone position was 0.1 ± 3.8 mm in the anterior-posterior direction, -0.01 ± 4.2 mm in the superior-inferior direction, and 0.2 ± 2.5 mm in the lateral direction. A clinically noteworthy trend (net change >5 mm in any direction) in GTV position relative to the bone was observed in 23 cases (20%). Soft tissue target position can change significantly beyond the motion envelope defined in the original internal target volume in four-dimensional CT-based treatment planning for SBRT of lung cancer. Additional margin should be considered for adequate coverage of interfractional changes. (Keyword) Bone and Bones / Carcinoma, Non-Small-Cell Lung / Dose Fractionation / Female / Humans / Lung Neoplasms / Male / Movement / Radiosurgery / Radiotherapy, Computer-Assisted / Reproducibility of Results / Retrospective Studies / Time Factors / Tomography, X-Ray Computed / Tumor Burden (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijrobp.2009.11.009 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20399032 ● Search Scopus @ Elsevier (PMID): 20399032 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijrobp.2009.11.009 (DOI: 10.1016/j.ijrobp.2009.11.009, PubMed: 20399032)
70.	Hitoshi Ikushima, L Dong, J Erasmus, P Allen, MF Macaleer, Y Zhuang, R Sasaki and R Komaki : Predictive Value of 18F-Fluorodeoxyglucose Uptake by Positron Emission Tomography for Non-Small Cell Lung Cancer Patients Treated with Radical Radiotherapy, Journal of Radiation Research, Vol.51, No.4, 465-471, 2010. (Summary) The purpose of this study is to assess predictive value of the positron emission tomography (PET) with 18F-fluoro-deoxyglucose (FDG) for recurrence and survival after radiotherapy (RT) for non-small cell lung cancer (NSCLC). One hundred forty-nine patients underwent pretreatment PET (n = 67) or PET/computed tomography (CT) (n = 82) and definitive RT for NSCLC. We evaluated the relationship between the maximum-pixel standardized uptake value (SUV(max)) and clinical tumor features. Univariate Cox proportional hazard analysis (UVA) was used to quantify the risk for local-regional recurrence, distant metastases, and death. Multivariate Cox proportional hazard analysis (MVA) was used to assess the potential independent effect of SUV(max). In the PET group, T1 tumors showed significantly lower SUV(max) than T2, T3, and T4 tumors; in the PET/CT group, T1 tumors showed significantly lower SUV(max) than T3 and T4 tumors. A high SUV(max )was a negative factor for local-regional control (LRC) (p < 0.001), distant metastasis-free survival (DMFS) (p = 0.02), and overall survival (OS) (p = 0.001) on UVA in the PET group. However, the significance decreased to 0.05 for LRC, 0.04 for DMFS, and 0.04 for OS by MVA when tumor size was included in the analysis. A high SUV(max) was not a negative factor for LRC, DMFS, or OS on UVA and MVA in the PET/CT group. In conclusion, assessment of predictive value of SUV(max) for NSCLC requires consideration of primary tumor size, and the evidence is not sufficient to suggest that FDG uptake in a primary NSCLC provides prognostic information. (Keyword) Adult / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Female / Fluorine Radioisotopes / Fluorodeoxyglucose F18 / Humans / Kaplan-Meier Estimate / Lung Neoplasms / Male / Middle Aged / Neoplasm Staging / Positron-Emission Tomography / Predictive Value of Tests / Prognosis / Proportional Hazards Models / Radiopharmaceuticals / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1269/jrr.10024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20508373 ● Search Scopus @ Elsevier (PMID): 20508373 ● Search Scopus @ Elsevier (DOI): 10.1269/jrr.10024 (DOI: 10.1269/jrr.10024, PubMed: 20508373)
71.	Y Kishida, Hitoshi Ikushima, Motoharu Sasaki, Y Hara, M Oita and Hiromu Nishitani : Use of a diagnostic positron emission tomography-computed tomography system for planning radiotherapy positioning: distortion of the tabletop., Japanese Journal of Radiology, Vol.28, No.2, 143-148, 2010. (Summary) The aim of this study was to evaluate distortion of the tabletop in a diagnostic positron emission tomography-computed tomography (PET-CT) system to determine its suitability for planning radiotherapy positioning. Distortion of the tabletop was compared among PET-CT, lineac CT, and CT simulator systems. A phantom or angiography catheter was fixed to the tabletop and imaged after iron plate weight loading. The acquired images were analyzed using radiotherapy planning software. Distortion of the tabletop was measured based on the displayed coordinates. Sinking represented the greatest distortion of the tabletop in all systems. Using the same baseline, the maximum sinking were -0.4, -0.2, and +0.4 cm, respectively. The distortion of the tabletop in the PET-CT system was more similar to that in the lineac CT than in the CT simulator system. Distortion of the tabletop in a diagnostic PET-CT system may be within the acceptable range to allow its use for planning radiotherapy positioning. (Keyword) Image Processing, Computer-Assisted / Perceptual Distortion / Phantoms, Imaging / Positron-Emission Tomography / Radiotherapy Planning, Computer-Assisted / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-009-0398-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20182849 ● Search Scopus @ Elsevier (PMID): 20182849 ● Search Scopus @ Elsevier (DOI): 10.1007/s11604-009-0398-0 (DOI: 10.1007/s11604-009-0398-0, PubMed: 20182849)
72.	Hitoshi Ikushima : Radiation therapy: state of the art and the future., The Journal of Medical Investigation : JMI, Vol.57, No.1, 2, 1-11, 2010. (Summary) Technical innovation in radiation therapy (RT) such as stereotactic irradiation, intensity modulated RT, image-guided RT, and brachytherapy using remote controlled after-loading system have made it possible to deliver ideally distributed radiation dose to the target with great accuracy, while sparing the adjacent organs at risk. As a result, tumor control rate by RT improved markedly and became excellent alternative to surgery for asymptomatic or mildly symptomatic brain tumors, early stage lung cancer, and low-risk prostate cancer. In locally advanced stage of cancer, randomized controlled trials established the chemoradiation therapy as a standard treatment option for patients with head and neck cancer, lung cancer, esophageal cancer, and cervical cancer. RT is also a valuable treatment for palliation of local symptoms caused by cancer with consistently high response rates. Minimally invasive therapy has come to be emphasized its needs in the background of increased tendency of elderly patients with cancer, and advances in conformal dose delivery technique raise the RT at a more important position in cancer therapy. However, adequate number of RT profession is indispensable to utilize highly-sophisticated RT technology. Substantiality of an education system for radiation oncologist, RT technologist, and medical physicists is our current most important issue. (Keyword) Humans / Neoplasms / Palliative Care / Radiosurgery / Radiotherapy / Radiotherapy, Conformal / Radiotherapy, Intensity-Modulated (Tokushima University Institutional Repository) ● Metadata: 66513 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.57.1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299738 ● CiNii @ National Institute of Informatics (CRID): 1390001204243522048 ● Search Scopus @ Elsevier (PMID): 20299738 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.1 (Tokushima University Institutional Repository: 66513, DOI: 10.2152/jmi.57.1, PubMed: 20299738, CiNii: 1390001204243522048)
73.	Takaharu Kudoh, Hitoshi Ikushima, Keiko Kudoh, Reiko Tokuyama, Kyosuke Osaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Hiromu Nishitani and Eiichi Honda : High-dose-rate brachytherapy for patients with maxillary gingival carcinoma using a novel customized intraoral mold technique., Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, Vol.109, No.2, e102-8, 2010. (Summary) OBJECTIVE: The purpose of this study was to introduce a novel customized intraoral mold treatment for maxillary gingival carcinoma (UGC). STUDY DESIGN: Two patients with UGC were treated as salvage therapy using this technique. The mold was designed to keep normal soft tissues adjacent to the tumor away from the radioactive source as much as possible, and it was shielded by lead. The radiation dose on the buccal mucosa and tongue was measured at the inner and outer surfaces of the intraoral mold before starting high-dose-rate brachytherapy by the remote afterloading system, and was reduced to almost one tenth. RESULTS: The patient had no recurrence and no severe adverse effects on the normal soft tissue adjacent to the tumor until the end of the follow-up period. CONCLUSION: High-dose-rate brachytherapy using the novel customized intraoral mold might be a treatment option of not only salvage therapy, but definitive therapy of UGC. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.tripleo.2009.10.019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20123391 ● Search Scopus @ Elsevier (PMID): 20123391 ● Search Scopus @ Elsevier (DOI): 10.1016/j.tripleo.2009.10.019 (DOI: 10.1016/j.tripleo.2009.10.019, PubMed: 20123391)
74.	Hitoshi Ikushima : -state of the art and in the future-, Shikoku Acta Medica, Vol.65, No.5,6, 155-162, 2009.
75.	Akiko Kubo, Kyosuke Osaki, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiromu Nishitani : Risk factors for radiation pneumonitis caused by whole breast irradiation following breast-conserving surgery., The Journal of Medical Investigation : JMI, Vol.56, No.3,4, 99-110, 2009. (Summary) We evaluated risk factors of radiation pneumonitis (RP) after whole breast irradiation following breast-conserving surgery. Four hundred and seventy-two cases underwent whole breast irradiation with tangential field following breast-conserving surgery in our hospital, between January 2005 and April 2007. Of these cases, we performed statistical analyses for 423 breasts of 413 patients, using a pulmonary dose-volume histogram. Patient characteristics, treatment regimens and irradiation methods were included as variables in the analyses on risk factors of RP. As a result, 89 breasts of 84 cases (21%) were diagnosed with RP. The version 3.0 of the NCI Common Terminology Criteria for Adverse Events was used to evaluate the grade of pneumonitis: 77 cases (18.2%) were diagnosed as Grade 1 RP, 10 cases (2.3%) as Grade 2, and 2 cases (0.5%) as Grade 3. Multivariate analysis indicated that the significant risk factors for RP were central lung distance (CLD) (>1.8 cm) and the short axis length of the radiation field. The incidence of radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome significantly correlated only with CLD. The lung volume within the radiation field was shown to be a significant risk factor for RP and radiation-induced BOOP syndrome. (Keyword) Adult / Aged / Aged, 80 and over / Breast Neoplasms / Combined Modality Therapy / Cryptogenic Organizing Pneumonia / Dose-Response Relationship, Radiation / Female / Humans / Lung / Mastectomy, Segmental / Middle Aged / Postoperative Complications / Radiation Pneumonitis / Risk Factors / Young Adult (Tokushima University Institutional Repository) ● Metadata: 111315 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.56.99 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19763021 ● Search Scopus @ Elsevier (PMID): 19763021 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.56.99 (Tokushima University Institutional Repository: 111315, DOI: 10.2152/jmi.56.99, PubMed: 19763021)
76.	Hitoshi Ikushima, Seiji Iwamoto, Kyohsuke Osaki, Shunsuke Furutani, Kyoh Yamashita, Takashi Kawanaka, Akiko Kubo, Yoshihiro Takegawa, Takaharu Kudoh, Hiroomi Kanayama and Hiromu Nishitani : Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer., Radiation Medicine, Vol.26, No.3, 156-163, 2008. (Summary) PURPOSE: The aim of this study was to evaluate retrospectively the toxicity and response, bladder preservation, and survival of patients with muscle-invasive bladder cancer treated with multimodality therapy consisting of low-dose radiation therapy (RT) and concurrent intraarterial chemotherapy (IACT). METHODS AND MATERIALS:. Between November 1999 and July 2005, a total of 27 consecutive, previously untreated patients with muscle-invasive bladder cancer underwent transurethral bladder tumor resection followed by concurrent low-dose RT and IACT. Patients who achieved a complete response (CR) were followed up closely without further therapy, and patients who did not achieve a CR underwent further treatment. RESULTS: Complete response was achieved in 22 of 27 patients (81%). Of these 22 patients, 7 developed recurrences, and 3 died of their disease. In five patients who did not achieve CR, one died from bone metastases. The 3-year overall survival rate was 81%, with a median follow-up time of 27 months; and 22 of 27 patients (81%) with a preserved bladder were tumor-free at the last follow-up. Three patients (11%) developed grade 3 acute hematological toxicity. CONCLUSION: Multimodality therapy consisting of low-dose RT and concurrent IACT for muscle-invasive bladder cancer can achieve survival rates similar to those in patients treated with radical cystectomy, with successful bladder preservation and minimal adverse effects. (Keyword) Antineoplastic Combined Chemotherapy Protocols / Combined Modality Therapy / Cystectomy / Female / Humans / Infusions, Intra-Arterial / Male / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Radiotherapy Dosage / Retrospective Studies / Survival Rate / Treatment Outcome / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-007-0211-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18683571 ● Search Scopus @ Elsevier (PMID): 18683571 ● Search Scopus @ Elsevier (DOI): 10.1007/s11604-007-0211-x (DOI: 10.1007/s11604-007-0211-x, PubMed: 18683571)
77.	Takashi Kawanaka, Akiko Kubo, Hitoshi Ikushima, Toshiaki Sano, Yoshihiro Takegawa and Hiromu Nishitani : Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy., The Journal of Medical Investigation : JMI, Vol.55, No.1-2, 78-86, 2008. (Summary) Hypoxia-inducible factor (HIF)-2alpha, a basic helix-loop-helix (bHLH)-PAS protein, is the principal regulator of the hypoxic transcriptional response. An immunohistochemical study reported strong HIF-2alpha expression in the cytoplasm of tumor infiltrative macrophages (TIMs). Thus we assessed the expression of HIF-2alpha in human cervical cancer tissue before radiation therapy and its relationship to the clinical outcome. Seventy three patients with histologically proven primary advanced squamous cell carcinoma of the uterine cervix underwent radiotherapy in Tokushima University Hospital after biopsy specimens were taken. Among 73 specimens stained for HIF-2alpha, 53 (72.6%) exhibited HIF-2alpha immunoreactivity in the TIMs. In only 5 of 73 cases, HIF-2alpha immunoreactivity was observed in the nuclei of tumor cells. The HIF-2alpha positive cell count ratio in TIMs was associated with disease-free survival (DFS) with the worst DFS (p=0.024) being in cases in the group with a high positive cell count ratio. A high HIF-2alpha positive cell count ratio in TIMs increased the risk of local recurrence (p=0.0142). These findings might suggest that the ratio of the HIF-2alpha positive cell in TIMs may be a new predictive indicator for prognosis before radiation therapy for uterine cervical cancer. (Keyword) Adult / Aged / Aged, 80 and over / Basic Helix-Loop-Helix Transcription Factors / Carcinoma, Squamous Cell / Female / Gene Expression Regulation, Neoplastic / Humans / Macrophages / Middle Aged / Predictive Value of Tests / Prognosis / Retrospective Studies / Tumor Markers, Biological / Uterine Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110842 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.55.78 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18319549 ● Search Scopus @ Elsevier (PMID): 18319549 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.55.78 (Tokushima University Institutional Repository: 110842, DOI: 10.2152/jmi.55.78, PubMed: 18319549)
78.	Yoshihiro Takegawa, Hitoshi Ikushima, Kyosuke Osaki, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh and Masafumi Harada : Can Kampo Therapy prolong the life of cancer patients?, The Journal of Medical Investigation : JMI, Vol.55, No.1,2, 99-105, 2008. (Summary) Our policy regarding the performance of radiotherapy to squamous cell carcinoma of the uterine cervix has not changed since 1969. We have already reported the treatment results which were as good as those from other institutions. Since 1978, Kampo therapy was first introduced in the treatment of cancer patients in dealing with problems such as the side effects of radiotherapy and chemotherapy and various types of general malaise. We analyzed our treatment results in order to re-evaluate the chemo-radiotherapy in combination with Kampo. Survival rates for 5, 10 and 15 years, respectively, were 90.9%, 71.6% and 71.6% for Stage IB, 78.9%, 61.8% and 41.8% for Stage II, 62.3%, 49.1% and 41.2% for Stage III and 53.1%, 36.5% and 16.7% for Stage IV. The Kampo significantly extended the survival of patients with uterine cervical cancer. We intend to perform further research with more patients to explore how this therapy contributes to the prolonging of patients survival. (Keyword) Adult / Aged / Aged, 80 and over / Carcinoma, Squamous Cell / Combined Modality Therapy / Drugs, Chinese Herbal / Female / Follow-Up Studies / Humans / Medicine, Kampo / Middle Aged / Neoplasm Staging / Phytotherapy / Quality of Life / Retrospective Studies / Survival Rate / Time Factors / Treatment Outcome / Uterine Cervical Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110845 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.55.99 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18319551 ● Search Scopus @ Elsevier (PMID): 18319551 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.55.99 (Tokushima University Institutional Repository: 110845, DOI: 10.2152/jmi.55.99, PubMed: 18319551)
79.	Hitoshi Ikushima, Yoshihiro Takegawa, Kyohsuke Osaki, Shunsuke Furutani, Kyoh Yamashita, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh and Hiromu Nishitani : Radiation therapy for cervical cancer in the elderly, Gynecologic Oncology, Vol.107, No.2, 339-343, 2007. (Summary) To evaluate the long-term results of radical radiation therapy (RT) for cervical cancer in elderly patients. We reviewed the clinical records of 727 patients with cervical cancer who underwent radical RT at the Tokushima University Hospital and compared the treatment results of three age groups: </=64 years (younger group [YG], 337 patients), 65-74 years (young-old group [YOG], 258 patients), and >/=75 years (older group [OG], 132 patients). At the last follow-up, 155 YG (46%), 77 YOG (30%), and 48 OG patients (36%) had died of cervical cancer; the median follow-up periods were 82, 87, and 68 months, respectively. The 5-/10-year disease-specific survival rates were 60%/52% in YG, 76%/68% in YOG, and 66%/57% in OG. Differences between OG and the other groups were not significant. The 5-/10-year disease-specific survival rate of YOG was significantly superior to that of YG (p<0.001). Clinical stage was the only significant prognostic variable (p<0.001). Late radiation morbidity of grades 2-4 in the bladder and/or rectum occurred in 22% of YG, 31% of YOG, and 8% of OG patients. RT was well tolerated in elderly patients, and age was not a significant prognostic factor. In the management of cervical cancer, advanced age is not a contraindication to radical RT. (Keyword) Adenocarcinoma / Adult / Age Factors / Aged / Aged, 80 and over / Brachytherapy / Carcinoma, Squamous Cell / Chemotherapy, Adjuvant / Disease-Free Survival / Female / Humans / Japan / Medical Records / Middle Aged / Multivariate Analysis / Neoplasm Staging / Prognosis / Radiation Injuries / Radiotherapy / Retrospective Studies / Risk Factors / Treatment Outcome / Uterine Cervical Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ygyno.2007.07.058 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17707075 ● Search Scopus @ Elsevier (PMID): 17707075 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ygyno.2007.07.058 (DOI: 10.1016/j.ygyno.2007.07.058, PubMed: 17707075)
80.	Hitoshi Ikushima and 西谷弘 : 緩和ケアにおける放射線治療の役割, Shikoku Acta Medica, Vol.61, No.3 4, 71-79, 2006. (Summary) Radiation therapy is a valuable treatment for palliation of local symptoms with consistentlyhigh response rates in the relief and control of bone pain, neurological symptom, obstructivesymptoms, and tumor hemorrhage. Over than 80% of patients who developed bone metastasisand superior vena cava syndrome obtained symptom relief by radiation therapy. Radiation therapyis also well established as an effective treatment for brain metastasis, improving symptoms andpreventing progressive neurological deficits, and recently stereotactic irradiation had became aalternative treatment of surgery for small metastatic brain tumors. Both radiation therapy andsurgery are effective in the initial treatment of malignant spinal cord compression syndrome, andno advantages of surgery over radiation therapy has been demonstrated in published series whenpatients have a previously conformed diagnosis of malignant disease and no evidence of vertebralcollapse. The outcome of treatment depends primarily upon the speed of diagnosis and neurologicalstatus at initiation of treatment. It is very important to start radiation therapy before patientbecome non-ambulant. Low irradiation dose and short treatment period of palliative radiationtherapy can minimize disruption and acute morbidity for the patients with advanced cancer withenabling control of symptoms and palliative radiation therapy is applicable to the patient even inpoor general condition. (Keyword) radiation therapy / palliative care / cancer (Tokushima University Institutional Repository) ● Metadata: 65696 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050020697878128640 (Tokushima University Institutional Repository: 65696, CiNii: 1050020697878128640)
81.	Hitoshi Ikushima, Kyousuke Osaki, Shunsuke Furutani, Kyou Yamashita, Takaharu Kudoh and Hiromu Nishitani : Pelvic bone complications following radiation therapy of gynecologic malignancies: clinical evaluation of radiation-induced pelvic insufficiency fractures, Gynecologic Oncology, Vol.103, No.3, 1100-1104, 2006. (Summary) To investigate the incidence, clinical and imaging finding of insufficiency fractures (IF) of the female pelvis following radiation therapy. We reviewed the radiation oncology records of 158 patients with gynecologic malignancies who underwent external beam radiation therapy of the whole pelvis between April 1993 and March 2004. All patients underwent computed tomography (CT) scan every 6 months in follow-up after radiation therapy and magnetic resonance imaging (MRI) and radionuclide bone scan were added when the patients complained of a pelvic pain. Eighteen of 158 patients (11.4%) developed IF in the irradiated field with a median interval of 6 months (range 3-51) from the completion of external beam radiation therapy. The cumulative incidence of symptomatic IF at 5 years calculated with Kaplan-Meyer methods was 13%. Median age of the patients who developed IF was 70 years (range 48-88), and all of them were postmenopausal. IF occurred in the sacloiliac joints, upper limb of pubic bone, acetabulum, sacral body and 5th lumbar vertebra. Twelve of 18 patients had multiple lesions and 8 had symmetric longitudinal fracture lines parallel to the sacroiliac joints. Avoidance of weight bearing by bed rest and analgesics provided good pain relief in all patients, although symptoms lasted from 3 to 20 months. Radiation-induced pelvic IF following radiation therapy for gynecologic malignancies were frequently observed in the postmenopausal patients within 1 year after external beam radiation therapy. Symmetric fractures of the both sacroiliac joints were the characteristic pattern of pelvic IF. Knowledge of characteristic imaging pattern of IF is essential in order to rule out the bone metastasis. Therapy recommendations are conservative with analgesics. (Keyword) Aged / Aged, 80 and over / Female / Fractures, Bone / Humans / Japan / Middle Aged / Pelvic Bones / Pelvic Pain / Radiation Injuries / Tomography, X-Ray Computed / Uterine Cervical Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ygyno.2006.06.038 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16919711 ● Search Scopus @ Elsevier (PMID): 16919711 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ygyno.2006.06.038 (DOI: 10.1016/j.ygyno.2006.06.038, PubMed: 16919711)
82.	Shunsuke Furutani, Takuya Saze, Hitoshi Ikushima, Masataka Oita, Kyosuke Osaki, Yoshiomi Kishida, Yoshihiro Takegawa and Hiromu Nishitani : Quality Assurance of I-125 Seed for Prostate Brachytherapy Using an Imaging Plate, International Journal of Radiation OncologyBiologyPhysics, Vol.66, No.2, 603-609, 2006. (Summary) OncoSeed is delivered in a sterile environment in the form of a cartridge, so it is impractical to resterilize and reload seeds after calibration. We investigated a new method using an imaging plate dosimetry system to characterize all seeds in the OncoSeed cartridge in a sterile environment. Seeds within the cartridge were placed on an imaging plate, and the imaging plate irradiated. To remove scatter radiation, and improve spatial resolution of seed images, we used X-ray parallel cross grids. The irradiated imaging plate was scanned using a Bio-imaging Analyzer System, and radioactivity intensities of seed images were given in counts. Counts could be translated to profiles, and each seed within the cartridge was analyzed. Results showed a good correlation between counts and total radioactivity of the seeds within the cartridge. Thus, using a least-squares line, it was possible to characterize a cartridge with unknown apparent activity. By analyzing the profiles, it was possible not only to detect a miscalibrated seed in the cartridge from its relative difference in counts, but also to identify its position in the cartridge. No significant changes in counts were seen between sterile and nonsterile environments. Using an imaging plate dosimetry system, all seeds in a cartridge could be characterized in a sterile environment. (Keyword) Brachytherapy / Humans / Iodine Radioisotopes / Least-Squares Analysis / Male / Prostatic Neoplasms / Quality Control / radioactivity / Radiotherapy Dosage (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijrobp.2006.05.052 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16966003 ● Search Scopus @ Elsevier (PMID): 16966003 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijrobp.2006.05.052 (DOI: 10.1016/j.ijrobp.2006.05.052, PubMed: 16966003)
83.	Hitoshi Ikushima, Kyousuke Osaki, Shunsuke Furutani, Kyou Yamashita, Takashi Kawanaka, Yoshiomi Kishida, Seiji Iwamoto, Yoshihiro Takegawa, Takaharu Kudoh and Hiromu Nishitani : Chemoradiation Therapy for Cervical Cancer:Toxicity of Concurrent Weekly Cisplatio, Radiation Medicine, Vol.24, No.2, 115-121, 2006. (Summary) To retrospectively evaluate the toxicity of concurrent weekly cisplatin and radiation therapy (RT) for locally advanced cervical cancer. Between April 2001 and December 2004, 21 consecutive previously untreated patients with locally advanced cervical cancer were treated with concurrent chemoradiation therapy (CCRT) at the Tokushima University Hospital. Clinical stages were II: 5, III: 15, IVA: 1. External beam radiation therapy (EBRT) was delivered with 10 MV X-rays, 2 Gy fraction per day; total dose to the whole pelvis was 50 Gy. Iridium-192 high-dose-rate (HDR) intracavitary radiation therapy was performed with 10-30 Gy (median, 24 Gy) targeted at point A. Concurrent chemotherapy consisted of cisplatin, administered weekly at a dose of 40 mg/m2 for patients who were younger than 65 years and 30 mg/m2 for those 65 years or over. A maximum single dose of cisplatin, up to 70 mg/body, was administered in 5 cycles during EBRT. A total of 86 cycles of cisplatin were administered to the 21 patients, with a median of 4 cycles (range, 2-5). Severe hematological toxicity occurred in 18 patients (86%), including grade 3 in 17 patients (81%) and grade 4 in one patient (4.8%). Moderate or severe gastrointestinal toxicity occurred in 11 patients (52%), including grade 2 in 10 patients (48%) and grade 3 in one patient (4.8%). The grades of hematological toxicity were significantly greater in the 40 mg/m2 group than in the 30 mg/m2 group. All of the patients who were administered 40 mg/m2 of cisplatin developed grade 3 or greater hematological toxicity, including one patient with grade 4 toxicity. In the 30 mg/m2 group, 3 of 10 patients developed less than grade 3 toxicity, and all patients completed radiation therapy without interruption. The incidence of severe acute hematological toxicity was significantly higher in this study than in previously reported randomized controlled trials (RCTs), especially in the group of 40 mg/m2 cisplatin. A dose of 30 mg/m2 of cisplatin was considered to be feasible in weekly cisplatin and radiation therapy. (Keyword) radiation therapy / concurrent chemotherapy / cervical cancer / acute toxicity (Link to Publication Site) ● Publication site (DOI): 10.1007/BF02493277 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16715672 ● Search Scopus @ Elsevier (PMID): 16715672 ● Search Scopus @ Elsevier (DOI): 10.1007/BF02493277 (DOI: 10.1007/BF02493277, PubMed: 16715672)
84.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Masataka Oita, Motoharu Sasaki, Yoshihiro Takegawa and Hiromu Nishitani : Quality Assurance of I-125 Seed Permanent Implant Therapy Using a Self-color Developing Reflection-type Dosimetry Sheet Film, Radiation Medicine, Vol.23, No.7, 474-477, 2005. (Summary) We evaluated a self-color developing sheet-type film for the detection of dead seeds in I-125 permanent implant therapy for prostate cancer. As a preliminary study, we irradiated X-rays to a self-developing reflection-type sheet film and created a relational curve between absorbed dose and film density. I-125 seeds were placed on a film and the approximate absorbed dose of I-125 was calculated from the relational curve of X-rays. A cartridge in which a dead seed was loaded among 10 I-125 seeds was placed on the film and the detectability of the dead seed was evaluated. Using the relational curve of X-rays, it was possible to measure the approximate absorbed dose of I-125 seeds and to easily detect a dead seed at a glance. Using sterilized film, it was possible to detect a dead seed. The self-developing film method is feasible for the detection of a dead seed in a cartridge without re-sterilization of seeds. (Keyword) I-125 seed / dead seed / quality assurance (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16485537 ● Search Scopus @ Elsevier (PMID): 16485537 (PubMed: 16485537)
85.	Hitoshi Ikushima, Yoshihiro Takegawa, Hirokazu Mathuki, Hiroaki Yasuda, Takashi Kawanaka, Atsushi Shiba, Yoshiomi Kishida, Seiji Iwamoto and Hiromu Nishitani : Insufficiency fractures following radiation therapy for gynecologic malignancies, The Official Jpurnal of The Japanese Society for Therapeutic Radiology and Oncology, Vol.14, No.4, 229-232, 2002.
86.	Hitoshi Ikushima, Koichi Tokuuye, Minako Sumi, Yoshikazu Kagami, Shigeyuki Murayama, Hiroshi Ikeda, Minoru Tanaka, Hiroshi Oyama, Soichiro Shibui and Kazuhiro Nomura : Fractionated stereotactic radiation therapy for brain metastasis from renal cell carcinoma, International Journal of Radiation OncologyBiologyPhysics, Vol.48, No.5, 1389-1393, 2000. (Link to Publication Site) ● Publication site (DOI): 10.1016/S0360-3016(00)00804-X (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/S0360-3016(00)00804-X (DOI: 10.1016/S0360-3016(00)00804-X)
87.	Hirokazu Matsuki, Hitoshi Ikushima, Yoshihiro Takegawa, Kenichi Kashihara and Hiromu Nishitani : A comparison of the results of radiotherapy and surgical treatment of tangue cancer, The Official Jpurnal of The Japanese Society for Therapeutic Radiology and Oncology, Vol.12, No.02, 143-152, 2000.
88.	Hitoshi Ikushima, Yoshihiro Takegawa, Hirokazu Mathuki, Kenichi Kashihara and Hiromu Nishitani : Radiotherapy for Carcinoma of the Uterine Cervix using Low-Dose-Rate Intercavitary Brachytherapy- A Retrospective Analysis of Pretreatment and Treatment Prognostic Factore-, The Official Jpurnal of The Japanese Society for Therapeutic Radiology and Oncology, Vol.11, No.1, 37-46, 1999.
89.	Hitoshi Ikushima, Yoshihiro Takegawa, Hiroaki Yasuda, Yumi Makimoto, Kenji Matsuzaki, Kenichi Kashihara, Junji Ueno, Mitsunori Sasa, Tadaoki Morimoto and Hiromu Nishitani : Radiation Complications Following Breast Conserving Therapy, Breast Cancer, Vol.5, No.4, 395-400, 1998.
90.	Miki Tanouchi, Osamu Sui, Kenichi Kashihara, Masafumi Harada, Toshihumi Mukaijo, Kaoru KItsukawa, Noritami Tokuyama, Ryouichi Ohtsuka, Hitoshi Ikushima, Hiromu Nishitani and Yoshihiro Takegawa : A study of skeletal metastasis of Carcinoma of the Uterine Cervix, The Official Jpurnal of The Japanese Society for Therapeutic Radiology and Oncology, Vol.02, No.02, 111-117, 1990.
91.	Masafumi Harada, Ryouiti Ootsuka, Oshamu Sui, Toshihumi Mukaijyo, Yoshitami Tokuyama, Kaoru Kitsukawa, Miki Tanouchi, Hitoshi Ikushima, Hiromu Nishitani and Yoshihiro Takegawa : Eight Cases of Intracranial Arteriovenous Malformations Conducted Conventional Radiation Therapy, Japanese Journal of Clinical Radiology, Vol.35, No.03, 315-319, 1990.

Academic Paper (Unrefereed Paper):

1.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 泌尿器外科, Vol.27, No.8, 1651-1654, 2012.
2.	Yoshihiro Takegawa, S. Kawano, Hirofumi Yagi, Sumiko Yoshinaga, H. Saito, Masafumi Harada, Hitoshi Ikushima, M. Takahashi and K. Sasaka : Clinical results of radiotherapy and B-M therapy for advanced cervical cancer, Bulletin of School of Medical Sciences, the University of Tokushima, Vol.7, 105-110, 1997.
3.	Yoshihiro Takegawa, Hirofumi Yagi, Sumiko Yoshinaga, Hitoshi Ikushima and M. Takahashi : Radiation therapy and Chinese immunotherapy of malignant tumor - from clinical aspects -, Bulletin of School of Medical Sciences, the University of Tokushima, Vol.6, 175-184, 1996.

Review, Commentary:

1.	Hitoshi Ikushima : 小線源治療の現状と医学物理への期待, 放射線治療かたろう会会誌, No.29, Jun. 2024.
2.	Hitoshi Ikushima : 第3回放射線科医の動向に関するアンケート調査報告(後編), 日本放射線専門医会・医会誌, No.234, 17-39, Jul. 2020.
3.	Hitoshi Ikushima : 第3回放射線科医の動向に関するアンケート調査報告, 日本放射線科専門医会・医会誌, No.233, 19-39, Apr. 2020.
4.	Hitoshi Ikushima : 治療のワンポイントアドバイスー子宮頸癌に対する腔内照射ー, 日本放射線科専門医会・医会誌, No.233, 13-14, Apr. 2020.
5.	Hitoshi Ikushima : がん放射線療法, 医用画像情報学会誌, Vol.34, No.1, 7-12, Mar. 2017.
6.	Masahide Tominaga, 下窪康史, Hitoshi Ikushima, 本田道隆 and Motoharu Sasaki : Cone-beam CT 画像を用いた小線源治療計画への応用, 画像通信, Vol.77, No.2, 55-61, Oct. 2016.
7.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, H Kashihara, Chie Takasu and Hitoshi Ikushima : Preoperative radiotherapy combined with S-1 for advanced lower rectal cancer: phase I trial., Hepato-Gastroenterology, Vol.59, No.117, 1428-1432, Jul. 2012. (Summary) S-1 based chemoradiation is the recommended treatment for rectal cancer; however, the optimal scheduling and dosing are not yet established. A Phase I study was conducted to determine the maximum tolerated dose (MTD) of S-1 with radiotherapy (RT). Endpoints were the toxicity profile of this regimen and to determine the recommended dose (RD). Conformal RT was given using 4 fields at daily fractions of 2Gy on 5 days per week to a total dose of 40Gy. Concurrently S-1 was given twice daily throughout RT. Eligible patients had a newly diagnosed clinical stage T3-4 N0-2 M0 rectal adenocarcinoma located within 12cm of the anal verge suitable for curative resection. Surgery was performed 6 weeks from completion of preoperative chemoradiotherapy. The dose escalating from S-1 80mg/m2/day (Level 1) to 100mg/m2/day (Level 2). Nine patients were valid for safety. In all patients, S-1 was administered. There was no dose-limiting toxicity (DLT) in patients treated at dose Level 1. Six patients were enrolled in the dose-escalation phase. At dose Level 2, two patients developed DLT and this was considered the MTD. Objective response according to RECIST were observed in 5 of 9 patients who had measurable disease (56%). The RD of S-1 with concurrent RT was determined to be 80mg/m2/day. Preoperative RT combined with S-1 was feasible and well tolerated. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge11699 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22155856 ● Search Scopus @ Elsevier (PMID): 22155856 ● Search Scopus @ Elsevier (DOI): 10.5754/hge11699 (DOI: 10.5754/hge11699, PubMed: 22155856)
8.	Shunsuke Furutani, Tomoharu Fukumori, Hitoshi Ikushima and Hiro-omi Kanayama : リアルタイムプランニングによる辺縁配置法の実践, Interplant ver. 3.3を用いた術中計画ハンドブック, Jun. 2012.

Proceeding of International Conference:

1.	Kanon Monda, Hitoshi Ikushima, Yuki Matsumoto, Motoharu Sasaki, Micihito Shimokawa and Akihiro Haga : Proposal of a differential diagnostic index for recurrent brain metastasis or radiation-induced brain necrosis by radiomics analysis using C-11 methionine PET, The 3rd ICRPT, Apr. 2024.
2.	Kanon Monda, Hitoshi Ikushima, Yuki Matsumoto, Motoharu Sasaki, Michihito Shimokawa and Akihiro Haga : The differential diagnosis of recurrent brain metastasis or radiationinduced brain necrosis by radiomics analysis using C-11 methionine positron emission tomography, ECR 2024, Feb. 2024.
3.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima, Masafumi Harada and Kawanaka Taeko : Initial Experience and Evaluation of Safety in Hypofractionated Accelerated Partial Breast irradiation using a Brachytherapy Multi-catheter Approach, FARO & KOSRO 2023, Seul, Korea, Oct. 2023.
4.	Kanon Monda, Hitoshi Ikushima, Yuki Matsumoto, Motoharu Sasaki, Michihito Shimokawa and Masafumi Harada : Proposal of a rigid registration method for contrast-enhanced MRI and C-11 methionine PET using iterative closest point and convolutional Neural Network, ISMRM JPC2023, The 8th Annual Scientific Meeting of the ISMRM Japanese Chapter, Sep. 2023.
5.	Bollos Anne Christine L. Leah, Ryosuke Kasai, Shoichiro Takao, kawabata Yuka, Tetsuya Tanioka, Hitoshi Ikushima and Hideki Otsuka : Multimodal Image Analysis for Cardiac Sarcoidosis: A Narrative Review, 6TH SPUP INTERNATIONAL INTERDISCIPLINARY RESEARCH CONFERENCE, Tuguegarao City ,Philippines, Aug. 2023. (Keyword) 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) / cardiac magnetic resonance (CMR) / cardiac sarcoidosis / PET/MRI
6.	Motoharu Sasaki, Nakaguchi Yuji, Shoji Ueda, ENDO Yuto, KAJINO Akimi, SATOH Daisuke and Hitoshi Ikushima : Predicting the complexity of head and neck VMAT planning using a TPS quality assurance software, 2022 AAPM 64th Annual Meeting, Jul. 2022.
7.	Tamaki Otani, Hitoshi Ikushima, Yoshimi Bando, Kenmei Kuwahara, Hideki Otsuka, Kazuya Kondo and Hirokazu Miyoshi : Efficacy of 18F-fluorothymidine and 18F-fluorodeoxyglucose Positron Emission Tomography in Determining a Radiotherapy Effect., Annual Congress of the European Association of Nuclear Medicine, Oct. 2021.
8.	Motoharu Sasaki, Hitoshi Ikushima, KOHBUCHI Satoshi, KUWAHARA Kenmei, KAJINO Akimi, SATOH Daisuke, Sugimoto Wataru and Masataka Oita : Prediction of Dose Discrepancies Using Differences in Plan Normalization Values of Head-And-Neck VMAT Plans, 2021 AAPM Virtual 63rd Annual Meeting, Jul. 2021.
9.	Motoharu Sasaki, Nakaguchi Yuji, Takeshi Kamomae, KOHBUCHI Satoshi, KUWAHARA Kenmei, KAJINO Akimi, SATOH Daisuke and Hitoshi Ikushima : Effect of VMAT Improvement Before and After Referring to Radiation Therapy Planning QA Software, 2021 AAPM Virtual 63rd Annual Meeting, Jul. 2021.
10.	Hitoshi Ikushima, Akihiro Haga, Ando Ken, Kato Shingo, Kaneyasu Yuko, Uno Takashi, Okonogi Noriyuki, Yoshida Kenji, Ariga Takuro, Isohashi Fumiaki, Harima Yoko, Kanemoto Ayae, Ii Noriko, Wakatsuki Masaru and Ohno Tatsuya : Prediction of survival in cervical cancer patients treated with chemoradiotherapy by imaging analysis using artificial intelligence -A multi-institutional survey study of Japanese Radiation Oncology Study Group (JROSG)-, The 62nd annual meeting of the Japan Society of gynecologic oncology, International Session, Jan. 2021.
11.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo and Hitoshi Ikushima : Compatibility of SAVI applicator and resection cavity underwent cylindrical breast resection for early-stage breast cancer and its solution: initial experience of Hybrid APBI, RSNA2021, Chicago, Nov. 2020.
12.	Motoharu Sasaki, Hitoshi Ikushima, Kenta Kitagawa, Yohsuke Kanoh, Masahide Tominaga, Hirofumi Honda, Wataru Sugimoto and Masataka Oita : Impact of Changes in Body Shapes on Radiation Therapy Dose Distribution After Uterine Cervical Cancer Surgery, AAPM 62th annual meeting (WEB), Jul. 2020.
13.	Tomita Emi, Hayashi Hiroaki, Asahara Takashi, Kimoto Natsumi, Goto Sota, Yuki Kanazawa, Shitakubo Yasufumi, Sakuragawa Kanako, Hitoshi Ikushima, Okazaki Tohru and Hashizume Takuya : Development of a Clinically Applicable Rectum Dosimeter for Brachytherapy using an Optically Stimulated Luminescence Dosimeter, 19th International Conference on Solid State Dosimetry (SSD19), Hiroshima, Sep. 2019.
14.	Emi Tomita, Hiroaki Hayashi, Takashi Asahara, Yasufumi Shitakubo, Kanako Sakuragawa, Hitoshi Ikushima, Yuki Kanazawa, Tohru Okazaki and Takuya Hashizume : Evaluation of dose to risk organ during brachytherapy for cervical cancer using a novel passive rectum dosimeter, European Congress of Radiology, Wien, Mar. 2019.
15.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : Long-Term Outcome of Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patients: A Propensity Score-Matched Analysis, RSNA2018, Nov. 2018.
16.	Chisato Tonoiso, Hitoshi Ikushima, Akihiro Haga, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Masato Nishimura, Akiko Abe, Minoru Irahara and Masafumi Harada : Investigation of prognostic factors of cervical cancer using pre-treatment MRI images, The 2018 International Gynecologic Cancer Society Meeting, Sep. 2018.
17.	Tomita Emi, Hiroaki Hayashi, Asahara Takashi, Shitakubo Yasufumi, Sakuragawa Kanako, Hitoshi Ikushima, Yuki Kanazawa, Okazaki Tohru and Hashizume Takuya : First Trial of Actual Dose Measurement of Organ at Risk During Brachytherapy for Cervical Cancer in Tokushima University Hospital, Second International Seminar and Workshop on Technological Competency as Caring in the Health Science, Tokushima, Aug. 2018.
18.	Hiroaki Hayashi, Emi Tomita, Takashi Asahara, Yasufumi Shitakubo, Kanako Sakuragawa, Hiroshi Saegusa, Hitoshi Ikushima, Yuki Kanazawa, Sota Goto, Natsumi Kimoto, Yoshiki Mihara, Yoshinori Miyahara, Tohru Okazaki, Takuya Hashizume and Vergil Estacio Lorenzo Cruz : Development of a new in-vivo measurement system by means of OSL dosimeters during brachytherapy for cervical cancer, RSNA2017 (Radiological Society of North America), Chicago, Nov. 2017.
19.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patient: A Japanese Single Institutional Study, ASTRO's 59th Annual Meeting, San Diego, Oct. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijrobp.2017.06.1191 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijrobp.2017.06.1191 (DOI: 10.1016/j.ijrobp.2017.06.1191)
20.	Takashi ASAHARA, Hiroaki Hayashi, Emi TOMITA, Kanako SAKURAGAWA, Yasufumi SHITAKUBO, Hitoshi Ikushima and Tohru OKAZAKI : Development of a Novel Rectum Dosimeter for Evaluation of Organ Dose Exposure during Brachytherapy using High-Dose-Rate Ir-192, The 3rd International Conference on Radiological Science and Technology, Hiroshima, Oct. 2017.
21.	Emi TOMITA, Hiroaki Hayashi, Takashi ASAHARA, Kanako SAKURAGAWA, Yasufumi SHITAKUBO, Hiroshi SAEGUSA, Hitoshi Ikushima, Yuki Kanazawa, Sota GOTO, Tohru OKAZAKI, Takuya HASHIZUME and Vergil LE CRUZ : Direct Radiation Dose Measurement of Rectum during High-Dose-Rate 192Ir Brachytherapy for Cervical Cancer Treatment, International Symposium On Radiation Safety and Detection Technology (ISORD-9), Nagoya, Jul. 2017.
22.	Takashi ASAHARA, Hiroaki Hayashi, Emi TOMITA, Kanako SAKURAGAWA, Hiroshi SAEGUSA, Yasufumi SHITAKUBO, Hitoshi Ikushima, Yuki Kanazawa, Yoshiki MIHARA, Yoshinori MIYAHARA, Tohru OKAZAKI, Takuya HASHIZUME and Vergil CRUZ : Development of Novel Rectum Dosimeter using OSL sheet with the aim of Direct Dose Measurement of Organ Dose during Brachytherapy, International Symposium On Radiation Safety and Detection Technology (ISORD-9), Nagoya, Jul. 2017.
23.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : Long-Term Outcome of Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patients, 2017 ABS Annual Conference, Boston, Apr. 2017.
24.	Hitoshi Ikushima, M Wakatsuki, T Ariga, Y Kaneyasu, S Tokumaru, F Isohashi, N Ii, T Uno, T Ono and T Toita : Current practice and outcomes of radiotherapy for vaginal cancer: A multi-institutional retrospective study of Japan Radiation Oncology Study Group (JROSG), 16th biennial meeting of the international gynecologic cancer society, Oct. 2016.
25.	Shunsuke Furutani, Hitoshi Ikushima, Takashi Kawanaka, Akiko Kubo, Ayaka Takahashi, Kanako Miyamoto, Yuta Arai, Saki Nagase and Masafumi Harada : Clinical Outcomes of Fractionated Stereotactic Radiotherapy using Volumetric Modulated Arc Therapy for Multiple Brain Metastases, 58th Annual meeting of the American society for therapeutic radiology and oncology, Boston, Sep. 2016.
26.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Impact of Salvage Chemoradiation Therapy With Triple-Drug Combination(Docetaxel,5-FU, and CDDP)for Postoperative Locoregional Recurrence of Esophageal Cancer, 58th Annual meeting of the American society for therapeutic radiology and oncology, Boston, Sep. 2016.
27.	Motoharu Sasaki, Hitoshi Ikushima, Masahide Tominaga, 川下徹也, Takeshi Kamomae, Ryota Bandoh, Kanako Sakuragawa and Masataka Oita : Dose impact of rectal gas on prostate VMAT, AAPM 58th Annual Meeting, Jul. 2016.
28.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Long-term Outcome of I125 Low-dose-rate Brachytherapy for Clinically Localized Prostate Cancer at Single University Hospital,Which Is One of The Initial Institutions Using I125 Low-dese-rate Brachytherapy in Japan, 2016 ABS Annual Meeting(World Congress of Brachytherapy), San Francisco, Jun. 2016.
29.	Minoru Sakama, Hitoshi Ikushima, Shunsuke Furutani, Takaharu Yamada and Teruki Ichiraku : Compact designed automation device for accurate independent calibration of Brachytherapy seeds of Iodine-125, MMND-IPCT conference 2014, Oct. 2014.
30.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Salvage chemoradiation therapy with triple-drug combination (Docetaxel, 5-FU and CDDP) for postoperative locoregional recurrence of esophageal cancer, 56th annual meeting of ASTRO, San Francisco, Sep. 2014.
31.	Akiko Kubo, Hitoshi Ikushima, Shunsuke Furutani, Takashi Kawanaka and Masafumi Harada : Contribution of imaging in diagnosis of local recurrence after radiation therapy for cervical cancer, San Francisco, Sep. 2014.
32.	Minoru Sakama, Hitoshi Ikushima, Takuya Saze, 長野裕介, Takashi Yamada, Teruki Ichiraku, Hisashi Takai, Yoshinori Kuwahara and Shintaro Nakayama : Development of automated measurement system for radioactive intensities of sealed small radiation sources (Iodine-125 seed source) for brachytherapy, 5th Asia-Pacific symposium on radiochemistry, Sep. 2013.
33.	Hitoshi Ikushima : New technology to support brachytherapy in Japan, The MD Anderson Radiation Oncology Gilbert H. Fletcher Society 37th Annual Scientific Meeting, Apr. 2013. (Keyword) brachytherapy
34.	Hitoshi Ikushima, Kazuya Kondoo, Youichi Otomi and Hiroshi Maezawa : Treatment Effect of Neoadjuvant Chemoradiation Therapy for Non-Small Cell Lung Cancer Evaluated by Multi-Modality Imaging and Histopathological Analyses, 54thAnnual meeting of American society of therapeutic radiation and oncology, Boston, Oct. 2012.
35.	Hitoshi Ikushima, Kazuya Kondo and Youichi Otomi : Treatmet effect of eoadjuvat chemoradiatio therapy for osmall cell lug cacer evaluated by multi-modality imaging and histopathological analyses, ASTRO 54, Sep. 2012.
36.	Youichi Otomi, Hideki Otsuka, Hayato Nose, Kaori Terazawa, Hitoshi Ikushima and Masafumi Harada : FDG-PET/CT in esophageal lesions other than squamous cell carcinoma and adenocarcinoma, Miami, Jun. 2012.
37.	Youichi Otomi, Hideki Otsuka, Hayato Nose, Kaori Terazawa, Hitoshi Ikushima and Masafumi Harada : Does the H/M ratio of I-123 MIBG match the cardiac function in Parkinson's disease patients?, Miami, Jun. 2012.
38.	Youichi Otomi, Hideki Otsuka, Hayato Nose, Kaori Terazawa, Hitoshi Ikushima and Masafumi Harada : FDG-PET/CT in non-cutaneous malignant melanoma, Miami, Jun. 2012.
39.	Youichi Otomi, Hideki Otsuka, Hayato Nose, Kaori Terazawa, Hitoshi Ikushima and Masafumi Harada : Muscle FDG accumulation under physiological and non-physiological conditions, Miami, Jun. 2012.
40.	Yoshihiro Tanaka, Hitoshi Ikushima, Hiroshi Maezawa and Kazuya Kondo : Usefulness of diagnostic imaging in neoadjuvant chemoradiation therapy for non-small cell lung cancer, ESTRO 31, May 2012.
41.	佐々木幹治, 岸太郎, 原康男, 福永有希子, 富永正英, Hitoshi Ikushima and Masataka Oita : Impact of MLC positioning accuracy on IMRT, 2011Joint AAPM/COMP meeting, Jul. 2011.
42.	Kyo Yamashita, Hirokazu matsuki, Takashi Kawanaka, S Taguchi, Kenichi Kashihara and Hitoshi Ikushima : Local Graft Irradiation for ABO Mismatched Renal Transplantation, RSNA2010, Dec. 2010.
43.	Hitoshi Ikushima : Predictive value 18F-Fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy requires consideration of primary tumor size, LA, Sep. 2008. (Keyword) H Ikushima / L Dong / J Erasmus / P Allen / R Komaki
44.	Hitoshi Ikushima : Prognostic Significance of HIF-2 alpha Expression on Tumor Infiltrating Macrophages in Patients with FIGO Stage IIIb Uterine Cervival Cancer undergoing Radiotherapy, LA, Sep. 2008. (Keyword) T Kawanaka / H Ikushima / K Osaki / S Furutani / A Kubo
45.	Z Yu, H Liu, P Balter, Hitoshi Ikushima and S Hunjan : Motion Characterization for Early Stage Non-Small Cell Lung Cancer, Motion Characterization for Early Stage Non-Small Cell Lung Cancer, Houston, Aug. 2008.
46.	Hitoshi Ikushima, P Balter, J Chang, S Hunjan and S Hunjan : Daily Alignment Results for In-Room CT-Guided Stereotactic Body Radiation Therapy for Lung Cancer, 50th American Association of Physicists in Medicine, Houston, Aug. 2008.
47.	Yoshihiro Takegawa, Hitoshi Ikushima, Osaki Kyohsuke, Furutani Shunsuke, Yamashita Kyoh, Kawanaka Takashi and Takaharu Kudoh : Can Kampo Therapy (Juzentaihoto) Prolong the Life of Cancer Patients?, The 14th International Congress of Oriental Medicine, Taipei, Dec. 2007.
48.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Kyo Yamashita, Takashi Kawanaka, Seiji Iwamoto, Akiko Kubo, Yoshihiro Takegawa and Hiromu Nishitani : Intraarterial chemotherapy and concurrent radiation for locally advanced bladder cancer, 49th Annual meeting of the American society for therapeutic radiology and oncology, Los Angeles, Oct. 2007.
49.	Shunsuke Furutani, Hitoshi Ikushima, Takuya Saze, Kyosuke Osaki, Masataka Oita, Yoshihiro Takegawa and Hiromu Nishitani : Quality assurance of Iodine 125 seeds for prostate brachytherapy using an imaging plate, 48th Annual meeting of the American society for therapeutic radiology and oncology, Philadelphia, Nov. 2006.
50.	Kishida Yoshiomi, Masataka Oita, Hitoshi Ikushima, Ozaki Kyousuke, Furutani Shunsuke, Yoshihiro Takegawa and Hiromu Nishitani : Basic study for radiation treatment planning using PET/CT - Accuracy of a table-, Sapporo, Jul. 2006.
51.	Hitoshi Ikushima, Kyosuke Osaki, Shunsuke Furutani, Yoshihiro Takegawa and Hiromu Nishitani : Pelvic insufficiency fractures following radiation therapy for gynecologic malignancy, American Society for Therapeutic Radiology and Oncology 47th annualmeeting, Denver, Nov. 2005.
52.	Hitoshi Ikushima, Takashi Kawanaka and Hiromu Nishitani : Long-term results of radiation therapy for carcinoma of the uterine cervix, radiological society of north america 91st scientific assembly and annual meeting, Chicago, Nov. 2005.
53.	Masataka Oita, Yoshihiro Takegawa, Hitoshi Ikushima, Kyosuke Osaki and Hiromu Nishitani : Quality control of FOCAL unit with a micro-multi leaf collimator (mMLC) using new Gafchromic film for non-invasive stereotactic radiotherapy, 8th BIENIAL ESTRO MEETING ON PHYSICS AND RADIATION TECHNOLOGY FOR CLINICAL RADIOTHERAPY, Lisbon, Sep. 2005.
54.	Takashi Kawanaka, Hitoshi Ikushima, Hiromu Nishitani, Kyousuke Osaki and Yoshihiro Takegawa : Myelosuppression which happens in succession to concurrent cisplatin-based chemoradiation therapy to uterine cervical cancer, --- prevention of this side effect ---, Chicago, Nov. 2003.
55.	Takashi Kawanaka, Hitoshi Ikushima, Hiromu Nishitani, Kyousuke Osaki and Yoshihiro Takegawa : The expression of the hypoxia-inducible factor-2 alpha (HIF-2 alpha) in human cervical cancer, --- relationship between the expression and clinical outcomes ---, Chicago, Nov. 2003.
56.	Yoshihiro Takegawa and Hitoshi Ikushima : The Long-term Result of Combined Radiotherapy with Immunotherapy using KRESTIN (PSK) in Primary Uterin Cervical Cancer, Sixth Biennial Meeting of the International Gynecologic Cancer Society, Fukuoka, Oct. 1997.

Proceeding of Domestic Conference:

1.	渡部未歩, Hitoshi Ikushima and 大西洋 : 次世代の小線源治療を考えるー施設間や他診療科との連携体制ー, 日本放射線腫瘍学会第36回学術大会,
2.	Keiko Kudoh, Kazuhito Satomura, 高野栄之, Hiroaki Nakanishi, Takaharu Kudoh, Hitoshi Ikushima and Masaru Nagayama : 放射線性口内炎に対する蛍光診断の可能性, 第16回日本口腔粘膜学会総会・学術集会, (Summary) 1
3.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka and Hitoshi Ikushima : 当院における高リスク前立腺癌患者に対する外照射併用小線源治療の治療成績, 第141回日本医学放射線学会中国四国地方会, Dec. 2024.
4.	Locsin Leah Anne Christine Bollos, Youichi Otomi, 岡田直子, Tomoki Matsushita, Hideki Otsuka, Ryosuke Kasai, Shoichiro Takao, Koji Fujita, Yuishin Izumi, Takayoshi Shinya, Hitoshi Ikushima and Masafumi Harada : Comparative Imaging of Creutzfeldt-Jakob Disease: Two Cases with and without CCD, 第141回日本医学放射線学会中国・四国地方会, Dec. 2024.
5.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka and Masafumi Harada : 子宮頸癌に対する2種類の組織内併用腔内照射アプリケータ使用の初期使用経験, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
6.	Chisato Tonoiso, Takashi Kawanaka, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 膀胱癌に対する動注化学療法併用放射線治療の治療成績, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
7.	Hitoshi Ikushima, 伊井憲子, 木下留美子, 野田真永, 増井浩二, 村上直也, 吉田謙, 渡辺未歩, 大野達也 and 大西洋 : シンポジウム「厚労科研の現状」小線源治療, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
8.	伊井憲子 and Hitoshi Ikushima : 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
9.	Hitoshi Ikushima, 伊井憲子, 木下留美子, 野田真永, 増井浩二, 村上直也, 吉田謙, 渡辺未歩, 大野達也 and 大西洋 : ワークショップ「放射線治療のセンター化と均てん化」小線源治療の立場から, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
10.	戸板孝史 and Hitoshi Ikushima : 放射線治療計画ガイドライン・婦人科章の改定のポイント, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
11.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : Multicatheter法によるVAPBIの短期治療成績と有害事象の評価, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
12.	岸本悠斗, Motoharu Sasaki, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Takaharu Kudoh and Hitoshi Ikushima : F-18 FDG-PETによる子宮頸癌放射線治療後の予後予測, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
13.	門田香音, Yuki Matsumoto, Hitoshi Ikushima, Motoharu Sasaki and Akihiro Haga : 11C-Methionine PETラジオミクスによる脳腫瘍の再発と壊死の鑑別, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
14.	YOSHIDA Masahiro, Motoharu Sasaki, 中口裕二, Kanako Sakuragawa and Hitoshi Ikushima : 治療計画QAソフトウェアによる前立腺癌VMAT治療計画の改善効果と線量検証への影響, 第20回中四国放射線医療技術フォーラム, Oct. 2024.
15.	Hitoshi Ikushima : 子宮頸癌放射線療法アップデート, 京都府立医科大学第15回放射線治療研究会, Aug. 2024.
16.	Hitoshi Ikushima : 婦人科腫瘍の放射線療法, 第54回鹿児島放射線治療研究会, Jul. 2024.
17.	Takashi Kawanaka, Hitoshi Ikushima, Masato Nishimura, Akiko Abe, Akiko Kubo and Chisato Tonoiso : 18=F Fluorodeoxyglucose Positron Emission Tomographyによる子宮頸癌放射線治療後の予後予測, 第66回日本婦人科腫瘍学会学術講演会, Jul. 2024.
18.	Chisato Tonoiso, Hitoshi Ikushima, Akihiro Haga, Motoharu Sasaki, Takashi Kawanaka, Akiko Kubo, Masato Nishimura and Akiko Abe : 子宮頸癌リンパ節転移の術前予測におけるMRIレディオミクス解析の有用性, 第66回日本婦人科腫瘍学会学術講演会, Jul. 2024.
19.	Takaharu Kudoh, Keiko Kudoh, Natsumi Takamaru, Akira Takahashi, Naito Kurio, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Youji Miyamoto and Hitoshi Ikushima : Unilateral Neck Volumetric-Modulated Arc Therapy, 日本歯科放射線学会第64回学術大会, May 2024.
20.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 小線源治療によるAPBIを地域連携で行うBra-Shiの取り組み, 日本放射線腫瘍学会小線源治療部会第26回学術大会, May 2024.
21.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka, 上野恵輝, Yoshito Kusuhara and Hitoshi Ikushima : 当院における高リスク前立腺癌患者に対する外照射併用小線源治療, 日本放射線腫瘍学会小線源治療部会第26回学術大会, May 2024.
22.	伊井憲子, 増井浩二, 村上直也, 吉田謙, 渡辺未歩, 野田真永, Hitoshi Ikushima and 大野達也 : 子宮頸がん経直腸エコーガイド下組織内照射刺入の練習用ファントムの作成, 日本放射線腫瘍学会小線源治療部会第26回学術大会, May 2024.
23.	BOLLOS CHRISTINE ANNE LEAH LOCSIN, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Tomomi Matsuura, Tamaki Otani, BANDOH Takanori, UEKI Yuya, MATSUDA Noritake, 高志智, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis After Atrial Fibrillation Ablation, 第268回徳島医学会学術集会, Mar. 2024.
24.	Kanon Monda, Yuki Matsumoto, Motoharu Sasaki, Michihito Shimokawa, Akihiro Haga and Hitoshi Ikushima : 転移性脳腫瘍に対する放射線治療後の脳壊死と再発を鑑別する11C-Mthionine PET Radiomicsモデルの開発, 37, Mar. 2024.
25.	Hitoshi Ikushima : 画像誘導放射線治療ーさらなる画像の活用を目指してー, 第2階沖縄高精度放射線治療研究会, Dec. 2023.
26.	Chisato Tonoiso, 梶野晃未, Motoharu Sasaki, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Masafumi Harada : 放射線治療効果を検出するMRI Radiomics特徴量の探索, 第139回日本医学放射線学会中国・四国地方会, Dec. 2023.
27.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Yoshiteru Ueno, Yoshito Kusuhara, Tomoharu Fukumori, Hitoshi Ikushima and Masafumi Harada : 高リスク前立腺癌外照射併用小線源治療の後方視的検討, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
28.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Masafumi Harada and Hitoshi Ikushima : 小線源治療を用いたMulticatheter法によるHypofractionated APBIの初期導入経験, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
29.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Masafumi Harada : 中枢神経に再発を来した眼内悪性リンパ腫の2例, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
30.	下川通仁, Motoharu Sasaki, Akihiro Haga and Hitoshi Ikushima : 脳転移放射線治療後の壊死と再発の鑑別におけるMTI Radiomicsの有用性, 日本放射線腫瘍学会第36回学術大会, Nov. 2023.
31.	SAWADA Sohma, Motoharu Sasaki, SHIBUYA Kohki, 中口裕二 and Hitoshi Ikushima : 前立腺超寡分割照射時代における知識ベース治療計画システム構築の二次利用促進, 第19回中四国放射線医療技術フォーラム, Nov. 2023.
32.	SHIBUYA Kohki, Motoharu Sasaki, SAWADA Sohma, 中口裕二 and Hitoshi Ikushima : 知識ベース治療計画のモデル構築における標準化に向けて, 第19回中四国放射線医療技術フォーラム, Nov. 2023.
33.	ENDO Yuto, Motoharu Sasaki, Hitoshi Ikushima, 中口裕二 and Masafumi Harada : 知識ベース治療計画のモデル構築の効率的な作成に向けた取り組み, 第126回日本医学物理学会学術集会, Sep. 2023.
34.	Bollos Leah, Ryosuke Kasai, Youichi Otomi, Shoichiro Takao, Hitoshi Ikushima, Hideki Otsuka and Masafumi Harada : Prediction model of coronary artery calcification risk basis for radiomics features of pericoronary fat in coronary computed tomography, 第59回日本医学放射線学会秋季臨床大会, Sep. 2023.
35.	ENDO Yuto, Motoharu Sasaki, Hitoshi Ikushima, 中口裕二 and Masafumi Harada : 2種類のLINACによる前立腺VMATにおけるOARの線量低減の可能性, 第126回日本医学物理学会学術集会, Sep. 2023.
36.	Kanon Monda, Hitoshi Ikushima, Yuki Matsumoto, Motoharu Sasaki, Michihito Shimokawa and Masafumi Harada : Proposal of a rigid transformation method for contrast-enhanced MRI and C-11 methionine PET using iterative closest point and convolutional Neural Network, ISMRM Japanese Chapter, Sep. 2023.
37.	Hitoshi Ikushima : 小線源治療の現状と医学物理への期待, 第154回放射線治療かたろう会, Jun. 2023.
38.	Takashi Kawanaka, Akiko Kubo, 外礒千智, 川中妙子, Hitoshi Ikushima and Masafumi Harada : Multicatheter法を用いたHypofractionated Accelerated Partial Breast Irradiationの初期経験, 日本放射線腫瘍学会小線源治療部会第25回学術大会, May 2023.
39.	Hitoshi Ikushima : 小線源治療関連ガイソラインupdateー押さえておきたい改訂のポイントー, 日本放射線腫瘍学会小線源治療部会第25回学術大会, May 2023.
40.	小島徹, 小高喜久雄, 高橋健夫, 遠山尚紀, 川守田龍, 新保宗史, 谷正司, 大栗隆行 and Hitoshi Ikushima : RALS室CTの単独使用運用手順書案, 日本放射線腫瘍学会小線源治療部会第25回学術大会, May 2023.
41.	竹内秀真, Motoharu Sasaki, 山下恭, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 下窪康史, 櫻川加奈子 and Hitoshi Ikushima : Deformable image registrationを用いた子宮頸がん放射線治療の合算線量評価, 日本放射線腫瘍学会小線源治療部会第25回学術大会, May 2023.
42.	Yuka Hiroshima, Takayoshi Shinya, Hitoshi Ikushima, Youichi Otomi, Hideki Otsuka, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Yasushi Takagi and Masafumi Harada : Multi-modality Imaging for the Patients with Metastatic Brain Tumors After Stereotactic Irradiation, The 82nd Annual Meeting of the Japan Radiological Society, Apr. 2023.
43.	平田圭市郎, Hiroyuki Ueda, takanori miyake, takanori kashihara, Yasuyuki Okada, Hironori Tanaka, hironori wada, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Takashi Kawanaka, Hitoshi Ikushima, Yoshimi Bando, Yasushi Sato and Tetsuji Takayama : 切除不能・再発膵神経内分泌腫瘍(pancreatic neruoendocrine neoplasm:P-NEN)に対する集学的治療による治療成績の向上., 第109回日本消化器病学会総会, Apr. 2023.
44.	Motoharu Sasaki, Nagi Masumoto, 中口裕二, Shota Abe, KAJINO Akimi, SATOH Daisuke, ENDO Yuto, 都築明 and Hitoshi Ikushima : 知識ベース治療計画および治療計画QAソフトウェアを用いた計画者のばらつき, 第36回高精度放射線外部照射部会学術大会, Mar. 2023.
45.	KAJINO Akimi, Hitoshi Ikushima, Motoharu Sasaki, Tamaki Otani, Michiko Yamashita and Akihiro Haga : 放射線治療効果を早期に検出できるRadiomics特徴量の探索, 日本放射線腫瘍学会第35回学術大会, Nov. 2022.
46.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 再度の乳房加速部分照射を行った温存乳房内再発の1例, 日本放射線腫瘍学会第35回学術大会, Nov. 2022.
47.	YUTO Sadamasu, Motoharu Sasaki, KAJINO Akimi, Akimi Kajino, Daisuke Satoh, SHUMA Takeuchi, MICHIHITO Shimokawa, ENDO Yuto and Hitoshi Ikushima : 中咽頭IGRTにおけるCBCTの撮影回数の低減の可能性, 第18回中四国放射線医療技術フォーラム, Oct. 2022.
48.	Shota Abe, Motoharu Sasaki, 中口裕二, Nagi Masumoto and Hitoshi Ikushima : 頭頚部VMATにおける金属アーチファクト対策の新規提案, 第18回中四国放射線医療技術フォーラム, Oct. 2022.
49.	Nagi Masumoto, Motoharu Sasaki, 中口裕二, Akimi Kajino, Daisuke Satoh, Yuto Endo, Shota Abe and Hitoshi Ikushima : 知識ベース治療計画および治療計画QAソフトウェアを用いた計画者の変動, 第18回中四国放射線医療技術フォーラム, Oct. 2022.
50.	Motoharu Sasaki, Nagi Masumoto, 中口裕二, Shota Abe and Hitoshi Ikushima : 治療計画QAソフトウェアを利用した知識ベース治療計画データベース作成の有用性, 第50回日本放射線技術学会秋季学術大会, Oct. 2022.
51.	Hitoshi Ikushima : 小線源治療の現状と医学物理への期待, 第124回日本医学物理学会学術大会教育講演1, Sep. 2022.
52.	Erika Kawaguchi, Minoru Sakama, Ken'ichi Fujimoto, Hitoshi Ikushima and Takuya Saze : 131I内用療法のPHITSによる甲状腺と周辺リスク臓器の平均吸収線量評価, 日本放射化学会第66回討論会(2022), Sep. 2022.
53.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : APBI臨床における最新の知見(SAVIハイブリッド照射ほか), 第11回WASAVlsの会, Jul. 2022.
54.	Hitoshi Ikushima : 放射線療法概論, 日本癌治療認定医機構教育講演, Jul. 2022.
55.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : SAVIアプリケーターと乳房部分切除後の切離腔の検討とその改善方法, 第30回日本乳癌学会学術総会, Jun. 2022.
56.	Akiko Kubo, Hitoshi Ikushima, Takashi Kawanaka, Chisato Tonoiso and Masafumi Harada : 子宮頸癌放射線治療における標的体積内同時ブースト(SIB)併用についての試み, 第136回日本医学放射線学会中国・四国地方会, Jun. 2022.
57.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota, Hiroyoshi Watanabe, 福良翔子 and Hitoshi Ikushima : 急速な肝腫大に対し緊急放射線照射が奏功した神経芽腫4Sの乳児例, 第58回日本小児放射線学会学術集会, Jun. 2022.
58.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso and Takashi Kawanaka : 当院でのVenezia applicatorによる子宮頸がん小線源治療の使用経験, 日本放射線腫瘍学会小線源治療部会第24回学術大会, May 2022.
59.	Akiko Kubo, Hitoshi Ikushima, 川中崇 and Chisato Tonoiso : 当院でのVenezia applicatorによる子宮頸がん小線源治療の使用経験, 小線源治療部会第24回学術大会, May 2022.
60.	Hitoshi Ikushima : --, 日本放射線腫瘍学会小線源治療部会第24回学術大会, May 2022.
61.	Hitoshi Ikushima : 小線源治療臨床教育の現状と課題, 小線源治療部会第24回学術大会, May 2022.
62.	SATOH Daisuke, Motoharu Sasaki, 中口裕二, KUWAHARA Kemmei, KAJINO Akimi and Hitoshi Ikushima : 治療計画品質保証ソフトウェアが非小細胞Ⅲ期肺癌の正常臓器に対する線量低減へ与える影響, 第35回高精度放射線外部照射部会学術大会(WEB開催), Mar. 2022.
63.	Motoharu Sasaki, 中口裕二, ENDO Yuto, KUWAHARA Kemmei, KAJINO Akimi, SATOH Daisuke and Hitoshi Ikushima : 実現可能DVH参照後の汎用加速器とO-ring加速器を用いたリスク臓器への線量低減の可能性, 第35回高精度放射線外部照射部会学術大会(WEB開催), Mar. 2022.
64.	Motoharu Sasaki, Kanako Sakuragawa, KAJINO Akimi, SATOH Daisuke and Hitoshi Ikushima : 線量計算アルゴリズムの違いによる前立腺VMATの線量分布への直腸ガスの影響, 第17回中四国放射線医療技術フォーラム(WEB開催), Dec. 2021.
65.	Hiroaki Hayashi, 前田達哉, 淺原孝, 後藤聡汰, 竹上和希, 李青海, 安藤未来, Yuki Kanazawa, Hitoshi Ikushima, 岡崎徹 and 橋詰拓弥 : ディスポ型自作直腸線量計を用いた子宮頸がん治療における線量の実測, 第3回日本放射線安全管理学会・日本保健物理学会合同大会, Dec. 2021.
66.	Takaharu Kudoh, Keiko Kudoh, Hitoshi Ikushima, Akihiro Haga, Akira Takahashi and Youji Miyamoto : Dosimetric evaluation of contralateral neck in the unilateral neck volumetric modulated arc radiotherapy, 第19 回中国四国口腔癌研究会学術集会, Nov. 2021.
67.	村上直也, 渡辺未歩, 関井修平, 笠松高弘, 加藤真吾, 廣渡寿子, 兼安祐子, Hitoshi Ikushima, 安藤謙, 大野達也, 井垣浩 and 伊丹純 : 子宮頸癌に対する組織内照射併用腔内照射を用いた第I/II総試験の急性期有害事象, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
68.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and 原田雅史 : 乳房の照射後に発生した放射線誘発腫瘍の一例, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
69.	小島徹, 川村慎二, 大谷侑輝, 花田剛士, 大下崇, 山下修, 加茂前健, 岡本裕之, 黒澤忠弘, 脇谷雄一郎, 山田崇裕, 萬篤憲, Hitoshi Ikushima and 土器屋卓志 : 125Iシードの線源強度計測アンケートの報告, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
70.	Akiko Kubo, Hitoshi Ikushima, Takashi Kawanaka, Chisato Tonoiso, Takaharu Kudoh and 原田雅史 : 子宮頸癌化学放射線治療後の照射野内リンパ節転移についての検討, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
71.	安藤謙, 若月優, 渡邊未歩, 宇野隆, Hitoshi Ikushima, 土田圭祐, 村田和俊, 小此木範之, 伊井憲子, 加藤真吾, 野田真永, 有賀拓郎, 小川一成, 牛島弘毅 and 大野達也 : 子宮頸癌画像誘導小線源治療における高リスク臨床標的体積の画像モダリティ間比較研究, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
72.	福良翔子, Hiroyoshi Watanabe, 七條光市, Shuji Kondo, Noriko Yokota, Hiroki Mori, Hiroki Ishibashi, Jun Oto and Hitoshi Ikushima : 緊急放射線照射を施行した神経芽腫stage4Sの乳児例, 第63回日本小児血液・がん学会学術集会, Nov. 2021.
73.	KOHBUCHI Satoshi, 高倉亨, Motoharu Sasaki, 田嶋綾乃, 上原愛樹, 廣瀬知世, 木村仁人 and Hitoshi Ikushima : 電離箱線量計の印加電圧によるイオン再結合補正係数の変化, 第65回日本放射線技術学会近畿支部学術大会, Oct. 2021.
74.	Hitoshi Ikushima, 加納洋介, Motoharu Sasaki and Akihiro Haga : 深層学習を用いた子宮頸がん肉眼的腫瘍体積自動抽出, 第63回日本婦人科腫瘍学会, Jul. 2021.
75.	Hitoshi Ikushima, Tamaki Otani, Hideki Otsuka, Takashi Kawanaka, Akiko Kubo and 外磯千智 : 放射線治療における18F-3'-deoxy-3'-fluorothymidine の有用性, 第134回日本医学放射線学会中国四国地方会, Jun. 2021.
76.	Akiko Kubo, Hitoshi Ikushima, 外磯千智, Takashi Kawanaka, 下窪康史 and 櫻川加奈子 : Venezia applicatorによる子宮頸がん小線源治療の初期経験, 日本放射線腫瘍学会小線源治療部会第23回学術大会, May 2021.
77.	Motoharu Sasaki, 中口裕二, Yuto Endoh, Shoji Ueda, Yohsuke Kanoh, Kenta Kitagawa and Hitoshi Ikushima : 放射線治療計画QAソフトウェアの参照による前立腺VMAT計画の改善効果, 第34回高精度放射線外部照射部会学術大会(WEB開催), Apr. 2021.
78.	Yohsuke Kanoh, Hitoshi Ikushima, Akihiro Haga and Motoharu Sasaki : 人工知能を用いた子宮頸がんの自動輪郭抽出, 第34回高精度放射線外部照射部会学術大会(WEB開催), Apr. 2021.
79.	Hitoshi Ikushima : ベネチアアプリケータによる安全で効率的なハイブリッド照射, エレクタセミナー, Feb. 2021.
80.	戸板孝文, Hitoshi Ikushima and 加藤眞吾 : 子宮頸癌取り扱い規約の解説放射線療法, 第62回日本婦人科腫瘍学会学術講演会, Jan. 2021.
81.	Tamaki Otani, Hitoshi Ikushima, Yoshimi Bando, Hideki Otsuka, Kazuya Kondo and Hirokazu Miyoshi : 放射線治療効果判定における18F-FLT PETの有効性の検討, 第60回日本核医学学術総会, Nov. 2020.
82.	Takaharu Kudoh, Akihiro Haga, Motoharu Sasaki, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : Radiomicsの手法を用いたPETによる舌癌頸部リンパ節転移の予測, 日本放射線腫瘍学会第33回学術大会, Oct. 2020.
83.	Hitoshi Ikushima and Akihiro Haga : MRI画像解析による子宮頸癌化学放射線療法後の予後予測-JROSG多施設共同調査研究-, 日本放射線腫瘍学会, Oct. 2020.
84.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso and Hitoshi Ikushima : Single-entry applicatorとinterstitial needleを併用した小線源治療によるAPBIの1例, 日本放射線腫瘍学会第33回学術大会, Oct. 2020.
85.	Kenta Kitagawa, Motoharu Sasaki, Yohsuke Kanoh and Hitoshi Ikushima : 頭頸部VMATにおける義歯金属アーチファクト領域の物質変換体積の違いが線量分布に及ぼす影響, 第33回高精度放射線外部照射部会学術大会(WEB開催), May 2020.
86.	Motoharu Sasaki, 中口裕二, Kenta Kitagawa and Hitoshi Ikushima : 治療計画QAソフトウェアを用いた前立腺IMRTおよびVMAT計画のレトロスペクティブ解析, 第33回高精度放射線外部照射部会学術大会(WEB開催), May 2020.
87.	Motoharu Sasaki, Kenta Kitagawa, Yohsuke Kanoh, Masahide Tominaga and Hitoshi Ikushima : 体輪郭の変化が子宮頸がん術後照射VMATの線量分布へ及ぼす影響, 第33回高精度放射線外部照射部会学術大会(WEB開催), May 2020.
88.	Yoshihiro Uto, Daisuke Konishi, Nami Orimura, Hisatsugu Yamada, Masahide Tominaga, Hitoshi Ikushima, Kei Daizumoto and Hisanori Uehara : リニアックの FFFビームに対する新規増感剤の創製, 第22回癌治療増感シンポジウム, Feb. 2020.
89.	Hitoshi Ikushima : 婦人科小線源治療における鎮静鎮痛, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
90.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani and Masafumi Harada : 腋か領域を含めた乳癌術後照射における放射線肺臓炎の検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
91.	Chisato Tonoiso, Akihiro Haga, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 子宮頸部扁平上皮癌における予後因子の検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
92.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 当院におけるSAVIアプリケータを用いたAPBIの術式と整合性についての検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
93.	Shunsuke Furutani, Hitoshi Ikushima, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 非小細胞肺癌能転移に対する全脳照射の局所制御に関する検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
94.	Daisuke Konishi, Mana Futawaka, Yuri Fujiwara, Nami Orimura, Hisatsugu Yamada, Masahide Tominaga, Hitoshi Ikushima, Hisanori Uehara, Kei Daizumoto and Yoshihiro Uto : 医療用直線加速器の高線量率モードX線に対するGemcitabineの増感効果, 日本化学会中国四国支部大会徳島大会, Nov. 2019.
95.	Motoharu Sasaki, Masahide Tominaga, Kanako Sakuragawa, 横石道寛, Kyohei Ishikawa, Kenta Kitagawa, Yohsuke Kanoh and Hitoshi Ikushima : 3次元線量検証システムを用いた長期安定性の調査, 第47回日本放射線技術学会秋季学術大会, Oct. 2019.
96.	Yoshihiro Uto, Ayaka Hanyu, Yuki Kusuhashi, Mana Futawaka, Hisatsugu Yamada, Masahide Tominaga and Hitoshi Ikushima : 医療用直線加速器の高線量率モードX線を増感する抗がん剤の探索, 第25回癌治療増感研究会, Jun. 2019.
97.	下窪康史, Kanako Sakuragawa, 冨田恵美, 林裕晃, Yuki Kanazawa and Hitoshi Ikushima : 子宮頸癌RALSにおける自作直腸線量計を用いた実臨床データとその分析, 日本放射線腫瘍学会小線源治療部会第21回学術大会, May 2019.
98.	冨田恵美, 林裕晃, 淺原孝, 下窪康史, Kanako Sakuragawa, Yuki Kanazawa and Hitoshi Ikushima : 子宮頸癌の腔内照射における直腸線量実測に向けたディスポーザブル型直腸線量計の開発, 日本放射線腫瘍学会小線源治療部会第21回学術大会, May 2019.
99.	Motoharu Sasaki, Masahide Tominaga, 川下徹也, 横石道寛, Kanako Sakuragawa and Hitoshi Ikushima : VMATにおけるplan normalization valueが線量検証へ及ぼす影響, 第32回高精度放射線外部照射部会学術大会, Mar. 2019. (Keyword) VMAT / quality assurance / head and neck / plan normalization value
100.	外礒千智, Akihiro Haga, 高橋彩加, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 治療前MRI画像を用いた子宮頸癌予後因子の検討, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
101.	Takaharu Kudoh, 高橋彩加, 外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 当院における放射線性骨壊死に関する臨床的研究, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
102.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 高橋彩加, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : ビタミンA含有軟膏を予防的塗布した全乳房照射症例の検討, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
103.	高橋彩加, Shunsuke Furutani, 外礒千智, Akiko Kubo, Takashi Kawanaka, Akiko Abe, Masato Nishimura, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 子宮頸部及び腟の異型性・上皮内癌に対する高線量率小線源治療, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
104.	Akiko Kubo, 高橋彩加, 外礒千智, Takaharu Kudoh, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頸癌根治的化学放射線治療後の仙骨不全骨折についての検討, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
105.	Akiko Kubo, 高橋彩加, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頸部扁平上皮癌放射線治療後局所残存を疑った症例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
106.	Chisato Tonoiso, 高橋彩加, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 乳房原発悪性リンパ腫の1 例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
107.	Akiko Kubo, 高橋彩加, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頚部扁平上皮癌放射線治療後局所残存を疑った症例, Oct. 2018.
108.	高橋彩加, Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 乳癌放射線治療後の難治性潰瘍に対して胸壁再建を施行した1 例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
109.	Shunsuke Furutani, Hitoshi Ikushima, 外磯千智, Akiko Kubo, Takashi Kawanaka, Hidehisa Mori, Tomoharu Fukumori, Minoru Sakama and Masafumi Harada : 前立腺癌I-125シード治療におけるセラストランドの使用経験(オンコシードと比較して), 日本放射線腫瘍学会小線源治療部会第20回学術大会, Jun. 2018.
110.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka and Shunsuke Furutani : Image registration softwareを用いた子宮頸癌放射線治療の統合線量評価の検討, Jun. 2018.
111.	高橋彩加, Shunsuke Furutani, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima, Masafumi Harada, Akiko Abe and Masato Nishimura : 子宮頸部及び膣の異形成・上皮内癌に対する高線量率小線源治療, Jun. 2018.
112.	三橋遼太, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 高橋彩加, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頚部小細胞癌に対して放射線治療を行った2症例, Jun. 2018.
113.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 放射線治療を施行した乳房原発悪性リンパ腫の1例, May 2018.
114.	Takashi Kawanaka, Akiko Kubo, 外礒千智, 川中妙子, Hitoshi Ikushima and Masafumi Harada : 乳癌からの転移性腰椎腫瘍に対してVMAT を用いた再照射を行った1例, 第26回日本乳癌学会学術総会, May 2018.
115.	TOMITA Emi, Hiroaki Hayashi, SHITAKUBO Yasufumi, SAKURAGAWA Kanako, Yuki Kanazawa, Hitoshi Ikushima, OKAZAKI Tohru, ASAHARA Takashi, HASHIZUME Takuya and MIYAHARA Yoshinori : Rectum Dose Measurements Using Novel Dosimetric System During High-Dose-Rate 192Ir Brachytherapy Treatment of Cervical Cancer, 第74回日本放射線技術学会総会学術大会, Apr. 2018.
116.	Masahide Tominaga, Motoharu Sasaki, Motokatsu Yasutomo, Kenji Yamada, Takeshi Kojima, Akihiro Haga, Hitoshi Ikushima and 角谷倫之 : Digital Phantomを用いたImage Registrationソフトウェアの性能評価, 第31回高精度放射線外部照射部会学術大会, Feb. 2018.
117.	Shunsuke Furutani, Hitoshi Ikushima, 外磯千智, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 前立腺癌I-125シード治療におけるセラストランドの使用経験, 第129回日本医学放射線学会中国・四国地方会, Dec. 2017.
118.	Shunsuke Furutani, Hitoshi Ikushima, 外礒千智, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 肺癌脳転移に対する全脳照射の局所制御に関する検討, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
119.	外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh and Hitoshi Ikushima : 当院における外耳癌の治療成績, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
120.	Akiko Kubo, 外礒千智, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : Image registration softwareを用いた子宮頸がん放射線治療の統合線量評価, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
121.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 外礒千智, Hitoshi Ikushima and Masafumi Harada : 子宮頸癌根治的放射線治療における組織内照射併用腔内照射での線量分布に関する検討, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
122.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 高リスク限局性前立腺癌に対する I-125 密封小線源療法の治療成績と生化学的再発予測因子の検討, 第55回日本癌治療学会学術集会, Oct. 2017.
123.	下窪康史, 櫻川加奈子, Hiroaki Hayashi, 冨田恵美, 浅原孝, Hitoshi Ikushima, 岡崎徹, 三枝裕司, 橋詰拓弥 and Vergil LE Cruz : In-vivo dosimetry using a self-made rectal dosimeter for intraluminal irradiation using iridium 192 for cervical cancer, 第45回日本放射線技術学会秋季学術大会, Oct. 2017.
124.	外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 子宮頸部小細胞癌の1例, 第53回日本医学放射線学会秋季臨床大会, Sep. 2017.
125.	Akiko Kubo, 外礒千智, Kazuya Kondo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 腋窩・鎖骨上領域を含めた乳癌術後照射における放射線肺臓炎の検討, 第53回日本医学放射線学会秋季臨床大会, Sep. 2017.
126.	Hitoshi Ikushima : Oncological emergencyにおける放射線治療の役割, 日本外科系連合学会学術集会 in Tokushima, Jun. 2017.
127.	行重佐和香, 森本雅美, Hirokazu Takechi, Misako Nakagawa, Hiroaki Toba, Akira Tangoku, Seiji Iwamoto, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 輸血せずに集学的治療により止血せしめた薬剤抵抗性血管浸潤進行副乳癌の1例, 第42回日本外科系連合学会学術集会, Jun. 2017.
128.	Minoru Sakama, Hitoshi Ikushima, 松本(川口) 絵里佳, 井本尚吾 and 井原智也 : 小線源治療におけるリスク臓器の被ばく線量評価を目的とした最新モンテカルロシミュレーション計算コードPHITS ver.2.91, 小線源治療部会第19回学術大会,一般演題(物理),奈良県文化会館, May 2017.
129.	Masahide Tominaga, Motoharu Sasaki, 安友基勝, Takeshi Kojima, Kenji Yamada, Hitoshi Ikushima and 角谷倫之 : 市販Image registrationソフトウェアの評価用Digital Phantomの開発, 日本放射線腫瘍学会第30回高精度外部放射部会学術大会, Mar. 2017.
130.	外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 当院における聴器癌の治療成績, 第127回日本医学放射線学会中国・四国地方会, Dec. 2016.
131.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Sequential radioactive iodine treatment and intensity modulated radiotherapy:a case repot, The 29th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2016.
132.	下窪康史 and Hitoshi Ikushima : Quantitative Evaluation Of Metal Artifact Reduction of CT for treatment planning of brachytherapy, The 29th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2016.
133.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Presumed abscopal effect of radiation on bone and brain metastases of lung cancer:a case report, The 29th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2016.
134.	細谷未来, Motoharu Sasaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh and Hitoshi Ikushima : Dosimetric comparison of VMAT and 3DCRT in patients with cervical cancer, The 29th Annual Meeting of the Japanese Society for Radiation, Nov. 2016.
135.	Shunsuke Furutani, Hitoshi Ikushima, Takashi Kawanaka, Akiko Kubo, 高橋彩加, 宮本加奈子, 新井悠太, 長瀬紗季 and Masafumi Harada : 多発性脳転移に対するVMATを用いた分割定位放射線治療の治療成績, 日本放射線腫瘍学会, Nov. 2016.
136.	Hitoshi Ikushima : 特別企画1，JASTRO将来像，教育委員会の将来展望, 日本放射線腫瘍学会第29回学術大会, Nov. 2016.
137.	Takaharu Kudoh, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 頭頸部癌に対するIMRTにおける予防的頸部CTV設定の妥当性の検証, 日本放射線腫瘍学会第29回学術大会, Nov. 2016.
138.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : アブスコパル効果と思われる治療経過を示した肺癌の1症例, 第54回日本癌治療学会学術集会, Oct. 2016.
139.	Takashi Kawanaka, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 甲状腺乳頭癌頸部リンパ節転移に対してI-131による内容療法とIMRTを逐次併用した1症例, 第54回日本癌治療学会学術集会, Oct. 2016.
140.	Hitoshi Ikushima, 若月優, 有賀拓郎, 兼安祐子, 徳丸直郎, 礒橋文明, 伊井憲子, 宇野隆, 大野達也 and 戸板孝文 : 腟癌の放射線療法―日本放射線腫瘍学研究機構多施設調査―, 第54回日本癌治療学会, Oct. 2016.
141.	Tomohiro Sagawa, Masahide Tominaga, 田中翼, Motoharu Sasaki, 本田道隆 and Hitoshi Ikushima : Computed Radiography を用いた Multi-Leaf collimator の精度管理, 医用画像情報学会(MII), Oct. 2016.
142.	下窪康史, Masahide Tominaga, Ryosuke Kasai, Motoharu Sasaki, 田中翼, 佐川友啓, 本田道隆 and Hitoshi Ikushima : 子宮頸癌に対する腔内小線源治療計画時におけるCBCT画像の画質評価, 医用画像情報学会(MII), Oct. 2016.
143.	Hitoshi Ikushima : 画像誘導放射線治療, 第176回医用画像情報学会秋季大会, Oct. 2016.
144.	Hitoshi Ikushima : 婦人科腫瘍の放射線治療, 日本放射線科専門医会・医会ミッドサマーセミナー2016, Jul. 2016.
145.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 癌脳転移に対する放射線治療後のに開頭手術を施行した症例の検討, 第24回乳癌学会学術総会, Jun. 2016.
146.	Hitoshi Ikushima : 密封小線源治療をサポートする新たなテクノロジー, 日本放射線腫瘍学会小線源部会題18回学術大会, May 2016.
147.	Masahide Tominaga, Motoharu Sasaki, Motoharu Sasaki, Kento Tanaka, 安友基勝, 山田健二 and Hitoshi Ikushima : 市販Image registrationソフトウェアの画像類似度の比較評価, 日本放射線腫瘍学会第29回高精度外部放射部会学術大会, Feb. 2016.
148.	Hitoshi Ikushima : 婦人科腫瘍の放射線治療, 日本放射線専門医会ミッドウィンターセミナー, Jan. 2016.
149.	高橋彩加, Shunsuke Furutani, Seiji Iwamoto, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima, Masafumi Harada and Takaharu Kudoh : 鼻副鼻腔癌に対する強度変調放射線治療の初期経験, 日本医学放射線学会中国四国地方会, Dec. 2015.
150.	Takaharu Kudoh, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : Necessity of postoperative radiation therapy of contralateral neck for later alized oral squamous cell carcinoma, 日本放射線腫瘍学会第28回学術大会, Nov. 2015.
151.	Hitoshi Ikushima : ハイブリッドIGRT, The Official Jpurnal of The Japanese Society for Therapeutic Radiology and Oncology, Nov. 2015.
152.	Shunsuke Furutani, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh and Hitoshi Ikushima : Clinical outcomes of volumetric modulated arc therapy for multiple brain metastases, 日本放射線腫瘍学会, Nov. 2015.
153.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 高橋彩加, Hitoshi Ikushima and Masafumi Harada : Intensity modulated radiation therapy for cervical cancer: Potential efficacy for reducing the adverse pelvic bone event, 日本放射線腫瘍学会, Nov. 2015.
154.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : I-125密封小線源療法のPSA再発症例の臨床的検討, 第53回日本癌治療学会学術集会, Oct. 2015.
155.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Tomoharu Fukumori, Hitoshi Ikushima and Masafumi Harada : 当院におけるI-125シード永久刺入療法を行った前立腺癌の長期成績の検討, 第51回日本医学放射線学会秋季臨床大会, Oct. 2015.
156.	Hitoshi Ikushima : 婦人科腫瘍, 日本放射線腫瘍学会夏季セミナー, Aug. 2015.
157.	Minoru Sakama, Hitoshi Ikushima, Shunsuke Furutani, 市樂輝義, 高井久司, 山田隆治, 北島孝弘, 桑原明伸, 安野卓, 藤本憲市 and 嵯峨山和美 : 高精度・迅速・簡便な新ヨウ素シード品質管理システム(BS-2000)の開発, 日本放射線腫瘍学会小線源部会, Jun. 2015.
158.	小畑祐太, 三宅裕司, Motoharu Sasaki, 下窪靖史, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh and Hitoshi Ikushima : 子宮頸癌腔内照射におけるリンパ節領域の線量評価, 日本放射線腫瘍学会小線源治療部会, Jun. 2015.
159.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Tomoharu Fukumori, Hitoshi Ikushima, Hiro-omi Kanayama and Masafumi Harada : 当院で長期経過観察をした前立腺癌I-125シード永久挿入療法の検討, 日本放射線腫瘍学会小線源部会, Jun. 2015.
160.	Hitoshi Ikushima : 放射線腫瘍学論文の書き方, 第73回日本医学放射線学会総会, Apr. 2015.
161.	Naoto Uyama, Hideki Otsuka, Youichi Otomi, Masafumi Harada, Hitoshi Ikushima, Taito Yamago, Yuko Toyoda, Masaki Hanibuchi, Yasuhiko Nishioka, Hiromitsu Takizawa and Yoshimi Bando : 特異な経過を示した肺原発滑膜肉腫の一例, 第7回呼吸機能イメージング研究会学術集会, Feb. 2015.
162.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 転移性脳腫瘍に対する定位放射線治療に関する検討, 第123回日本放射線学会中国四国地方会, Dec. 2014.
163.	兼安祐子, 西村哲夫, 藤原久也, 大野達也, 櫻井英幸, 猪本智子, Hitoshi Ikushima, 宇野隆, 徳丸直郎, 播磨洋子, 戸板孝文 and 永田靖 : 子宮頸癌治療後のQOLに関する多施設共同調査(第3報)-放射線療法群と手術療法群の比較ー, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
164.	Kyo Yamashita, Hitoshi Ikushima, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Kyosuke Osaki, Takaharu Kudoh, Masahide Tominaga and 仁木孝明 : 放射線治療に携わるスタッフのストレス状況∼徳島県の場合∼, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
165.	Takaharu Kudoh, Motoharu Sasaki, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 頭頸部癌放射線治療中の転移リンパ節のサイズ変化と制御との関連, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
166.	Shunsuke Furutani, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh, Hitoshi Ikushima, Tomoharu Fukumori and Hiro-omi Kanayama : 5年以上経過した前立腺癌I-125シード治療症例における線量増加の有効性と安全性の検討, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
167.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 転移性骨腫瘍に対する外部方射線療法と塩化ストロンチウム-89併用に関する検討, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
168.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 子宮頸癌根治的科学放射線化学療法後のFDG集積と予後との関連, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
169.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 転移性骨腫瘍に対する外部方射線療法と塩化ストロンチウム-89併用に関する検討, 第52回日本癌治療学会学術集会, Aug. 2014.
170.	Hitoshi Ikushima : 子宮頸癌に対する強度変調放射線治療, 第56回日本婦人科腫瘍学会学術講演会, Jul. 2014.
171.	Shunsuke Furutani, Hitoshi Ikushima, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 当院における原発性肺癌に対する定位放射線治療成績, 第122回日本医学放射線学会中国・四国地方会, Jun. 2014.
172.	Hitoshi Ikushima : How to write a scientific paper on radiation oncology, 日本医学放射線学会総会, Apr. 2014.
173.	Takashi Kawanaka, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 食道癌術後再発に対する放射線治療症例の検討, 第34回四国食道疾患研究会, Feb. 2014.
174.	高橋直希, Atsuro Saijo, Souji Kakiuchi, Masaki Hanibuchi, Hiromitsu Takizawa, Takeshi Nishino, 森住俊, 岸昌美, Katsuhiro Kinoshita, Hisatsugu Goto, Youichi Otomi, Hitoshi Ikushima, Shoji Sakiyama and Yasuhiko Nishioka : PET/CTにて集積を認めなかった嚢胞状縦隔リンパ節腫大を伴う肺腺癌の一例, 第6回呼吸機能イメージング研究会学術集会, Jan. 2014.
175.	Hitoshi Ikushima : cone beam CTによる治療計画, マイクロセレクトロンHDR研究会, Dec. 2013.
176.	Minoru Sakama, 長野裕介, Yoshinori Kuwahara, 山田隆治, 市樂輝義, 高井久司, Takuya Saze, Hitoshi Ikushima, Shunsuke Furutani and Shintaro Nakayama : 前立腺がん治療用ヨウ素シード品質管理測定システムにおける測定精度の評価, 日本放射線安全管理学会第12回学術大会, Nov. 2013.
177.	Ryosuke Fukura, Masahide Tominaga, Hitoshi Ikushima, Keigo Masuda, 岸太郎 and Motoharu Sasaki : 前立腺 IMRT および VMAT 計画評価におけるレトロスペクティブ解析, 中四国放射線医療技術フォーラム2014, Nov. 2013.
178.	Keigo Masuda, Masahide Tominaga, Hitoshi Ikushima, Ryosuke Fukura, 岸太郎 and Motoharu Sasaki : 6 軸治療寝台システムを用いた位置精度に関する基礎的検討, 中四国放射線医療技術フォーラム2014, Nov. 2013.
179.	Takaharu Kudoh, Kenji Fujisawa, Keiko Kudoh, Masako Fujioka-Kobayashi, Nobuyuki Kuribayashi, Natsumi Takamaru, Go Ohe, Daisuke Uchida, Akira Takahashi, Tetsuya Tamatani, Hirokazu Nagai, Hitoshi Ikushima and Youji Miyamoto : 当科における強度変調放射線治療(IMRT)の経験, 第12回中国四国口腔癌研究会学術講演会, Nov. 2013.
180.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima, lto Emma and Liu Fei-Fei : 子宮頸癌細胞でUROD knockdownを用いた放射線化学療法に関する基礎的検討, 日本放射線腫瘍学会第26回学術大会, Oct. 2013.
181.	三宅悠太, Takashi Kawanaka, 三枝裕司, 下窪康史, Motoharu Sasaki, 岸太郎, Shunsuke Furutani, Akiko Kubo, Takaharu Kudoh and Hitoshi Ikushima : Cone beam CTによる3次元画像誘導小線源治療, 日本放射線腫瘍学会第26回学術大会, Oct. 2013.
182.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, 尾崎享祐, Kyo Yamashita and Hitoshi Ikushima : 外陰癌大腿鼠径リンパ節転移に関する照射野の検討, 日本放射線腫瘍学会第26回学術大会, Oct. 2013.
183.	Tomoharu Fukumori, Tomokazu Senzaki, Takashi Kawanaka, Akiko Kubo, Jun-ichiro Kagawa, Masatsugu Komori, Hisaya Takahashi, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対するI-125密封小線源療法のPSA再発予測因子の検討, 第48回日本がん治療学会学術集会, Sep. 2013.
184.	Hitoshi Ikushima, Akiko Kubo, Takaharu Kudoh, Takashi Kawanaka and Shunsuke Furutani : 子宮頸癌放射線治療の新展開子宮頸癌放射線治療後局所再発の診断, 第54回日本婦人科腫瘍学会学術講演会, Jul. 2013.
185.	中島和弥, Seiji Iwamoto, Takashi Kawanaka, Takaharu Kudoh, Takaharu Kudoh, Akiko Kubo, Youichi Otomi, Shunsuke Furutani, Hideki Otsuka and Hitoshi Ikushima : 頭頸部癌の化学放射線療法における11C-Methionine PETの有用性, 日本放射線腫瘍学会第26回学術大会, Jul. 2013.
186.	Hitoshi Ikushima, 三枝裕司, 下窪康史, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh, 原康男, Motoharu Sasaki, 川下徹也 and 岸太郎 : 第120回日本医学放射線学会中国・四国放射線治療懇話会, Jun. 2013.
187.	Hitoshi Ikushima and Hiroshi Maezawa : 192-Ir高線量率密封小線源治療における細胞致死効果に対する線量率効果, 日本放射線腫瘍学会小線源部会第15回学術大会, May 2013.
188.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani and Hitoshi Ikushima : 子宮頸癌放射線治療後の予後予測因子としてのUROD, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
189.	Takaharu Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo and Hitoshi Ikushima : 口腔癌の放射線治療に用いる新型マウスピースの開発, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
190.	Akiko Kubo, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh, 尾崎享祐, Kyo Yamashita and Hitoshi Ikushima : 子宮頸癌放射線治療後局所再発の画像診断に関する検討, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
191.	木村雅司, Akiko Kubo, Motoharu Sasaki, Yasuo Hara, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh and Hitoshi Ikushima : 放射線治療期間中に生じる標的の変化, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
192.	Hitoshi Ikushima, Youichi Otomi, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo and Takaharu Kudoh : III期局所進行非小細胞肺癌の術前導入化学放射線療法, 第119回日本医学放射線学会中国四国地方会, Dec. 2012.
193.	Akiko Kubo, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh, Kyosuke Osaki, Kyo Yamashita and Hitoshi Ikushima : 子宮頸癌放射線治療後局所再発の画像診断に関する検討, 日本放射線腫瘍学会第25回学術大会, Nov. 2012.
194.	廣田充宏, Masahide Tominaga, Motoharu Sasaki, 鎌田真奈, Yoshihiro Tanaka, Yasuo Hara, 坂東良太 and Hitoshi Ikushima : 三次元検出器システムの特性に関する検討, 第8回中四国放射線医療技術フォーラム, Oct. 2012.
195.	鎌田真奈, Masahide Tominaga, Motoharu Sasaki, 廣田充宏, Yoshihiro Tanaka, Yasuo Hara, 坂東良太 and Hitoshi Ikushima : 三次元検出器システムの特性に関する検討, 第8回中四国放射線医療技術フォーラム, Oct. 2012.
196.	Masahide Tominaga, Motoharu Sasaki, 鎌田真奈, 廣田充宏, Yoshihiro Tanaka, Yasuo Hara, 坂東良太 and Hitoshi Ikushima : 三次元検出器の特性に関する検討, 第25回高精度放射線治療研究会, Jul. 2012.
197.	Shunsuke Furutani, Takuya Saze, Yoshinori Kuwahara, 山田隆治, 市楽輝義, 篠原敏徳, 高井久司, Akiko Kubo and Hitoshi Ikushima : 臨床用全自動型I-125シード放射線強度測定システムの開発, 日本放射線腫瘍学会小線源部会, May 2012.
198.	Shunsuke Furutani, Takuya Saze, Yoshinori Kuwahara, 山田隆治, 市樂輝義, 篠原敏徳, 高井久司, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Masafumi Harada : 臨床用全自動型 I-125シード放射線強度測定システムの開発, 日本放射線腫瘍学会第14回小線源治療部会, May 2012.
199.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 第27回前立腺シンポジウム, Dec. 2011.
200.	Akiko Kubo, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh, Kyosuke Osaki, Kyo Yamashita and Hitoshi Ikushima : 子宮頚癌化学放射線治療のリンパ節制御に関する検討, 日本放射線腫瘍学会第24回学術大会, Nov. 2011.
201.	Shunsuke Furutani, Hitoshi Ikushima, Maki Ohtomo, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh, Tomoharu Fukumori, Hiro-omi Kanayama and Masafumi Harada : 前立腺癌 I-125 シード単独治療における線量増加の有効性と安全性の検討, 日本放射線腫瘍学会第24回学術大会, Nov. 2011.
202.	Takaharu Kudoh, Hiroshi Maezawa, Shunsuke Furutani, Akiko Kubo and Hitoshi Ikushima : 子宮頸癌に対する 192-Ir 高線量率照射 in vitro 実験モデルの作成, 日本放射線腫瘍学会第24回学術大会, Nov. 2011.
203.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 前立腺密封小線源療法前のcombined androgen blockade(CAB)療法の臨床的検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 677, Oct. 2011. (Keyword) *Androgen Antagonists(治療的利用)
204.	Hitoshi Ikushima, Takaharu Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo and Kazuya Kondo : 胸腺腫の放射線治療, 第115回日本医学放射線学会中国・四国地方会, May 2011.
205.	山崎浩実, Shunsuke Furutani, 岩河早保, Akiko Kubo, Akiko Kubo, Takashi Kawanaka and Hitoshi Ikushima : 神経膠芽腫に対するテモゾロミド併用放射線治療成績, 第115回日本医学放射線学会中国・四国地方会, Dec. 2010.
206.	Takaharu Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, 村上千尋, 岩河早保, 山埼浩実 and Hitoshi Ikushima : 192-Ir モールド照射時の鉛とアクリルによる遮蔽効果の検討, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
207.	村上千尋, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, 尾崎享祐 and Hitoshi Ikushima : 子宮頸癌に対するclinical target volume 設定ガイドラインの検証, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
208.	坂東良太, Takashi Kawanaka, Takaharu Kudoh, 原康男, 佐々木幹治, Akiko Kubo, Shunsuke Furutani and Hitoshi Ikushima : 頭頚部腫瘍に対する放射線治療中の解剖学的変化に関する検討, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
209.	Akiko Kubo, Shunsuke Furutani, 山崎浩実, 岩河早保, Takaharu Kudoh, Takashi Kawanaka and Hitoshi Ikushima : 根治的化学放射線治療後再発子宮頸癌に対する救済療法の検討, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
210.	木村雅司, 佐々木幹治, 岸太郎, 川下徹也, 原康男, 福永有希子, 下窪康史, 高志智 and Hitoshi Ikushima : 2次元半導体検出器における線量測定精度について, 第18回(社)日本放射線技師会中四国放射線技師学術大会・第51回日本放射線技術学会中国四国部会学術大会, Oct. 2010.
211.	田辺円花, 湯浅千尋, Masahide Tominaga, Motoharu Sasaki and Hitoshi Ikushima : MUの独立検証, Oct. 2010.
212.	湯浅千尋, 田辺円花, Masahide Tominaga, Motoharu Sasaki and Hitoshi Ikushima : CR装置を用いたMLCのQAについての一考察, Oct. 2010.
213.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 二宮郁, 白戸玲臣, 橋根勝義, Shunsuke Furutani, Hitoshi Ikushima, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 早期前立腺がんの治療戦略早期前立腺癌に対する密封小線源療法の臨床的検討, 第48回日本癌治療学会学術集会, Oct. 2010. (Keyword) *近距離照射治療法
214.	Hiroyoshi Watanabe, 岡村和美, Nami Inoue, 花岡尚賢, Kenji Endo, Shoji Sakiyama, Hitoshi Ikushima, Natsuo Yasui and Shoji Kagami : 再発骨軟部腫瘍の3例, 第62 回中国四国小児科学会, Oct. 2010.
215.	Shunsuke Furutani, Takuya Saze, Takashi Kawanaka, Akiko Kubo and Hitoshi Ikushima : シンチレーション式サーベイメーターを用いた簡易的なヨウ素125密封小線源の線源強度測定システムの検討, 日本放射線腫瘍学会小線源治療部会第12回研究会, May 2010.
216.	Koichiro Kenzaki, Hitoshi Ikushima, Kazuya Kondo, Hiroaki Toba, Yasushi Nakagawa, Hiromitsu Takizawa, Shoji Sakiyama and Akira Tangoku : 原発性肺癌Ⅰ期における消極的肺部分切除と定位放射線治療との比較, 第27回日本呼吸器外科学会総会, May 2010.
217.	河淵聡, 福永正明, 岸太郎, 佐々木幹治, 山田健二, Masahide Tominaga and Hitoshi Ikushima : MUの独立検証, 中四国放射線医療技術フォーラム CSFRT2009 in SHIMANE, Nov. 2009.
218.	Shunsuke Furutani, Hitoshi Ikushima, Seiji Iwamoto, Akiko Kubo, Takashi Kawanaka, Kyosuke Osaki, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Hiromu Nishitani : 膀胱温存を目的とした浸潤性膀胱癌に対するTUR-Bt+動注化学放射線療法の治療成績, 第47回日本癌治療学会学術集会, Oct. 2009.
219.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Takashi Kawanaka, Akiko Kubo and Hiromu Nishitani : 当院における前立腺癌密封小線源療法の治療成績, 日本放射線腫瘍学会第22回学術大会, Sep. 2009.
220.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Takashi Kawanaka, Akiko Kubo and Hiromu Nishitani : 当院における前立腺癌術後のPSA再発に対する放射線治療成績, 日本放射線腫瘍学会第21回学術大会, Oct. 2008.
221.	越智耕平, Kyosuke Osaki, Shunsuke Furutani, Kyo Yamashita, 中川崇, 久保亜貴子, Hitoshi Ikushima, Yoshihiro Takegawa and Hiromu Nishitani : 多発肺転移・骨転移をきたしたWilms腫瘍の治療経験, 第108回日本医学放射線学会中国・四国地方会(岡山), Jun. 2007.
222.	尾崎亨祐, Hitoshi Ikushima, Shunsuke Furutani, Kyo Yamashita, 岸田義臣, Seiji Iwamoto, Yoshihiro Takegawa and Hiromu Nishitani : 徳島大学病院における子宮頸癌の治療成績, 日本放射線腫瘍学会第19回学術集会(仙台)日本放射線腫瘍学会誌, Vol.18, No.Supplement 1, 231, Nov. 2006.
223.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Kyo Yamashita, Seiji Iwamoto, Seiji Iwamoto, Yoshihiro Takegawa and Hiromu Nishitani : 前立腺癌に対するI-125密封小線源療法の1年後の治療成績, 日本放射線腫瘍学会第19回学術集会(仙台)日本放射線腫瘍学会誌, Vol.18, No.Supplement 1, 201, Nov. 2006.
224.	岸田義臣, Hitoshi Ikushima, Seiji Iwamoto, Kyo Yamashita, Shunsuke Furutani, Kyosuke Osaki, Yoshihiro Takegawa, Takaharu Kudoh and Hiromu Nishitani : PET-CTによる放射線治療計画に関する基礎的検討ー寝台についてー, 日本放射線腫瘍学会第19回学術大会(仙台) 日本放射線腫瘍学会誌, Vol.18, No.Supp. 1, 151, Nov. 2006.
225.	Seiji Iwamoto, Hitoshi Ikushima, 岸田義臣, Kyo Yamashita, Shunsuke Furutani, Kyosuke Osaki, Yoshihiro Takegawa, Takaharu Kudoh and Hiromu Nishitani : 浸潤性膀胱癌に対する動注化学療法併用放射線治療の検討, 日本放射線腫瘍学会第19回学術大会(仙台)2006.11 (日本放射線腫瘍学会誌), Vol.18, No.Supp. 1, 220, Oct. 2006.
226.	岸田義臣, Hitoshi Ikushima, 寺澤かおり, Seiji Iwamoto, Shunsuke Furutani, Kyo Yamashita, Kyosuke Osaki, Takaharu Kudoh, Yoshihiro Takegawa and Hiromu Nishitani : 放射線治療においてPET/CTが有用であると考えられた症例, 第44回日本癌治療学会総会(東京), Oct. 2006.
227.	Keiko Kudoh, Kazuhito Satomura, Takaharu Kudoh, Hitoshi Ikushima and Masaru Nagayama : 放射線性口内炎に対する蛍光診断の可能性, Jun. 2006.
228.	岸田義臣, Seiji Iwamoto, Shunsuke Furutani, 尾崎享祐, Hitoshi Ikushima, Hiromu Nishitani and Yoshihiro Takegawa : PET-CTによる放射線治療計画に関する基礎的検討ー寝台についてー, 第106回日本医学放射線学会中国・四国地方会(山口), Jun. 2006.
229.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, 岸田義臣, Yoshihiro Takegawa and Hiromu Nishitani : イメージングプレートを用いたヨウ素125密封小線源の線源強度測定法の検討, 小線源治療部会第8回研究会(栃木), Jun. 2006.
230.	尾崎享祐, Hitoshi Ikushima, Shunsuke Furutani, 岸田義臣, 岩本誠司, Yoshihiro Takegawa and Hiromu Nishitani : 前立腺癌に対するヨウ素125密封小線源永久挿入療法の急性期有害事象の検討, 日本放射線腫瘍学会第18回学術大会(埼玉), Nov. 2005.
231.	Masataka Oita, Kyosuke Osaki, Hitoshi Ikushima, Hirofumi Yagi, Yoshihiro Takegawa and Hiromu Nishitani : QCファントムを用いた自走式CTリニアック装置の精度評価, 日本放射線腫瘍学会第18回学術大会(埼玉)日本放射線腫瘍学会第18回学術大会報告集, Vol.17, No.Supplement 1, 168, Nov. 2005.
232.	Shunsuke Furutani, Hitoshi Ikushima, Takuya Saze, Kyosuke Osaki, Seiji Iwamoto, 岸田義臣, Yoshihiro Takegawa and Hiromu Nishitani : IPを用いたヨウ素125密封小線源のQA, 日本放射線腫瘍学会第18回学術大会(埼玉)日本放射線腫瘍学会第18回学術大会報告集, Vol.17, No.Suppl. 1, 158, Nov. 2005.
233.	Masataka Oita, Kyosuke Osaki, Hitoshi Ikushima, Hirofumi Yagi, Yoshihiro Takegawa and Hiromu Nishitani : 簡易測定ファントムと反射型フィルムを用いたI-125 SeedのQA/QC, Japanese Journal of Radiological Technology, Vol.61, No.9, 1287, Oct. 2005.
234.	Tetsuya Tsujikawa, Junji Ueno, 湊雅子, Kyosuke Osaki, Hitoshi Ikushima and Akira Tangoku : CT volume dataを用いたセンチネルリンパ節のナビゲーション診断法, Sep. 2005.
235.	Takaharu Kudoh, Keiko Kudoh, Tetsuya Yuasa, Kyosuke Osaki, Hitoshi Ikushima, Masaru Nagayama and Eiichi Honda : 上歯肉扁平上皮癌に対する高線量率モールド照射の治療経験, Shikoku Dental Research, Vol.18, No.2, 253, Jun. 2005. (Tokushima University Institutional Repository) ● Metadata: 273 (Tokushima University Institutional Repository: 273)
236.	Masataka Oita, Kyosuke Osaki, Hitoshi Ikushima, Hirofumi Yagi, Yoshihiro Takegawa and Hiromu Nishitani : 反射型フィルムを用いたI-125 SeedのQA/QCに関する検討第1報反射型フィルムおよびフィルム解析システムの諸特性, 第64回日本医学放射線学会学術総会(横浜)第64回日本放射線技術学会学雑誌, Vol.61, No.2, 192, Apr. 2005.
237.	Hitoshi Ikushima, Hirofumi Yagi, Kyosuke Osaki, Shunsuke Furutani, Yoshihiro Takegawa and Hiromu Nishitani : 反射型線量測定用フイルムを用いたヨウ素125治療用密封小線源のquality assurance, 第64回日本医学放射線学会学術総会(横浜)第64回日本医学放射線学会学術集会抄録集, Vol.61, No.2, 228, Apr. 2005.
238.	川中崇, Hitoshi Ikushima, Kyosuke Osaki, Hiroaki Yasuda, 池山鎮夫, Hiromu Nishitani, Takaharu Kudoh, Toru Takeuchi, Eiichi Honda and Yoshihiro Takegawa : 上顎炎症性偽腫瘍の放射線治療経験と治療成績, 第101回日本医学放射線学会中国·四国地方会(鳥取)日本医学放射線学会雑誌, Vol.65, No.1, 80, Jan. 2005.
239.	Kyosuke Osaki, Hitoshi Ikushima, 川中崇, Tomoya Murase, 王億, Hiromu Nishitani, Takaharu Kudoh, Toru Takeuchi, Eiichi Honda and Yoshihiro Takegawa : 頬粘膜癌の治療成績, 第101回日本医学放射線学会中国·四国地方会(鳥取)日本医学放射線学会雑誌, Vol.65, No.1, 80, Jan. 2005.
240.	Shunsuke Furutani, Hitoshi Ikushima, 尾崎享祐, Yoshihiro Takegawa and Hiromu Nishitani : 反射型線量測定用フイルムを用いたヨウ素125治療用密封小線源のquality assurance, 第103回日本医学放射線学会中国·四国地方会(高知), Dec. 2004.
241.	Masataka Oita, Hitoshi Ikushima, Masahide Tominaga, Hirofumi Yagi, Kyosuke Osaki, Yoshihiro Takegawa, Hiromu Nishitani and 渡辺良晴 : マイクロMLC搭載自走式CTリニアック装置のQA/QC, 日本放射線腫瘍学会第17回学術大会(千葉)日本放射線腫瘍学会誌, Vol.16, No.Suppl. 1, 142, Nov. 2004.
242.	Hitoshi Ikushima, Kyosuke Osaki, Shunsuke Furutani, 川中崇, Masataka Oita, Yoshihiro Takegawa and Hiromu Nishitani : 子宮頸癌に対する化学放射線治療療法の治療成績, 日本放射線腫瘍学会第17回学術大会(千葉)日本放射線腫瘍学会誌, Vol.16, No.Suppl. 1, 115, Nov. 2004.
243.	Hitoshi Ikushima, 尾崎享祐, Shunsuke Furutani, 川中崇 and Masataka Oita : 子宮頸癌に対する化学放射線治療療法の治療成績, 日本放射線腫瘍学会第17回学術大会(千葉), Nov. 2004.
244.	Masataka Oita, Hitoshi Ikushima, Yoshihiro Takegawa, Kyosuke Osaki, Hirofumi Yagi and Hiromu Nishitani : Quality control of a new CT on rail (CT-Linac) system using a micro-Multi Leaf Collimator (mMLC) unit, 日本放射線腫瘍学会第17回学術大会(千葉), 142, Nov. 2004.
245.	Shunsuke Furutani, Kyosuke Osaki, Hitoshi Ikushima, Hiromu Nishitani, 竹脇弘嗣, Yoshihiro Takegawa and Takaharu Kudoh : 木村氏病の治療経験, 第102回日本医学放射線学会中国·四国地方会(香川)日本放射線腫瘍学会雑誌, Vol.65, No.2, 75, Jun. 2004.
246.	Kyosuke Osaki, Hitoshi Ikushima, Shunsuke Furutani, Hiromu Nishitani and Yoshihiro Takegawa : III期非小細胞肺癌の放射線治療成績, 第102回日本医学放射線学会中国·四国地方会(香川)日本放射線腫瘍学会雑誌, Vol.65, No.2, 75, Jun. 2004.
247.	川中崇, Hitoshi Ikushima, Kyosuke Osaki, Hiroaki Yasuda, Yoshihiro Takegawa and Hiromu Nishitani : 子宮頸癌いおけるHIF-2αの発現と放射線治療成績, 第63回日本医学放射線学会学術会(横浜)日本放射線腫瘍学会雑誌, Vol.64, No.2, 212, Apr. 2004.
248.	Kyosuke Osaki, Hitoshi Ikushima, 川中崇, 芝篤志, Hiromu Nishitani and Yoshihiro Takegawa : 高線量率腔内照射を用いた子宮頸癌の治療成績, 第100回日本医学放射線学会中国·四国地方会(岡山)日本医学放射線学会雑誌, Vol.64, No.5, 60, Apr. 2004.
249.	川中崇, Hitoshi Ikushima, Hiroaki Yasuda, Kyosuke Osaki, Hiromu Nishitani and Yoshihiro Takegawa : 非小細胞肺癌の脳転移に対するstereotactic radiosurgeryの検討, 第100回日本医学放射線学会中国·四国地方会(岡山)日本医学放射線学会雑誌, Vol.64, No.5, 58, Apr. 2004.
250.	川中崇, Hitoshi Ikushima, Kyosuke Osaki, Yoshihiro Takegawa and Hiromu Nishitani : 高線量率腔内照射を用いた子宮頸癌の放射線治療成績, 日本放射線腫瘍学会第16回学術集会(東京)日本放射線腫瘍学会誌, Vol.15, No.Suppl. 1, 141, Nov. 2003.
251.	川中崇, Hitoshi Ikushima, Yoshihiro Takegawa and Hiromu Nishitani : 喉頭癌に対する放射線治療の甲状腺機能障害, 第99回日本医学放射線学会中国·四国地方会(島根)日本医学放射線学会雑誌, Vol.63, No.5, 57, Apr. 2003.
252.	芝篤志, 川中崇, Hiroaki Yasuda, Hiromu Nishitani, Hitoshi Ikushima and Yoshihiro Takegawa : Medulloblastomaの治療成績, 第99回日本医学放射線学会中国·四国地方会(島根), Dec. 2002.
253.	芝篤志, Hiroaki Yasuda, 中川崇, Hiromu Nishitani, Hitoshi Ikushima, Yoshihiro Takegawa, Tadaoki Morimoto and 笹三徳 : 乳房温存療法の長期予後, 第98回日本医学放射線学会中国·四国地方会(岡山) 2002.6. 日本医学放射線学会雑誌, Vol.62, No.14, 54, Dec. 2002.
254.	川中崇, Hitoshi Ikushima, Yoshihiro Takegawa and Hiromu Nishitani : 放射線治療を施行した中耳癌の3症例, 第97回日本医学放射線学会中国·四国地方会(広島) 2001.12. 日本医学放射線学会雑誌, Vol.62, No.4, 57, Apr. 2002.
255.	亀井誠二, Hitoshi Ikushima, Yoshihiro Takegawa and Koichi Tamura : 上咽頭癌の治療成績, 第39回日本頭頸部腫瘍学会(札幌) 2001.6. 頭頸部腫瘍, Vol.27, No.2, 424, Dec. 2001.
256.	Hitoshi Ikushima, 山下恭, 川中崇, 亀井誠二, Hiromu Nishitani and Yoshihiro Takegawa : 女性骨盤骨の晩期放射線有害事象への対策, 第102回日本医学放射線学会中国·四国地方会放射線談話会(山口), Jun. 2001.
257.	塩田博文, 棚上彰仁, Hitoshi Ikushima, Yoshihiro Takegawa and Koichi Tamura : 上咽頭癌の放射線治療成績, 第94回日本医学放射線学会中国·四国地方会(香川) 2000.6. 日本医学放射線学会雑誌, Vol.60, No.12, 51, Dec. 2000.
258.	塩田博文, 棚上彰仁, Hitoshi Ikushima, Hiromu Nishitani and Yoshihiro Takegawa : 上咽頭癌の放射線治療成績, 日本放射線腫瘍学会第13回学術大会(新潟)日本放射線腫瘍学会雑誌, Vol.12, No.Suppl. 1, 267, Nov. 2000.
259.	発知啓子, 松木弘量, Hitoshi Ikushima, Hiromu Nishitani and Yoshihiro Takegawa : 外陰部 rhabdoid tumor の 1 治験例, 第93回日本医学放射線学会中国・四国地方会(高知)日本医学放射線学会誌, Vol.60, No.6, 43, Jun. 2000.
260.	松木弘量, 梅林成憲, Kazuhide Yoneda, 山口康男, Hitoshi Ikushima, Hiromu Nishitani and Yoshihiro Takegawa : 早期声門癌の放射線治療成績, 第92回日本医学放射線学会中国・四国地方会(松山) 1999.6. 日本医学放射線学会誌, Vol.59, No.12, 78, Dec. 1999.
261.	松木弘量, Hitoshi Ikushima, 梅林成憲, 柏原賢一, Yoshihiro Takegawa and Hiromu Nishitani : 舌癌の治療成績ー放射線治療と手術成績との比較ー, 日本放射線腫瘍学会第12回学術大会(横浜)日本放射線腫瘍学会誌, Vol.11, No.Suppl. 1, 128, Nov. 1999.
262.	Hitoshi Ikushima, 松木弘量, 梅林成憲, 柏原賢一, Yoshihiro Takegawa and Hiromu Nishitani : 要望演題乳癌に対する乳房温存療法の臨床的評価, 日本放射線腫瘍学会第12回学術大会(横浜)日本放射線腫瘍学会誌, Vol.11, No.Suppl. 1, 119, Nov. 1999.
263.	松木弘量, Hitoshi Ikushima, Kyosuke Osaki, 谷勇人, Hiromu Nishitani and Yoshihiro Takegawa : 舌癌の放射線治療成績, 第91回日本医学放射線学会中国・四国地方会放射線談話会(米子)日本医学放射線学会誌, Vol.59, No.3, 47, Jun. 1999.
264.	松木弘量, Hitoshi Ikushima, Hiromu Nishitani, Yoshihiro Takegawa, Masaru Nagayama and Mitsunobu Sato : 舌癌の放射線治療成績, 第218回徳島医学会, Jan. 1999.
265.	Yoshihiro Takegawa, Yasushi Kurokawa, Susumu Kagawa, Hitoshi Ikushima, Matsuki Hirokazu and Hiromu Nishitani : 徳島大学における進行前立腺癌の放射線治療, The 14^th Tokyo Symposium on Prostate Cancer, Dec. 1998.
266.	Hitoshi Ikushima, 松木弘量, Shusaku Yoshida, Hiromu Nishitani, Yoshihiro Takegawa, 柏原賢一 and 棚上彰仁 : 子宮頸癌の放射線治療ー徳島大学における30年間の治療成績ー, 第90回日本医学放射線学会中国・四国地方会(岡山) 1998.5. 日本医学放射線学会誌, Vol.58, No.12, 48, Dec. 1998.
267.	Hitoshi Ikushima, 松木弘量, 柏原賢一, Hiromu Nishitani and Yoshihiro Takegawa : 要望演題子宮頸癌の放射線治療:治療成績, 日本放射線腫瘍学会第11回学術大会(群馬)日本放射線腫瘍学会誌, Vol.10, No.Suppl. 1, 207, Nov. 1998.
268.	北川学, Hitoshi Ikushima, 山口康男, 松木弘量, Shusaku Yoshida, Hiromu Nishitani and Yoshihiro Takegawa : 子宮頸癌の放射線治療における動注化学療法併用の意義について, 第12回日本血管造影・インターベンショナルラジオロジー学会(米子), Sep. 1998.
269.	牧本裕美, Hitoshi Ikushima, 野田聡, 渡辺克介, Shusaku Yoshida, Hiromu Nishitani and Yoshihiro Takegawa : 高齢者子宮頸癌の放射線治療成績, 日本医学放射線学会第88回中国・四国地方会(岡山) 1997.6. 日本医学放射線学会誌, Vol.58, No.3, 125, Apr. 1998.
270.	Yoshihiro Takegawa and Hitoshi Ikushima : 子宮頸癌の放射線治+BM療法(シンポ), 日本医学放射線学会生物部会第27回放射線による制癌シンポジウム(大阪)1979.8.9. 癌の臨床, Vol.44, No.2, 215-216, Feb. 1998.
271.	Hitoshi Ikushima, 牧本裕美, Shusaku Yoshida, Hiromu Nishitani and Yoshihiro Takegawa : 高齢者子宮頸癌の長期放射線治療成績, 第10回日本放射線腫瘍学会学術大会(高松)日本放射線腫瘍学会誌, Vol.9, No.Suppl. 1, 215, Oct. 1997.
272.	Hitoshi Ikushima and Yoshihiro Takegawa : 高齢者子宮頸癌の放射線治療成績, 第35回日本癌治療学会(京都), Oct. 1997.
273.	Hitoshi Ikushima, 安田浩明, Toshiko Okada, 佐藤和美, Hiromu Nishitani and Yoshihiro Takegawa : 徳島大学における乳房温存療法の現状, 第29回日本医学放射線学会中国・四国地方会放射線談話会(広島), Dec. 1996.
274.	橘川薫, Hitoshi Ikushima, 高橋雅子, Masafumi Harada, 向所敏文, 須井修, 山子勇仁, Hiromu Nishitani and Yoshihiro Takegawa : 子宮頸癌進行再発症例の治療, 日本医学放射線学会第71回中国・四国地方会(岡山) 1988.11. 日本医学放射線学会雑誌, Vol.49, No.9, 86, Apr. 1989.

Et cetera, Workshop:

1.	Yoshihiro Tanaka, Masahide Tominaga, Motoharu Sasaki, 廣田充宏, 鎌田真奈, Yasuo Hara, 坂東良太 and Hitoshi Ikushima : 三次元線量検出システムを用いたDVHに関する基礎的検討, 第26回高精度放射線治療研究会, Feb. 2013.
2.	Masahide Tominaga, Motoharu Sasaki, 磯部昇, Hitoshi Ikushima and 岸太郎 : 前立腺癌のIG-IMRTにおいてinter-fractional organ motion errorが線量分布に及ぼす影響, 第26回高精度放射線治療研究会, Feb. 2013.
3.	池本哲也, 西岡将規, 安藤勤, 八和田裕子, Yoshiyasu Terashima, Hitoshi Ikushima and Mitsuo Shimada : 術前放射線化学療法が著効した下部進行直腸癌の1例, Japanese Journal of Cancer and Chemotherapy, Vol.32, No.1, 95-97, 2005.
4.	Hitoshi Ikushima, 塩田博文, Hiromu Nishitani and Yoshihiro Takegawa : 直線加速器による定位放射線治療, 第26回徳島乳腺疾患談話会, Mar. 2000.
5.	松木弘量, Hitoshi Ikushima, Junji Ueno, Hiromu Nishitani and Yoshihiro Takegawa : 乳癌の骨転移に関する放射線治療, 第24回徳島乳腺疾患懇話会, Aug. 1998.
6.	Hitoshi Ikushima, 安田浩明, Junji Ueno, Hiromu Nishitani and Yoshihiro Takegawa : 乳房温存療法における放射線治療, 第21回徳島乳腺疾患懇話会, Jan. 1997.
7.	高橋雅子, 田内美紀, 須井修, 柏原賢一, Hitoshi Ikushima, Masafumi Harada, 澤田葉子, 高砂まき, Shusaku Yoshida, Hiromu Nishitani and Yoshihiro Takegawa : TL-201, SPECTの肺腫瘍例での検討, 第4回徳島肺癌治療研究会, Mar. 1990.

Report:

1.	Yoshihiko Ueno, Yosuke Seki, Takuya YABE, Shigenobu Yonemura, Hiroshi Sakaue, Hitoshi Ikushima, Hideki Fujii, Yasuhiko Shirayama, Ken-ichi Yamada, Kazuhiko Kinoshita, Eiji Sakuradani, Ray S. Furuya and Maiko Kamioka : 令和2年度徳島大学高等教育研究センターアドミッション部門報告書, 令和2年度徳島大学高等教育研究センターアドミッション部門報告書, Mar. 2021.
2.	Yoshihiko Ueno, Yosuke Seki, keiji Ido, Yasushi Takagi, Hiroshi Sakaue, Hitoshi Ikushima, Hideki Fujii, Yasuhiko Shirayama, Hideji TANAKA, Masatake Kawada, Hideaki Nagamune, Ray S. Furuya and Maiko Kamioka : 令和元年度徳島大学高等教育研究センターアドミッション部門報告書, 令和元年度徳島大学高等教育研究センターアドミッション部門報告書, Mar. 2020.
3.	Yoshihiko Ueno, Yosuke Seki, Kenji Sato, Masako Nomaguchi, Takeshi Nikawa, Hitoshi Ikushima, Kenichi Hamada, Yasuhiko Shirayama, Ken-ichi Yamada, Akihiro Furube, Hitoshi Matsuki, Ray S. Furuya and Maiko Kamioka : 平成30年度徳島大学総合教育センターアドミッション部門報告書, 平成30年度徳島大学総合教育センターアドミッション部門報告書, Tokushima, Mar. 2019.

Patent:

1.	Minoru Sakama, Hitoshi Ikushima, 山田隆治, 高井久司 and 市樂輝義 : がん治療用密封小線源の放射線強度測定装置, (Oct. 2012), (Oct. 2012), 2012-223836 (Oct. 2012).

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

A randomized controlled trial to verify the synergistic effect of nivolumab and radiotherapy in metastatic renal cell carcinoma (Project/Area Number: 24K02397 )
Novel Cancer Treatment Strategies Based on Radiomics Imaging Analysis (Project/Area Number: 23K07158 )
Development of medical computer vision system and the clinical application (Project/Area Number: 23K07084 )
Molecular Imaging Radiomics Model for Prediction of Radiotherapy Effect (Project/Area Number: 20K07698 )
Prevention / medical treatment strategy by a blood vessel rebirth and osteogenic effect of establishment of a radiation nature jawbone necrosis model, and statin (Project/Area Number: 19K10268 )
Development of disposable dosimeter for in-vivo measurement of organ at risk during radiation therapy (Project/Area Number: 19K08223 )
Material estimation and functional estimation with medical image normalization (Project/Area Number: 19K08201 )
New treatment strategy for non-small-cell lung cancer by molecular imaging (Project/Area Number: 17K10479 )
Effect and safety of stereotactic radiotherapy for cancers in various organs except for lung and liver (Project/Area Number: 16H05389 )
Challenge of raiditoherapy for oral cancer -definition of appropriate combination both cetuximab and docetaxel- (Project/Area Number: 26462838 )
Prediction of outcomes after radiotherapy for the patients with advanced cervical cancer using the molecular technique (Project/Area Number: 25293266 )
Molecular biologic effect of neoadjuvant chemoradiotherapy followed by surgery for non-small cell lung cancer (Project/Area Number: 22591386 )
Elucidation and conquest of the radioresistant for the patients with advanced cervical cancer using the molecular technique (Project/Area Number: 22390237 )
Search by Researcher Number (90202861)

Professor : Ikushima, Hitoshi

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Report:

Patent:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)